---
document_datetime: 2025-08-13 16:33:53
document_pages: 123
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/amvuttra-h-c-005852-ii-0015-epar-assessment-report-variation_en.pdf
document_name: amvuttra-h-c-005852-ii-0015-epar-assessment-report-variation_en.pdf
version: success
processing_time: 103.9376684
conversion_datetime: 2025-12-15 00:48:07.944096
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 April 2025 EMA/CHMP/177587/2025 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Amvuttra

International non-proprietary name: Vutrisiran

Procedure No. EMEA/H/C/005852/II/0015

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................6                               |                                                                                                         |
|--------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ................................................................................................6 |                                                                                                         |
| 1.2. Steps taken for the assessment of the product                                                                       | .......................................................7                                                |
| 2. Scientific discussion                                                                                                 | ................................................................................8                       |
| 2.1. Introduction                                                                                                        | ......................................................................................................8 |
| 2.1.1. Problem statement                                                                                                 | ..........................................................................................8             |
| 2.1.2. About the product..........................................................................................       | 10                                                                                                      |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice......                                   | 11                                                                                                      |
| 2.1.4. General comments on compliance with GCP......................................................                     | 11                                                                                                      |
| 2.2. Non-clinical aspects                                                                                                | .......................................................................................... 12           |
| 2.2.1. Ecotoxicity/environmental risk assessment........................................................                 | 12                                                                                                      |
| 2.2.2. Discussion on non-clinical aspects ....................................................................           | 12                                                                                                      |
| 2.2.3. Conclusion on the non-clinical aspects                                                                            | .............................................................. 12                                       |
| 2.3. Clinical aspects ................................................................................................   | 13                                                                                                      |
| 2.3.1. Introduction..................................................................................................    | 13                                                                                                      |
| 2.3.2. Pharmacokinetics...........................................................................................       | 14                                                                                                      |
| 2.3.3. Pharmacodynamics ........................................................................................         | 18                                                                                                      |
| 2.3.4. Discussion on clinical pharmacology                                                                               | ................................................................. 24                                    |
| 2.3.5. Conclusions on clinical pharmacology................................................................              | 25                                                                                                      |
| 2.4. Clinical efficacy                                                                                                   | ................................................................................................ 26     |
| 2.4.1. Dose response study(ies)................................................................................          | 26                                                                                                      |
| 2.4.2. Main study(ies)                                                                                                   | ............................................................................................. 26        |
| 2.4.3. Discussion on clinical efficacy ..........................................................................        | 84                                                                                                      |
| 2.4.4. Conclusions on the clinical efficacy ...................................................................          | 93                                                                                                      |
| 2.5. Clinical safety ..................................................................................................  | 94                                                                                                      |
| 2.5.1. Discussion on clinical safety ..........................................................................          | 106                                                                                                     |
| 2.5.2. Conclusions on clinical safety.........................................................................           | 107                                                                                                     |
| 2.5.3. PSUR cycle .................................................................................................      | 107                                                                                                     |
| 2.6. Risk management plan....................................................................................            | 107                                                                                                     |
| 2.7. Update of the Product information.....................................................................              | 111                                                                                                     |
| 2.7.1. User consultation.........................................................................................        | 111                                                                                                     |
| Balance............................................................................112                                   |                                                                                                         |
| 3. Benefit-Risk                                                                                                          |                                                                                                         |
| 3.1. Therapeutic Context........................................................................................         | 112                                                                                                     |
| 3.1.1. Disease or condition.....................................................................................         | 112                                                                                                     |
| 3.1.2. Available therapies and unmet medical need....................................................                    | 113                                                                                                     |
| 3.1.3. Main clinical studies                                                                                             | ..................................................................................... 114               |
| 3.2. Favourable effects ..........................................................................................       | 115                                                                                                     |
| 3.3. Uncertainties and limitations about favourable effects..........................................                    | 116                                                                                                     |
| 3.4. Unfavourable effects .......................................................................................        | 117                                                                                                     |
| 3.5. Uncertainties and limitations about unfavourable effects                                                            | ...................................... 117                                                              |
| 3.6. Effects Table..................................................................................................     | 117                                                                                                     |
| 3.7. Benefit-risk assessment and discussion .............................................................                | 121                                                                                                     |
| 3.7.1. Importance of favourable and unfavourable effects...........................................                      | 121                                                                                                     |

<div style=\"page-break-after: always\"></div>

| 3.7.2. Balance of benefits and risks .........................................................................       | 122   |
|----------------------------------------------------------------------------------------------------------------------|-------|
| 3.7.3. Additional considerations on the benefit-risk balance ........................................                | 122   |
| 3.8. Conclusions ................................................................................................... | 122   |
| 4. Recommendations ...............................................................................122                |       |
| 5. EPAR changes......................................................................................123             |       |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation      | Definition                                                                                              |
|-------------------|---------------------------------------------------------------------------------------------------------|
| 6-MWT             | 6-minute walk test                                                                                      |
| ADA               | Anti-drug antibody                                                                                      |
| ADR               | Adverse drug reaction                                                                                   |
| AE                | Adverse event                                                                                           |
| ALT               | Alanine aminotransferase                                                                                |
| APOLLO            | ALN-TTR02-004 pivotal Phase 3 study of patisiran in patients with hATTR amyloidosis with polyneuropathy |
| APOLLO-B          | ALN-TTR02-011 Phase 3 study of patisiran in patients with ATTR amyloidosis with cardiomyopathy          |
| AST               | Aspartate aminotransferase                                                                              |
| ATTR amyloidosis  | Transthyretin-mediated amyloidosis                                                                      |
| ATTR-ACT          | Phase 3 study of tafamidis in patients with ATTR amyloidosis with cardiomyopathy                        |
| ATTRibute-CM      | Phase 3 study of acoramidis in patients with ATTR amyloidosis with cardiomyopathy                       |
| C 4h              | Plasma concentrations 4 hour postdose                                                                   |
| CEC               | Clinical Events Committee                                                                               |
| CI                | Confidence interval                                                                                     |
| CM                | Cardiomyopathy                                                                                          |
| CSR               | Clinical study report                                                                                   |
| CV                | Cardiovascular                                                                                          |
| CYP               | Cytochrome P450                                                                                         |
| DB                | Double-blind                                                                                            |
| ECG               | Electrocardiogram                                                                                       |
| eGFR              | Estimated glomerular filtration rate                                                                    |
| EMA               | European Medicines Agency                                                                               |
| EOP2              | End of Phase 2                                                                                          |
| EU                | European Union                                                                                          |
| FDA               | Food and Drug Administration                                                                            |
| GalNAc            | N -acetylgalactosamine                                                                                  |
| GCP               | Good Clinical Practice                                                                                  |
| hATTR amyloidosis | Hereditary ATTR amyloidosis                                                                             |
| HELIOS-A          | ALN-TTRSC02-002 Phase 3 study of vutrisiran in patients with hATTR amyloidosis with polyneuropathy      |
| HELIOS-B          | ALN-TTRSC02-003 Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy       |
| HF                | Heart failure                                                                                           |
| HR                | Hazard ratio                                                                                            |
| IPTW              | Inverse Probability of Treatment Weighting                                                              |

<div style=\"page-break-after: always\"></div>

| Abbreviation       | Definition                                       |
|--------------------|--------------------------------------------------|
| ISR                | Injection site reaction                          |
| KCCQ               | Kansas City Cardiomyopathy Questionnaire         |
| KCCQ-OS            | KCCQ Overall Summary                             |
| LFT                | Liver function test                              |
| LS                 | Least square                                     |
| LV                 | Left ventricular                                 |
| MedDRA             | Medical Dictionary for Regulatory Activities     |
| MMRM               | Mixed-effects model repeated measures            |
| mRNA               | Messenger RNA                                    |
| NT-proBNP          | N-terminal prohormone B-type natriuretic peptide |
| NYHA               | New York Heart Association                       |
| OLE                | Open-Label Extension                             |
| PASS               | Post-authorization safety study                  |
| PD                 | Pharmacodynamic(s)                               |
| PK                 | Pharmacokinetic(s)                               |
| PMDA               | Pharmaceuticals and Medical Devices Agency       |
| PT                 | Preferred term                                   |
| q3M                | Once every 3 months                              |
| QTcF               | QT corrected using Fridericia's formula          |
| RNAi               | RNA interference                                 |
| SAE                | Serious adverse event                            |
| SAP                | Statistical Analysis Plan                        |
| SC                 | Subcutaneous                                     |
| SGLT2              | Sodium-glucose cotransporter 2                   |
| siRNA              | Small interfering RNA                            |
| SMQ                | Standardized MedDRA Query                        |
| SOC                | System organ class                               |
| TTR                | Transthyretin                                    |
| ULN                | Upper limit of normal                            |
| US                 | United States                                    |
| wt                 | Wild-type                                        |
| wtATTR amyloidosis | Wild-type ATTR amyloidosis                       |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Alnylam Netherlands B.V. submitted to the European Medicines Agency on 15 October 2024 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of wild-type or hereditary transthyretin-mediated amyloidosis in adult patients with cardiomyopathy (ATTR-CM), based on primary analysis results from study HELIOS-B (ALN-TTRSC02-003); a Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy).  As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. An updated version 1.3 of the RMP has also been submitted. As part of the application the MAH applied for +1 year of additional market protection.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information relating to orphan designation

Amvuttra, was designated as an orphan medicinal product (EMA/OD/019/18) on 25 May 2018 in the following indication:

Treatment of transthyretin-mediated amyloidosis

Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) reviewed the designation of Amvuttra as an orphan medicinal product in the approved indication. More information on the COMP's review can be found in the orphan maintenance assessment report published under the 'Assessment history' tab on the Agency's website:

https://www.ema.europa.eu/en/medicines/human/EPAR/amvuttra

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s)

(EMEA-002425-PIP01-18 - P/0015/2019) on the granting of a product-specific waiver covering all subsets of the paediatric population (0 to 18 years).

<div style=\"page-break-after: always\"></div>

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication.

The Marketing Authorisation Holder (MAH) decided to withdraw the request for an additional year of market protection in accordance with the provisions of Article 14(11) of Regulation (EC) No 726/2004. Accordingly, a withdrawal letter in this regard was sent to the EMA Product Lead for this procedure of AMVUTTRA on 14 February 2025.

## Protocol assistance

The MAH received Protocol Assistance from the CHMP on 20 May 2021 (EMA/SA/0000055285), 27 June 2019 (EMEA/H/SA/3876/2/2019/PA/II) and 24 March 2022 (EMA/SA/0000071629). The Protocol Assistance pertained to clinical aspects of the dossier.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

| Rapporteur:                                                                                                | Fátima Ventura   |
|------------------------------------------------------------------------------------------------------------|------------------|
| Timetable                                                                                                  | Actual dates     |
| Submission date                                                                                            | 15 October 2024  |
| Start of procedure: 2                                                                                      | November 2024    |
| CHMP Rapporteur's preliminary assessment report circulated on                                              | 2 January 2025   |
| PRAC Rapporteur's assessment report circulated on                                                          | 6 January 2025   |
| PRAC members comments                                                                                      | 8 January 2025   |
| CHMP Co-Rapporteur's comments circulated on                                                                | 13 January 2025  |
| PRAC Outcome                                                                                               | 16 January 2025  |
| CHMP members comments                                                                                      | 20 January 2025  |
| Updated CHMP Rapporteur(s) (Joint) assessment report circulated on                                         | 23 January 2025  |
| Request for supplementary information (RSI) adopted by the CHMP on:                                        | 30 January 2025  |
| Withdrawal of request for one-year extra market protection                                                 | 14 February 2025 |
| MAH's responses submitted to the CHMP on:                                                                  | 24 February 2025 |
| CHMP and PRAC Rapporteur's joint assessment report assessment report on the MAH's responses circulated on: | 31 March 2025    |

<div style=\"page-break-after: always\"></div>

| Timetable                                 | Actual dates   |
|-------------------------------------------|----------------|
| PRAC members comments                     | 2 April 2025   |
| PRAC Outcome                              | 10 April 2025  |
| CHMP members comments                     | 14 April 2025  |
| Updated CHMP Rapporteur Assessment Report | 17 April 2025  |
| CHMP Opinion                              | 25 April 2025  |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Transthyretin-mediated amyloidosis is a rapidly progressive, multisystem, debilitating, and ultimately fatal disease encompassing wtATTR and hATTR amyloidosis. Wild-type ATTR amyloidosis is associated with aging, and hATTR amyloidosis results from genetic variants in the TTR gene. Progressive, chronically debilitating morbidity and mortality are caused by the deposition of TTR as amyloid in various organs and tissues, including the heart, peripheral nerves, and the gastrointestinal (GI) tract. The most common manifestations of ATTR amyloidosis are cardiomyopathy and polyneuropathy.

Vutrisiran  (AMVUTTRA ® )  is  a  ribonucleic  acid  interference  (RNAi)  therapeutic  designed  to  suppress production of both variant and wild-type TTR in the liver and was approved by the European Commission on 15  September  2022  for  the  treatment  of  hATTR  amyloidosis  in  adult  patients  with  stage  1  or  stage  2 polyneuropathy.

## State the claimed the therapeutic indication

## Current approved therapeutic indication:

'Amvuttra is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.'

## Proposed new additional ATTR-CM indication:

Within this procedure the MAH applies for an extension of the indication as follows:

Amvuttra  is indicated for the  treatment  of  hereditary  transthyretin-mediated  amyloidosis  (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN).

Amvuttra is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

<div style=\"page-break-after: always\"></div>

## Epidemiology and risk factors, screening tools/prevention

Variant transthyretin amyloid cardiomyopathy (ATTRv-CM) is thought to be present in over 40,000 persons worldwide. The prevalence of wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) has been more difficult to estimate accurately but is increasing, due to an evolving diagnostic landscape (including enhanced disease awareness and the broadening availability of a non-invasive diagnostic methods like scintigraphy with technetium 99m). Recent estimates found ATTR-CM to be the etiology in up to 13% of an otherwise unselected population of patients presenting with heart failure and preserved ejection fraction.

## Biologic features, aetiology and pathogenesis

The mechanisms underlying the pathophysiology of ATTRwt and its association with aging are currently poorly understood. In contrast, for ATTRv, more than 120 intrinsically destabilizing TTR gene variants have been  identified  that  are  transmitted  in  an  autosomal  dominant  fashion.  V122I  is  the  most  common pathogenic variant found in the United Kingdom (UK) and in the United States (US), affecting 3% to 4% of people of Afro-Caribbean descent, with a variable documented penetrance and clinical expressivity. The V30M pathogenic variant was the first to be described and is most commonly found in three geographic locations demonstrating a founder effect. The clinical syndrome associated with the early onset V30M variant was initially described in Portugal in 1952 as Familial Amyloid Polyneuropathy, and subsequently in unrelated populations in Northeastern Sweden and Southwestern Japan, where the V30M variant displays an older age of disease onset than in Portugal. Also first described in Portugal was a highly stabilizing (~37-fold more stable than wild-type) variant (T119M) that protects V30M carriers (compound heterozygotes) from either developing or progressing the otherwise rapidly progressive polyneuropathy associated with V30M carriage.

## Clinical presentation, diagnosis and stage/prognosis

Patients diagnosed with ATTR-CM tend to be male, on average 60 years old or older, and present with heart failure  with  preserved  ejection  fraction,  often  with  cardiac  conduction  abnormalities  (varying  degrees  of heart block) on an electrocardiogram (ECG), along with thickened ventricular walls, and evidence of diastolic dysfunction on echocardiogram. In addition, a carefully taken medical history might reveal prior bilateral carpal tunnel syndrome (without predisposing risk factors for that condition) or lumbar spinal stenosis in the prior 5 to 10 years.

Until  recently,  ATTR-CM  was  underdiagnosed  due  to  non-specific  signs  and  symptoms  often  mistakenly attributed  to  more  common  conditions  and  the  need  to  perform  an  endomyocardial  biopsy  for  specific diagnostic confirmation in the absence of any available treatment. However, the past 10 years have borne witness to a profound transformation of the disease landscape due to several critical advances: (1) diagnostic confirmation is now possible by non-invasive means including scintigraphy (with bone radiotracers) coupled with the exclusion of a monoclonal gammopathy consistent with amyloid light chain (AL) amyloidosis by serum and urine protein biochemistry; (2) a widespread, global engagement by professional societies, and advocacy organizations to raise awareness among cardiologists and the broader medical community has driven increasingly earlier recognition and diagnosis. Disease awareness has been driven in part by the recognition of so-called red flags, like a history of bilateral carpal tunnel syndrome, leading to an earlier diagnosis  and  subsequent  treatment  than  was  previously  achieved.  The  availability  of  an  approved treatment, tafamidis, that was shown to reduce mortality and CV-related hospitalizations by 30% and 32%, respectively,  has  contributed  to  this  trend  in  earlier  recognition  of  ATTR-CM  as  well.  However,  despite increased disease awareness, earlier specific diagnosis, and therapeutic advances, ATTR-CM remains an important,  under-recognized  cause  of  heart  failure  leading  to  excess  mortality,  CV  morbidity,  impaired physical function, and QoL.

<div style=\"page-break-after: always\"></div>

Anticipating novel therapies in development that could alter the course of ATTR-CM, in 2021 an expert panel recommended a set of criteria to monitor disease progression. The assessments fall into three domains:

- Clinical  and  Functional  domains:  heart  failure-related  hospitalizations,  New  York  Heart  Association (NYHA) Classification, 6-Minute Walk Distance (6MWD), and Kansas City Cardiomyopathy Questionnaire (KCCQ)
- Laboratory  Biomarkers  domain:  N-terminal  prohormone  of  brain  natriuretic  peptide  (NT-proBNP), troponin I (TnI), and National Amyloidosis Centre (NAC) ATTR-CM disease staging
- Imaging  (with  imaging-based  assessments  of  left  ventricular  [LV]  structure  or  function)  and  ECG domains (conduction disturbances).

## Management

Historically, the treatment of ATTR amyloidosis with cardiomyopathy has focused on palliative therapies directed at symptoms, such as diuretics for congestive symptoms and antiarrhythmic drugs, pacemakers, and automatic implantable cardioverter defibrillators for arrhythmias and conduction defects.

Center-based studies suggest that heart transplantation in ATTR amyloidosis with cardiomyopathy can be an effective option with outcomes similar to those transplanted for other causes of HF.[Barrett 2020; Razvi 2022] However, cardiac transplantation continues to be a less pursued option due to the need for lifelong immunosuppression and long waiting times associated with transplantation.

In regions such as the United States (US), European Union (EU), and Japan, the only approved treatment for cardiomyopathy in adult patients with wtATTR or hATTR amyloidosis is tafamidis, which acts by stabilising the tetrameric TTR protein and reducing its rate of dissociation into amyloidogenic monomers. Acoramidis has been approved in the US and has received a positive opinion by the CHMP in December 2024. All together there is still an unmet medical need for patients with ATTR amyloidosis with cardiomyopathy.

## 2.1.2. About the product

AMVUTTRA  (vutrisiran)  is  a  chemically  stabilized  double-stranded  small  interfering  RNA  (siRNA)  that specifically targets variant and wild-type (wt) transthyretin (TTR) messenger RNA and is covalently linked to a ligand containing 3 N-acetylgalactosamine residues to enable delivery of the siRNA to hepatocytes. Based  on  the  mechanism  of  RNA  interference,  vutrisiran  is  specifically  designed  to  reduce  the  hepatic synthesis of variant and wt TTR protein. By reducing expression of TTR, vutrisiran ameliorates the signs and symptoms  of  transthyretin  mediated  amyloidosis  (ATTR).  Vutrisiran  is  categorized  to  the  Anatomical Therapeutic Chemical Classification System group N07XX18 Other nervous system drugs.

The active moiety is vutrisiran, and the active ingredient is vutrisiran sodium. AMVUTTRA is supplied as a 0.5-mL solution containing 25 mg of vutrisiran in a single-use 1-mL prefilled syringe with a needle shield. The recommended dose of AMVUTTRA (vutrisiran) is 25 mg administered once every 3 months (q3M) by subcutaneous (SC) injection.

The drug product is approved for hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2  polyneuropathy  (hATTR  -PN)  and  for  the  proposed  new  additional  wild-type  or  hereditary  ATTR-CM indication has the same formulation and presentation as commercial vutrisiran (AMVUTTRA®).

<div style=\"page-break-after: always\"></div>

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

Vutrisiran  (AMVUTTRA®)  was  approved  by  the  European  Commission  on  15  September  2022  for  the treatment of hATTR amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. Vutrisiran has also been approved for this indication in a number of other countries/regions, including the US (for the treatment of  the  polyneuropathy  of  hereditary  transthyretin-mediated  amyloidosis  in  adults)  and  Japan  (for  the treatment of transthyretin familial amyloid polyneuropathy).

Vutrisiran  is  currently  in  clinical  development  for  the  treatment  of  wild-type  or  hereditary  transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). The primary efficacy data to support this proposed new additional ATTR-CM indication come from HELIOS-B, an ongoing, Phase 3, global, randomized, double-blind, placebo-controlled study of vutrisiran in patients with ATTR amyloidosis (hATTR or wtATTR) with cardiomyopathy, who were either not on tafamidis at baseline (vutrisiran monotherapy subgroup) or were receiving concomitant tafamidis at baseline per the inclusion criteria (background tafamidis subgroup). The results from the completed double-blind period and the ongoing open-label extension (OLE) period of HELIOS-B comprise the primary focus of this type II variation.  The safety of vutrisiran has been established in HELIOS-B and across the vutrisiran clinical development program.

An overview of the vutrisiran clinical development program is presented below. The clinical program consists of a clinical pharmacology study in healthy volunteers (Study ALN-TTRSC02-001 [Study 001]), a Phase 3 study of patients with hATTR amyloidosis with polyneuropathy (HELIOS-A), and a Phase 3 study of patients with ATTR amyloidosis with cardiomyopathy (HELIOS-B).

<!-- image -->

## 2.1.4. General comments on compliance with  GCP

All clinical studies included in this submission were claimed to be conducted and reported in accordance with the ethical principles originating from the Declaration of Helsinki and in accordance with ICH Good Clinical Practice guidelines, applicable regulatory requirements, and in compliance with the respective protocols. The study protocol of the pivotal study (HELIOS-B) was reviewed and approved by an independent ethics committee (IEC)/institutional review board (IRB) prior to commencement of the study.

<div style=\"page-break-after: always\"></div>

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

The applicant provided an environmental risk assessment (ERA) in accordance with the Guideline on the environmental risk assessment of medicinal products for human use (EMEA/CHMP/SWP/4447/00 corr 2).

Vutrisiran is not a PBT substance as log Kow does not exceed 4.5.

The PECsurfacewater has been refined with prevalence data from the Orphan Designation EU/3/18/2026.

The PECsurfacewater value is below the action limit of 0.01 µg/L.

A Phase II environmental fate and effects analysis is not required.

## Summary of main study results

| Substance (INN/Invented Name): Vutrisiran   | Substance (INN/Invented Name): Vutrisiran      | Substance (INN/Invented Name): Vutrisiran      | Substance (INN/Invented Name): Vutrisiran      |
|---------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| PBT screening                               |                                                | Result                                         | Conclusion                                     |
| Bioaccumulation potential- log Kow          | OECD107                                        | < -2.9 at pH 7                                 | Potential PBT N                                |
| PBT-assessmen                               |                                                |                                                |                                                |
| Parameter                                   | Result relevant for conclusion                 |                                                | Conclusion                                     |
| Bioaccumulation                             | log Kow                                        | < -2.9 at pH 7                                 | not B                                          |
| PBT-statement:                              | The compound is not considered as PBT nor vPvB | The compound is not considered as PBT nor vPvB | The compound is not considered as PBT nor vPvB |
| Phase I                                     |                                                |                                                |                                                |
| Calculation                                 | Value                                          | Unit                                           | Conclusion                                     |
| PECsurfacewater, refined with prevalence    | 0.0000027                                      | µ g/L                                          | > 0.01 threshold N                             |
| Other concerns (e.g. chemical class)        |                                                |                                                | N                                              |

Considering the above data, vutrisiran is not expected to pose a risk to the environment.

## 2.2.2. Discussion on non-clinical aspects

Additional non-clinical data have not been generated for this proposed type II variation.

Vutrisiran PECsurfacewater value is below the action limit of 0.01 µg/L and is not a PBT substance as log Kow does not exceed 4.5. Therefore, vutrisiran is not expected to pose a risk to the environment.

## 2.2.3. Conclusion on the non-clinical aspects

The updated data submitted in this application do not lead to a significant increase in environmental exposure further to the use of vutrisiran

- Considering the above data, vutrisiran is not expected to pose a risk to the environment.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies
- Tabular overview of clinical studies

A tabular overview over the clinical studies supporting the clinical development of Vutrisiran in patients with amyloidosis  is  provided  in  Table  1  below.  Study  001  and  study  002  (HELIOS  A)  have  been  assessed previously, study 003 (HELIOS B) is the pivotal study to support the proposed extension of indication to include treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

Table 1. Vutrisiran clinical development program

| Study, Status, Data Cutoff                                                                           | Study Design/Objectives, Location                                                                                                                          | Vutrisiran Presentation(s) a                                                                                                                                                                                                                | Dose(s)                                                                                                                                            | N, Study Population                                                          | Data Collected                                                                                                                                                  |
|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ALN- TTRSC02- 001 (Study 001) Completed Data lock: 13 February 2018                                  | Phase 1, randomized, single-blind SAD to evaluate safety, tolerability, PK, PD, and ADA of vutrisiran 1 clinical study center in the United Kingdom        | Solution for injection, 0.5 mL in 2 mL glass vial administered with syringe Formulated in water for injection                                                                                                                               | Single SC injection of 5, 25, 50, 100, 200, and 300 mg                                                                                             | N=80, healthy volunteers N=60 on vutrisiran N=20 on placebo                  | Plasma and urine concentrations of vutrisiran Serum concentrations of TTR and vitamin A ADA Safety                                                              |
| ALN- TTRSC02- 002 (HELIOS-A) Ongoing 18-month Treatment Period completed Data cutoff: 26 August 2021 | Phase 3, randomized (3:1 vutrisiran:patisiran), open-label study to evaluate the efficacy, safety, PK, and PD of vutrisiran 57 centers across 22 countries | Solution for injection, 0.5 mL in 2 mL glass vial administered with syringe Solution for injection, 0.5 mL in 1 mL prefilled syringes with passive needle safety system Formulated in 10 mMsodium phosphate and 110 mMsodium chloride, pH 7 | 18-Month Treatment Period Vutrisiran: 25 mg SC injection administered q3M Patisiran (reference comparator): 0.3 mg/kg IV infusion administered q3w | N=164, patients with hATTR amyloidosis N=122 on vutrisiran N=42 on patisiran | Vutrisiran and patisiran plasma concentrations Serum concentrations of TTR and vitamin A Efficacy data (mNIS+7, Norfolk QoL- DN, 10-meter walk test) ADA Safety |

<div style=\"page-break-after: always\"></div>

| Study, Status, Data Cutoff                                                               | Study Design/Objectives, Location                                                                                                                                      | Vutrisiran Presentation(s) a                                                                                     | Dose(s)                                                                               | N, Study Population                                                                              | Data Collected                                                                                                                                                                                                                          |
|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ALN- TTRSC02- 003 (HELIOS-B) Ongoing Primary analysis completed Data cutoff: 08 May 2024 | Phase 3, randomized (1:1 vutrisiran:placebo), DB, placebo- controlled study to evaluate the efficacy, safety, PK, and PD of vutrisiran. 87 centers across 26 countries | Solution for injection, 0.5 mL in 1 mL PFS-S Formulated in 10 mMsodium phosphate and 110 mMsodium chloride, pH 7 | Vutrisiran: 25 mg SC injection administered q3M or placebo (sodium chloride 0.9% w/v) | N=654, patients with ATTR amyloidosis with cardiomyopathy N=326 on vutrisiran N=328 on placebo b | Vutrisiran plasma concentrations Serum concentrations of TTR and vitamin A All-cause mortality and CV events (CV hospitalizations and urgent HF visits) Functional secondary efficacy endpoints (6-MWT, KCCQ-OS, NYHA Class) ADA Safety |

## 2.3.2. Pharmacokinetics

The pharmacokinetic profile of vutrisiran has already been characterized after single ascending doses from 5 to 300 mg in healthy volunteers and after 25 mg q3m dosing in patients. The analytical methods and this results from Study 001 still have been assessed at the time of the initial marketing authorisation application.

In brief:

Study 001 utilized intensive sampling to characterize the plasma PK, PD, and urine excretion profiles of vutrisiran  after  a  single  dose.  This  study  characterized  the  clinical  pharmacology  aspects  (absorption, distribution, metabolism, and elimination) of vutrisiran in humans.

After  vutrisiran  is  administered  SC,  the  GalNAc  conjugate  ensures  targeted  delivery  of  the  siRNA  to hepatocytes in the liver. Once delivered to the cytoplasm of hepatocytes, vutrisiran is primarily metabolized by endo- and exonucleases to fragments of varying sizes.[An 2023; McDougall 2022] Plasma protein binding of vutrisiran was concentration-dependent, since the percent bound decreased with increasing concentrations  of  vutrisiran,  indicating  saturation  of  the  binding  sites,  and  is  expected  to  be  around 80%.[Jing 2023] The ADME properties are similar and consistent across intrinsic and extrinsic factors and indications (hATTR amyloidosis with polyneuropathy and ATTR amyloidosis with cardiomyopathy). Vutrisiran has not been studied in patients with severe hepatic impairment, severe renal impairment, or end-stage renal disease.

## Vutrisiran PK analysis

Vutrisiran plasma concentrations 4 hour postdose (C4h) at different visits during the DB Period were similar, and C4h values at steady state (Month 30) were similar to their respective first dose values, indicating lack of accumulation of vutrisiran in plasma after q3M dosing of 25 mg. These results are consistent with the observed PK of vutrisiran in patients with hATTR amyloidosis with polyneuropathy in HELIOS-A. Median

<div style=\"page-break-after: always\"></div>

plasma concentrations of vutrisiran 4 hours postdose at Month 30 were similar for patients with wtATTR and hATTR amyloidosis (Figure 1).

Figure 1. Vutrisiran plasma concentrations 3 to 4 hours after the first dose

<!-- image -->

Median plasma vutrisiran C4h at Month 30 were similar across TTR genotypes, and there was considerable overlap in the range of observed values (Figure 2 A and B).

Figure 2. Vutrisiran plasma concentrations at 4 hours by TTR genotype

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Intrinsic factors

Intrinsic factors such as sex, race, age, body weight, genotype, NYHA class, and mild to moderate renal impairment and hepatic impairment, and the extrinsic factor of tafamidis use did not meaningfully influence the PK of vutrisiran. Data for renal and hepatic impairment as analysed in HELIOS B are summarized below.

## Renal impairment

The impact of mild or moderate renal impairment on the PK and PD of vutrisiran was assessed in HELIOS B (Figure 3).  Overall, the plasma PK of vutrisiran was comparable in patients with mild or moderate renal impairment and those with normal renal function:

- Median plasma C4h of vutrisiran at Month 30 was similar for patients with normal renal function and those with mild or moderate renal impairment (Figure 3).
- There was one patient with severe renal impairment at baseline; the vutrisiran C4h for this patient was in the range of the other 3 groups (Figure 3.

These results were expected, as CLR is a minor pathway in the overall elimination of vutrisiran, representing approximately 15.4% to 25.4% of the total plasma clearance, hence a decrease in renal function is not expected to have a meaningful effect on plasma exposure.

<div style=\"page-break-after: always\"></div>

Figure 3. HELIOSB: Vutrisiran plasma concentrations 4 hours postdose at month 30 by renal impairment category (PK population)

Baseline Renal Impairment Category

<!-- image -->

Abbreviation:  PK=pharmacokinetics.

Note:  Renal Function categories:  normal renal function:  eGFR ≥90 mL/min/1.73 m 2 ; mild renal impairment:  eGFR ≥60 to &lt;90 mL/min/1.73 m 2 ; moderate renal impairment:  eGFR ≥30 to &lt;60 mL/min/1.73 m 2 ; severe renal impairment: eGFR ≥15 and &lt;30 mL/min/1.73 m 2 .

## Hepatic impairment

The impact of impaired hepatic function was evaluated in HELIOS B by comparing the PK and PD of vutrisiran in HELIOS-B patients with mild hepatic impairment (bilirubin ≤ upper limit of normal (ULN) and aspartate transaminase (AST) &gt; ULN; or ULN &lt; bilirubin ≤ 1.5 × ULN, National Cancer Institute Organ Dysfunction Working Group [NCI-ODWG] classification [Patel 2004]) or moderate (bilirubin &gt;1.5 to 3 × ULN, NCI ODWG classification) relative to patients with normal hepatic function (bilirubin ≤ ULN and AST ≤ ULN).  None of the patients had severe hepatic impairment at baseline. (Figure 4) Overall, the plasma PK of vutrisiran was comparable in patients with mild or moderate hepatic impairment and those with normal hepatic function:

- Plasma C4h of vutrisiran at Month 30 was comparable for patients with normal hepatic function and those with mild or moderate hepatic impairment (Figure 4).

<div style=\"page-break-after: always\"></div>

Figure 4. HELIOSB: Vutrisiran plasma concentrations 4 hours postdose at month 30 by hepatic impairment category (PK population)

<!-- image -->

Baseline Hepatic Impairment Category

Abbreviation:  PK=pharmacokinetics.

Vutrisiran  has  not  been  studied  in  patients  with  severe  hepatic  impairment,  patients  with  severe  renal impairment, or patients with end-stage renal disease.

## Extrinsic factors

Drug-Food Interactions

No studies were conducted to evaluate drug-food interactions because vutrisiran is administered SC.

## Drug-Drug Interactions

Dedicated drug-drug interaction studies in humans have not been performed with vutrisiran as it is not a substrate, inhibitor, or inducer of cytochrome P450 (CYP) enzymes or transporters and is not expected to cause  clinical  drug-drug  interactions  or  to  be  affected  by  inhibitors  or  inducers  of  CYP  enzymes  or transporters.

Baseline Tafamidis Use

Tafamidis use at baseline had no effect on the PK of vutrisiran.

## 2.3.3. Pharmacodynamics

## Mechanism of action

Vutrisiran  is  an  RNAi  therapeutic  comprised  of  a  synthetic,  chemically  modified,  double-stranded  small interfering RNA (siRNA) that specifically targets variant and wtTTR and silences TTR messenger RNA (mRNA).

<div style=\"page-break-after: always\"></div>

This is accomplished by incorporation of vutrisiran siRNA into the cellular multiprotein enzyme cleavage complex known as the RNA induced silencing complex (RISC). Based on the mechanism of RNA interference, vutrisiran is specifically designed to reduce the hepatic synthesis of variant and wt TTR protein

## Primary and secondary pharmacology

Primary and secondary pharmacodynamic effects of vutrisiran have been investigated in three clinical trials. A dose dependent reduction of TTR with a prolonged effect even after single doses was found.

## Serum TTR

Vutrisiran administration resulted in rapid and sustained reduction of TTR in patients with ATTR amyloidosis with cardiomyopathy (Figure 5).

Median TTR percent reduction from baseline was 69.0% at Week 6 and 68.6% at Month 3. Additional TTR lowering was observed with repeat q3M dosing leading to median steady-state trough TTR percent reductions of 82.5% during the period between Month 6 to Month 30. At Month 30, the median TTR percent reduction from baseline was 86.8% in the vutrisiran group and 7.9% in the placebo group.

Figure 5. HELIOS-B: mean (±SEM) percent change from baseline in serum TTR (ELISA) by visit during the DB period (PD analysis set)

<!-- image -->

Abbreviations: DB=double-blind; ELISA=enzyme-linked immunosorbent assay; PD=pharmacodynamic; SEM=standard error of the mean; TTR=transthyretin.

The PD effect of vutrisiran over time was similar between HELIOS A and HELIOS B. Overall (Figure 6), a durable and stable reduction of TTR has been established with corresponding secondary reductions of vitamin A, with 99% of predicted steady-state values reached by Month 18.

These results already established for hATTR patients with polyneuropathy have been confirmed in study Helios B for ATTR amyloidosis patients with cardiomyopathy.

<div style=\"page-break-after: always\"></div>

Figure 6. Mean (±SD) percent change in TTR from baseline

<!-- image -->

## Intrinsic factors

Intrinsic factors such as sex, race, age, body weight, genotype, NYHA class, and mild to moderate renal impairment and hepatic impairment, and the extrinsic factor of tafamidis use did not meaningfully influence the PD of vutrisiran.

## Renal impairment

## Impact on PD (in HELIOS B)

Overall, the PD of vutrisiran were comparable in patients with mild or moderate renal impairment and those with normal renal function:

- Median baseline TTR levels were comparable across renal function categories (refer to 2.7.2 PKPD Figure 12.22).
- At Month 30, median absolute TTR and percent change from baseline in TTR were similar for patients with normal renal function and those with mild and moderate renal impairment (Figure 7).
- There was one patient with baseline severe renal impairment; the absolute and percent change in TTR from baseline for this patient was in the range of the other 3 groups (Figure 7).

<div style=\"page-break-after: always\"></div>

Figure 7. HELIOS-B: Vutrisiran month 30 absolute TTR concentrations and percent change from baseline in TTR by renal impairment category (PD population)

Change from Baseline i

<!-- image -->

Baseline Renal Impairment Category

Abbreviations:  PD=pharmacodynamic; TTR=transthyretin. Source:  2.7.2 PKPD Figure 12.23 and Figure 12.24

Hepatic impairment

## Impact on PD (HELIOS B)

Overall, the PD effect of vutrisiran was comparable in patients with mild or moderate hepatic impairment and those with normal hepatic function:

- Baseline TTR levels were comparable in patients with mild or moderate hepatic impairment and those with normal hepatic function (refer to 2.7.2 PKPD Figure 12.25).
- Absolute serum TTR and TTR percent change from baseline values for patients with mild hepatic impairment was similar to patients with normal hepatic function (Figure 8).
- The TTR percent reduction from baseline at Month 30 for patients with moderate hepatic impairment was lower (73.9%) compared to patients with mild hepatic impairment (89.1%) and normal hepatic function (86.8%) (refer to 2.7.2 PKPD Table 6.9).
- -However, this difference may be attributable to the smaller number of patients with moderate hepatic impairment (n=8), and the observed values overlapped with the values for patients with normal and mild hepatic impairment.

<!-- image -->

Baseline Renal Impairment Category

<div style=\"page-break-after: always\"></div>

Figure 8. HELIOS-B: Vutrisiran month 30 absolute TTR concentrations and percent change from baseline in TTR by hepatic impairment category (PD population)

<!-- image -->

TTR Change from Baseline i %

Baseline Hepatic Impairment Category

Abbreviations:  PD=pharmacodynamic; TTR=transthyretin. Source:  2.7.2 PKPD Figure 12.26 and Figure 12.27

## Extrinsic factors

Baseline Tafamidis Use

At Month 30, absolute TTR concentrations and percent change from baseline in TTR were comparable in patients with and without background tafamidis use (Figure 9).

<!-- image -->

Baseline Hepatic Impairment Category

<div style=\"page-break-after: always\"></div>

Figure  9.  Serum  TTR  and  percent  change  in  TTR  from  baseline  in  HELIOS  B  by  background Tafamidis use category

<!-- image -->

Background Tafamidis Use Category

## Vitamin A (Helios B)

Patients were advised to take the recommended daily allowance of vitamin A, as included in the approved vutrisiran product labelling for patients with hATTR amyloidosis with polyneuropathy.

In the overall population, the median percent change from baseline in vitamin A levels at Month 12 was -66.7% in the vutrisiran group and 4.3% in the placebo group. At Month 36, the median percent change from baseline was -70.6 in the vutrisiran group and 0% in the placebo group.

## Immunogenicity

The potential for vutrisiran to elicit an immune response was evaluated by measuring ADA titers against vutrisiran drug substance in all clinical studies.

In HELIOS-B, the incidence of treatment-emergent ADA was 0.3% (1/313) in the vutrisiran group and 0.9% (3/322)  in  the  placebo  group.  Titers  were  low  (50)  and  transient  with  patients  testing  negative  at  a subsequent visit. One patient with treatment-emergent ADA in the placebo group died before their next ADA assessment.

In addition, a comprehensive immunogenicity assessment was conducted using data across the vutrisiran development  program  including  healthy  volunteers  (Study  001),  patients  with  hATTR  amyloidosis  with polyneuropathy (HELIOS-A), and patients with ATTR amyloidosis with cardiomyopathy (HELIOS-B). Across the clinical studies, a total of 1.2% (6/493) vutrisiran participants had low-titer (50), treatment-emergent ADA due to vutrisiran. Antidrug antibody positivity was transient, with most participants testing negative at a subsequent sampling timepoint.

There were no instances of treatment-boosted ADA.

In the rare occasion when ADA were detected, they did not affect the PK or PD profile of vutrisiran in HELIOSB (Figure 10).

Impact of ADA on Pharmacodynamics

Background Tafamidis Use Category

<div style=\"page-break-after: always\"></div>

Individual TTR profiles in ADA positive patients were similar to those seen in ADA negative patients indicating no clinically meaningful impact of ADA on pharmacodynamics of vutrisiran.

Impact of ADA on Pharmacokinetics

Individual  vutrisiran  plasma  concentrations  over  time  are  provided  for  ADA  positive  vutrisiran-treated patients in Figure 10. Plasma concentrations of vutrisiran were comparable in ADA positive and ADA negative patients at all post-baseline time points, indicating no impact of ADA on vutrisiran PK.

Figure 10. Individual Vutrisiran plasma concentrations (µg/mL) over time by ADA status during the DB period (Vutrisiran treated patients, PK population)

<!-- image -->

Abbreviations:  ADA=antidrug  antibody;  C4h=vutrisiran  plasma  concentrations  4  hours  postdose;  DB=double-blind; neg=negative; PK=pharmacokinetic; pos=positive.

## 2.3.4. Discussion on clinical pharmacology

Vutrisiran  drug  substance  (ALN-65492)  is  a  chemically  synthesized  double-stranded  oligonucleotide conjugated to a triantennary GalNAc moiety through a phosphodiester linkage at the 3'-end of the sense strand. The overall clinical development program of vutrisiran consists of a clinical pharmacology study in healthy volunteers (Study 001), a Phase 3 study of patients with hATTR amyloidosis with polyneuropathy (HELIOS-A), and a Phase 3 study of patients with ATTR amyloidosis with cardiomyopathy (HELIOS-B). The first two studies were assessed in the initial application for hATTR-PN and the third study is the focus of the current application.

HELIOS-B is an ongoing, Phase 3, randomized (1:1), double-blind (DB), placebo-controlled, multicenter study designed to evaluate efficacy, safety, PK, and PD of vutrisiran in adult patients with wtATTR and hATTR amyloidosis with cardiomyopathy that considers a completed, randomized, placebo-controlled DB Period for up to  36  months  and  an  ongoing  24-month  open-label  extension  (OLE)  Period.  Plasma  samples  for  PK analysis were made at Day 1, Week 36, Week 72 (Month 18), and Week 132 (Month 30) at pre-dose and 4 h after dose during the double-blind period and at 3h and 6h after dosing in the Open-label Treatment Extension (OLE) Period.

<div style=\"page-break-after: always\"></div>

The used analytical method - LC/MS-HRAM - is the same that was assessed in the original application being considered acceptable.

The PK of vutrisiran in plasma and urine from individual studies was characterized using non-compartmental analysis (NCA). This is acceptable. Vutrisiran C4h at different visits during the DB Period were similar, and C4h values at steady-state (Month 30) were similar to their respective first dose values, indicating lack of accumulation of vutrisiran in plasma after q3M dosing of 25 mg. Plasma concentrations of vutrisiran were comparable in ADA positive and ADA negative patients at all postbaseline time points indicating no impact of ADA on vutrisiran PK. Plasma PK of vutrisiran was comparable between male and female patients, different races, across age quartiles (&lt;72, ≥ 72 to &lt;77, ≥ 77 to &lt;81, and ≥ 81 years) and between wtATTR and hATTR (including all genotypes) amyloidosis patients. The plasma PK of vutrisiran was lower across higher baseline body weight quartiles (&lt;72 kg, ≥ 72 to &lt;79.5 kg, ≥ 79.5 to &lt;87.2 kg, and ≥ 87.2 kg) but without any PD relevant difference, like also observed in the HELIOS-A study. Overall, the plasma PK of vutrisiran was comparable in patients with mild or moderate renal impairment and those with normal renal function and was also comparable in patients with mild or moderate hepatic impairment and those with normal hepatic function. Since vutrisiran is metabolized by endo- and exo-nucleases and it is not a substrate, inhibitor, or inducer of CYP enzymes or transporters, it is not expected to cause clinical DDI, or to be affected by inhibitors or inducers of CYP enzymes or transporters. As such, no formal clinical DDI studies have been performed. In  any  case,  Plasma  C4h  values  for  vutrisiran  at  Month  30  were  similar  for  patients  with  and  without background tafamidis use at baseline. Overall, this is acceptable.

Regarding the comparison between studies, vutrisiran plasma concentrations 3 to 4 hours after the first dose were comparable across all 3 studies indicating similarity of PK in healthy volunteers, hATTR patients with polyneuropathy, and ATTR amyloidosis patients with cardiomyopathy.

Overall, it is agreed that the PK of vutrisiran is similar in the 3 studies and, thus, between healthy, patients with hATTR amyloidosis with polyneuropathy and patients with ATTR amyloidosis with cardiomyopathy. More detailed comparison of PK/PD data between HELIOS-A and HELIOS-B were provided indicationg no relevant differences between the two populations.

In HELIOS-B, the trough observed median percent TTR reduction from baseline at Month 30 was 86.8%. This sustained TTR reduction was comparable to the reduction previously observed with vutrisiran in patients with hATTR amyloidosis with polyneuropathy (HELIOS-A), as well as comparable to the reduction previously observed with patisiran in patients with hATTR amyloidosis with polyneuropathy (APOLLO).

## 2.3.5. Conclusions on clinical pharmacology

Intrinsic factors such as sex, race, age, body weight, genotype, NYHA class, and mild to moderate renal impairment and hepatic impairment, and the extrinsic factor of tafamidis use did not meaningfully influence the PK or PD of vutrisiran, indicating that the recommended dose regimen of 25 mg q3M is appropriate for all subgroups of ATTR amyloidosis patients with cardiomyopathy.

Vutrisiran  has  not  been  studied  in  patients  with  severe  hepatic  impairment,  patients  with  severe  renal impairment, or patients with end-stage renal disease.

Collectively,  the  results  of  Studies  001,  HELIOS-A,  and  HELIOS-B  support  the  recommended  vutrisiran dosing regimen of 25 mg administered q3M across all subgroups. No dose adjustment is necessary for any of the subpopulations studied.

In the occasion when ADA were detected, they did not affect the PK or PD profile of vutrisiran in HELIOS-B.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

The  same  dose  and  dosing  regimen  as  administered  in  HELIOS  A  supporting  the  initial  marketing authorisation was applied in HELIOS B.  The dose and dosing frequency for vutrisiran (25 mg q3M) were selected  to  achieve  TTR  reduction  with  minimal  peak-to-trough  fluctuation  over  the  dosing  interval. Reference is made to the EPAR (EMA/CHMP/689555/2022):

' Selection of the dosing regimen for vutrisiran was supported by TTR reduction data from the Phase 1 Study 001  in  healthy  subjects.  Additionally,  a  PK/PD  modeling  approach  was  employed  by  the  Applicant  to characterize the dose-TTR reduction property of vutrisiran and determine the optimal dosing regimen for the Phase 3 studies in patients. Adequacy of the selected Phase 3 dosing regimen was confirmed in the HELIOS-A study in patients with hATTR amyloidosis with polyneuropathy, where median steady-state trough TTR reduction of 85% was observed together with improvement of neurological disease manifestations at Month 9 (please see relevant  Clinical  Efficacy  sections).  […]  the  25  mg  q3M  regimen  of  vutrisiran  was predicted to provide sustained TTR reduction over the 3-month dosing interval similar to the observed TTR reduction profiles with intravenous 0.3 mg/kg q3w patisiran in the APOLLO study and it was well-tolerated. Intrinsic and extrinsic factors did not appear to influence the recommended fixed dose regimen of 25 mg q3M. It is noted, however, that a prefilled syringe equipped with a passive needle safety system (PFS-S) was used in HELIOS-A and it is intended for marketing. The phrase in section 4.2 of the SmPC 'Therapy should be initiated under the supervision of a physician knowledgeable in the management of amyloidosis' is acknowledged.

## 2.4.2. Main study(ies)

ALN-TTRSC02-003, IND Number: 141923, EudraCT Number: 2019-003153-28

## Title of Study

HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

## Methods

Study Initiation Date: 26 November 2019

Primary Analysis Data Cutoff Date: 08 May 2024

Primary Analysis Database Lock Date: 14 June 2024

Sponsor: Alnylam Pharmaceuticals, Inc. 300 Third Street Cambridge, MA 02142 USA

It was a multinational multicenter study conducted in 87 study centers in 26 countries in North America, South America, Europe, Asia, and Australia.

An external independent Data monitoring committee (DMC) was involved in the conduct of this study. The role of the DMC was to provide an independent review and assessment of accumulating safety data in order to further safeguard the interests and safety of the participating patients.

<div style=\"page-break-after: always\"></div>

Through the data cutoff date for the primary analysis, an independent Clinical Events Committee (CEC) reviewed deaths, hospitalizations, and urgent heart failure (HF) visits blinded to treatment assignment on an  ongoing  basis  for  endpoint  adjudication.  The  CEC  made  a  determination  on  whether  deaths  and hospitalizations could be attributed as cardiovascular (CV).

It is an ongoing Phase 3, randomized (1:1), DB, placebo-controlled, multicenter study evaluating the efficacy and safety of vutrisiran in 655 randomized patients with ATTR amyloidosis (hATTR or wtATTR amyloidosis) with cardiomyopathy. The study design is shown in Figure 11. Patients were stratified by baseline tafamidis use

Figure 11. Study design

<!-- image -->

Abbreviations: DB=double-blind; OLE=open-label extension; q3M=once every 3 months; SC=subcutaneous.

- a An individual patient's DB Treatment Period visits end after they complete their Month 36 visit, or 30 months after the last patient was randomized, whichever comes first. As such, a patient's last visit during the DB Treatment Period may have varied from 30 to 36 months after enrollment, and the first dose in the OLE Period was Month 33 or 36. The DB exposure period was 33 to 36 months and is referred to as the DB Period.
- b The dosing schedule is 25 mg vutrisiran every 12 weeks. Upon entry into the OLE Period (OLE Day 1), all eligible patients received open-label doses of 25 mg q3M vutrisiran administered as SC injections.
- c Following completion of the OLE Period (or completion of the DB Period for patients who did not continue into the OLE Period; or their last dose of vutrisiran for patients who discontinued study drug early), patients will commence Follow-up visits. For women of child-bearing potential, the duration of the Follow-up Period will be up to 18 months from their last dose of study drug.

After  screening,  eligible  patients  were  randomized  in  a  1:1  ratio  to  receive  blinded  doses  of  25  mg  of vutrisiran or placebo administered as an SC injection q3M (every 12 weeks ±7 days) for up to 36 months in the DB Period.

During the OLE Period, all patients receive open-label doses of 25 mg q3M vutrisiran administered as SC injections.

With Protocol Amendment 3 (13 May 2022), an Open-label Randomized Treatment Extension (RTE) Period was added wherein patients were randomized 1:1 to receive treatment with either 25 mg q3M vutrisiran or 50 mg once every 6 months (q6M) vutrisiran. With Protocol Amendment 4 (22 March 2023), the study design was revised to replace the 2-arm RTE Period with a single-arm OLE Period, and all patients in the 50 mg q6M vutrisiran group were transitioned to the 25 mg q3M vutrisiran regimen.

<div style=\"page-break-after: always\"></div>

Following completion of the OLE Period (or completion of the DB Period for patients who did not continue into the OLE Period; or their last dose of vutrisiran for patients who discontinued study drug early), patients commenced follow-up visits every 12 weeks for up to 1 year or up to 18 months for women of child-bearing potential.

In addition to study drug, all patients were instructed to take the recommended daily allowance of vitamin A in their country or region during their DB, OLE, and Follow-up Periods.

## Study participants

Key Inclusion Criteria

Patients were eligible to be included in the study if all the following criteria applied:

Age

1. Age 18 (or age of legal consent per local regulations, whichever was older) to 85 years, inclusive.

Patient and Disease Characteristics

2. Documented diagnosis of ATTR amyloidosis with cardiomyopathy, classified as either hATTR amyloidosis with cardiomyopathy or wtATTR amyloidosis with cardiomyopathy:

a.  Hereditary  ATTR  amyloidosis  with  cardiomyopathy  diagnosed  based  on  meeting  all  of  the  following criteria:

i. Documentation of a TTR pathogenic mutation consistent with hATTR amyloidosis.

ii.  Evidence of cardiac involvement by echocardiography with an end-diastolic interventricular septal wall thickness &gt;12 mm (based on central echocardiogram reading at Screening).

iii.  Amyloid deposits in cardiac or noncardiac tissue (e.g., fat pad aspirate, salivary gland, median nerve connective sheath) confirmed by Congo Red (or equivalent) staining OR technetium (99mTc) scintigraphy (99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid [DPD-Tc], 99mTc-pyrophosphate [PYP-Tc] or 99Tchydroxymethylene diphosphonate [HMDP]) with Grade 2 or 3 cardiac uptake, if MGUS had been excluded.

iv. If the patient had evidence of a MGUS based on serum and urine protein electrophoresis and serum free light chains, documentation of TTR protein in tissue with immunohistochemistry or mass spectrometry was required.

b. Wild-type ATTR amyloidosis with cardiomyopathy diagnosed based on meeting all of the following criteria:

i. Documentation of absence of pathogenic TTR mutation.

ii.  Evidence of cardiac involvement by echocardiography with an end-diastolic interventricular septal wall thickness &gt;12mm (based on central echocardiogram reading at Screening).

iii.  Amyloid  deposits  in  cardiac  tissue  with  TTR  protein  identification  by  IHC,  mass  spectrometry,  OR technetium (99mTc) scintigraphy (99mTc-3,3-diphosphono-1,2propanodicarboxylic acid [DPD-Tc], 99mTc-pyrophosphate  [PYP-Tc],  or  99Tc-hydroxymethylene  diphosphonate  [HMDP])  with  Grade  2  or  3 cardiac uptake, if MGUS had been excluded.

iv. If the patient had evidence of a MGUS based on serum and urine protein electrophoresis and serum free light chains, the following was required: documentation of TTR protein in cardiac tissue with immunohistochemistry or mass spectrometry; OR, documentation of TTR protein in noncardiac tissue (eg, fat  pad  aspirate,  salivary  gland,  median  nerve  connective  sheath)  with  immunohistochemistry  or  mass spectrometry AND Grade 2 or 3 cardiac uptake on 99mTc scintigraphy per item 2biii above.

<div style=\"page-break-after: always\"></div>

3. Medical history of HF with at least 1 prior hospitalization for HF (not due to arrhythmia or a conduction system  disturbance  treated  with  a  permanent  pacemaker)  OR  clinical  evidence  of  HF  (with  or  without hospitalization) manifested by signs and symptoms of volume overload or elevated intracardiac pressures (e.g., elevated jugular venous pressure, shortness of breath or signs of pulmonary congestion on X-ray or auscultation, peripheral edema) that currently required treatment with a diuretic.

## 4. Patient met one of the following criteria:

- a.  Tafamidis-naïve  and  not  actively  planning  to  commence  treatment  with  tafamidis  during  the  first  12 months following randomization (per exclusion criterion #7)

(Note: in addition to patients who had never taken tafamidis, those who had previously been on tafamidis and had not received any tafamidis for at least 30 days before the Screening visit were considered tafamidisnaïve for purposes of this study); or

- b.  On  tafamidis  (Note:  must  have  been  on-label  use  of  commercial  tafamidis  per  an  approved cardiomyopathy indication and dose in the country of use)
5. Patient was clinically stable, with no CV-related hospitalizations within 6 weeks prior to randomization, as assessed by the Investigator.
6.  Screening  NT-proBNP  &gt;300  ng/L  and  &lt;8500  ng/L;  in  patients  with  permanent  or  persistent  atrial fibrillation, Screening NT-proBNP &gt;600 ng/L and &lt;8500 ng/L.
7. Was able to complete ≥ 150 meters on the 6-MWT at Screening.
8. Had a Karnofsky performance status (KPS) of ≥ 60%.

## among others

## Key Exclusion Criteria

Patients were excluded from the study if any of the following criteria applied:

## Disease-specific Conditions

1. Had known primary amyloidosis (AL amyloidosis) or leptomeningeal amyloidosis.
2. NYHA class IV HF; or NYHA class III HF AND ATTR amyloidosis disease Stage 3 (defined as NT-proBNP &gt;3000 ng/L and eGFR &lt;45 mL/min).
3.  Had  a  polyneuropathy  disability  (PND)  Score  IIIa,  IIIb,  or  IV  (requires  cane  or  stick  to  walk  due  to polyneuropathy, or is wheelchair bound) at the Screening visit.

## Laboratory Assessments

4. Had any of the following laboratory parameter assessments at Screening:
- a. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels &gt;2.0× upper limit of normal (ULN),
- b. Total bilirubin &gt;2.0×ULN,
- c. International normalized ratio (INR) &gt;1.5 (unless patients were on anticoagulant therapy in which case excluded if INR ˃ 3.5).
5. Had eGFR &lt;30 mL/min/1.73m 2  (using the modification of diet in renal disease formula) at Screening.
6. Had known human immunodeficiency virus infection; or evidence of current or chronic hepatitis C virus or hepatitis B virus infection.

<div style=\"page-break-after: always\"></div>

## Prior/Concomitant Therapy

7.  Tafamidis-naïve  patients  (per  inclusion  criterion  #4a)  for  whom  the  Investigator  actively  planned  or anticipated commencing treatment with tafamidis either during the Screening Period or the first 12 months following  randomization,  taking  into  consideration  clinical  status,  patient  preference  and/or  commercial availability of tafamidis.

8. Received prior TTR-lowering treatment (including revusiran, patisiran or inotersen) or participated in a gene therapy trial for hATTR amyloidosis.

among others

Medical Conditions

14. Other non-TTR cardiomyopathy, hypertensive cardiomyopathy, cardiomyopathy due to valvular heart disease, or cardiomyopathy due to ischemic heart disease (e.g., prior myocardial infarction with documented history of cardiac enzymes and electrocardiogram [ECG] changes) that the Investigator felt was a significant contributor or the predominant cause of the patient's HF.

15.  Unstable  CHF  (including  patients  who  required  adjustment  of  existing  diuretics  or  addition  of  new diuretics at time of Screening for purposes of achieving optimal management of CHF).

16. Had acute coronary syndrome or unstable angina within the past 3 months.
17. Had history of sustained ventricular tachycardia or aborted ventricular fibrillation.

18. Had history of atrioventricular nodal or sinoatrial nodal dysfunction for which a pacemaker is indicated but will not be placed.

19. Had persistent elevation of systolic ( ˃ 170 mmHg) or diastolic ( ˃ 100 mmHg) blood pressure that was considered uncontrolled by physician.

among others

Instances on when to discontinue study drug or study participation were pre-specified.

## Treatments

Study drug (vutrisiran or placebo) was to be administered using single-use prefilled syringes. Each prefilled syringe is filled with either a 25 mg dose of vutrisiran or placebo with a fill volume of 0.5 mL. Each prefilled syringe includes a needle safety device which engaged to cover the exposed needle after injection.

During the DB Period, patients received 25 mg of vutrisiran or placebo administered as an SC injection q3M (every 12 weeks ±7 days) for up to 36 months.

During the OLE Period, patients were originally randomized 1:1 to receive treatment with either 25 mg q3M vutrisiran or 50 mg q6M vutrisiran; however, with Protocol Amendment 4 (22 March 2023), all patients will receive 25 mg of vutrisiran administered as an SC injection q3M (every 12 weeks ±7 days) for up to 2 years.

The Pharmacy Manual provided further details of study drug administration.

As of the data cutoff date (08 May 2024), the following study drug product lot numbers have been used in the study:

Vutrisiran: ADASA01, ADATA01, ADATJ03, ADATL05, ADAUH06, ADAUC02, ADAVI02, ADAWB01

Placebo: ADPSA02, ADPTA02, ADPTJ04, ADPVE01

<div style=\"page-break-after: always\"></div>

In addition to other investigations drugs the following prior and concomitant medications were prohibited:

tauroursodeoxycholic acid, and non-dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem) are also prohibited during the study. Doxycycline was permitted if being taken for short-term treatment of infection.

Topical steroids were not to be applied anywhere near the injection site(s) unless medically indicated.

All  patients  were asked to take the recommended daily allowance of vitamin A for the duration of their participation in the study while being administered study drug.

## Concomitant Tafamidis use:

Patients who were on tafamidis at baseline (background tafamidis subgroup) as per inclusion criteria were encouraged, if it was medically appropriate in the opinion of the Investigator, to remain on tafamidis for the duration of the study.

Initiating on-label use of tafamidis in previously naïve patients during the study (tafamidis drop-in) was allowed in countries where tafamidis was approved and commercially available in this patient population.

Compliance with study drug administration was to be verified through oversight by study staff or trained home healthcare professionals.

Doses with a delay of more than 8 weeks were considered 'missed' and not administered. Delayed doses within the 8 week frame were considered 'delayed'.

## Objectives and Outcomes/endpoints

Table 2 summarises the objectives and the respective predefined endpoints.

<div style=\"page-break-after: always\"></div>

Table 2. Study objectives and endpoints

| Objectives                                                                                                                                                                                                                                                                                                               | Endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| To evaluate the efficacy of vutrisiran compared to placebo on reducing all-cause mortality and CV events                                                                                                                                                                                                                 | Composite outcome of all-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) in the overall population Composite outcome of all-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) in the vutrisiran monotherapy subgroup (defined as the group of patients not on tafamidis at study baseline)                                                                                                                                                                                                  |
| Secondary                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| To evaluate the efficacy of vutrisiran compared with placebo treatment on: Functional capacity Patient-reported health status and health-related quality of life All-cause mortality Severity of clinical heart failure symptoms                                                                                         | The following secondary endpoints were defined in both the overall population and the vutrisiran monotherapy subgroup: Change from baseline in 6-MWT Change from baseline in the KCCQ-OS All-cause mortality Change from baseline in NYHA class                                                                                                                                                                                                                                                                                                                 |
| Exploratory                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| To evaluate the efficacy of vutrisiran compared with placebo treatment on:  Additional assessments of death, hospitalizations, and urgent HF visits Additional biomarkers and biomarker-based risk assessments Cardiac structure and function Concomitant use of heart failure medication Assessments of quality of life | Composite outcome of all-cause mortality and recurrent all-cause hospitalizations and urgent HF visits Time to first CV event (including CV hospitalizations and urgent HF visits) or all-cause mortality Time to second CV event (including CV hospitalizations and urgent HF visits) or all-cause mortality Time to first CV event (including CV hospitalization, urgent HF visit and any initiation of SGLT2 inhibitor due to cardiac disease progression), or all-cause mortality Time to first oral diuretic intensification, first CV event (including CV |

<div style=\"page-break-after: always\"></div>

The secondary endpoints were change from baseline in 6-MWT/KCCQ-OS at Month 30 (Week 132), allcause mortality in the DB Period and 6 months of the OLE Period, and change from baseline in NYHA class at Month 30 (Week 132).

Unless otherwise noted, all-cause mortality included heart transplantation and LVAD placement; recurrent CV events included CV hospitalizations and urgent HF visits.

For exploratory endpoints see results below.

PK, Pharmacodynamic and Anti Drug Antibody Evaluations

See PK/PD above. The PD parameters measured in HELIOS-B were serum TTR and vitamin A.

## Sample size

Based on the following assumptions and the actual enrollment of 655 patients randomized (654 patients dosed), the study had approximately 80% power in both the overall population and the vutrisiran monotherapy subgroup to detect a difference between the treatment groups using a modified AndersenGill model with a robust variance estimator, with a 2-sided α = 0.05:

- In the monotherapy subgroup, vutrisiran provided a 25% reduction in mortality rates and a 35% reduction in recurrent CV event rates compared to placebo over 30 months; 0.34 CV events per patientyear and 25% mortality rate at Month 30 were assumed in the placebo group.
- In the background tafamidis subgroup, vutrisiran plus tafamidis provided a 10% reduction in mortality rates and a 15% reduction in recurrent CV event rates compared to placebo plus tafamidis over 30 months; 0.24 CV events per patient-year was assumed in the placebo plus tafamidis group.
- A 9-month and 18-month delay to effect on CV events and death in both subgroups, respectively.
- In the vutrisiran monotherapy subgroup, approximately 20% of patients in both arms initiate tafamidis anytime during the first 24 months on study.
- CV events and mortality data were collected up to 36 months and no more than 15% of patients on both arms are lost to follow-up.

The estimates for death and recurrent CV event rates in the placebo arm (patients randomized to placebo in the tafamidis-naïve strata), and estimates for the reduction in these events for tafamidis (patients randomized to placebo in the baseline tafamidis strata) versus placebo, were based on published results from the tafamidis Phase 3 ATTR-ACT study [Maurer 2018], the patisiran Phase 3 APOLLO-B study [Maurer 2023], and the Phase 3 ATTRibute-CM study with acoramidis [Gillmore 2024]. Power calculations were performed using simulations given that no closed-form sample size estimation solution was available for this study design and primary analysis method.

## Randomisation

Using Interactive Response Technology (IRT), patients were randomized 1:1 to the vutrisiran or placebo arm. Randomization was stratified by:

1. Baseline tafamidis use (yes versus no)
2. ATTR amyloidosis disease type (hATTR versus wtATTR amyloidosis with cardiomyopathy)
3. NYHA class I or II and age &lt;75 years versus all other

<div style=\"page-break-after: always\"></div>

## Blinding (masking)

During the DB Period, all site personnel and patients were blinded to study drug treatment. Vutrisiran and placebo were packaged identically. Because vutrisiran may be visually distinguishable from placebo, the outside of the prefilled syringe barrel was masked in such a way as to hide the identity of the study drug contained within.

All study personnel were blinded to any clinical laboratory results scheduled as part of the study that could potentially unblind them, including TTR levels, vitamin A levels, PK data, and antidrug antibodies (ADA).

As it could affect the blind, patients and their physicians were prohibited from obtaining pre-albumin and vitamin A levels during the DB Period, other than the blinded assessments scheduled in the study, unless clinically indicated and after consultation with the Medical Monitor.

During  the  DB  Period,  Investigators,  study  personnel,  and  the  Sponsor  remained  blinded  to  treatment assignment until after the database lock for the primary analysis.

During the OLE Period, vutrisiran is administered in an open-label fashion.

Procedures related to emergency unblinding were prespecified.

## Statistical methods

## Populations Analyzed:

The following patient populations were evaluated and used for presentation and analysis of the data in this study:

· Full Analysis Set (FAS): All randomized patients who received any amount of study drug. Primary efficacy analyses were based on the FAS. Patients in the FAS were analyzed according to the treatment to which they were randomized.

· Vutrisiran Monotherapy Subgroup FAS (mono-FAS): All patients who were not on tafamidis at the study baseline in the FAS. Patients were analyzed according to the treatment to which they were randomized.

· Safety Analysis Set (SAF): All patients who received any amount of study drug. Safety analyses were based  on  the  SAF.  Patients  were  analyzed  according  to  the  treatment  received.  Patients  who  were randomized to placebo group but received any amount of vutrisiran during the DB Period were grouped into the vutrisiran arm.

· Vutrisiran Monotherapy Subgroup Safety Analysis Set (mono-SAF): All patients who were not on tafamidis at the study baseline in the SAF. Patients were analysed according to the treatment received.

· PK Analysis Set: All patients who received at least 1 full dose of study drug and had at least 1 postdose blood sample for PK parameters and had evaluable PK data. Patients were analyzed according to the first treatment received.

· PD Analysis Set: All patients who received at least 1 full dose of study drug and had an evaluable baseline and at least 1 evaluable postbaseline sample for TTR assessment. Patients were analyzed according to the first treatment received.

· All Vutrisiran Treated Set: All patients who received any amount of vutrisiran during the study, including patients who took vutrisiran during the DB Period and patients who first took placebo during the DB Period and switched to vutrisiran during the OLE Period.

<div style=\"page-break-after: always\"></div>

· Vutrisiran Monotherapy Subgroup All Vutrisiran Treated Set: All patients who were not on tafamidis at the first dose of vutrisiran in All Vutrisiran Treated Set.

Efficacy  endpoints  were  analyzed  using  the  FAS  and  mono-FAS.  As  an  important  subgroup,  efficacy endpoints were also analyzed in the background tafamidis subgroup. In general, the same statistical model was used for analyzing the efficacy endpoint for overall population, the vutrisiran monotherapy subgroup, and the background tafamidis subgroup, with the exception that in the analysis of the overall population, baseline tafamidis use was used as an additional covariate or stratification factor.

The  primary  endpoints  of  all-cause  mortality  and  recurrent  CV  events  were  analyzed  using  a  modified Andersen-Gill  model  with  a  robust  variance  estimator.  The  model  included  treatment  group,  ATTR amyloidosis  disease  type,  NYHA  class,  age  group,  and  baseline  NT-proBNP  as  covariates.  The  overall population analysis was also stratified by baseline tafamidis use.

All-cause mortality was analyzed by log-rank test, stratified by baseline NT-proBNP group. Treatment effect between treatment groups were quantified by Cox proportional hazard model, in which treatment, ATTR amyloidosis disease type, NYHA class, age group, and baseline NT-proBNP were included as covariates. The overall population analyses were also stratified by baseline tafamidis use. The analysis included the vital status data collected after study discontinuation.

The component of recurrent CV events was analyzed by Poisson regression model including treatment, ATTR disease type, NYHA class, age group, and baseline NT-proBNP as covariates, adjusting for the event followup time (i.e., including this duration as an offset). The overall population analysis also included baseline tafamidis use and treatment-by-baseline tafamidis use interaction as covariates. Recurrent CV events were also analyzed using a Joint Frailty Model (JFM) as a sensitivity analysis.

An overview of the sensitivity analyses for the primary endpoint is outlined in Table 3 below.

Table 3. Overview of the sensitivity analyses for the primary endpoint

| Sensitivity Analysis                                               | Analysis Details                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|--------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Win ratio analysis                                                 | Calculated from the ranking of each possible vutrisiran- placebo pair based on survival time and the frequency (count) of CV events in a hierarchical order. Stratification factor: baseline NT-proBNP group Overall population analysis: also stratified by baseline tafamidis use                                                                                                                                                                                                                                                                          |
| Analyses based on alternative definitions of the composite outcome | The same model from the primary analysis was applied. • All-cause mortality: Heart transplant and left ventricular assist device placement were not included in all-cause mortality. Patients were censored at the date of such procedure or at the censoring date, whichever was earlier. • CV events: In addition to the CV events defined in the primary analysis, SGLT2 inhibitor drop-in with cardiac disease progression as reason was treated as a CV event. • CV events: Using CV events per investigator assessment instead of per CEC adjudication |

<div style=\"page-break-after: always\"></div>

| Sensitivity Analysis                                             | Analysis Details                                                                                                                                                                                                                                                             |
|------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis based on the DB and the first 6 months of OLE Period    | The primary endpoints based on data in the DB Period and up to the first 6 months of OLE Period were also analyzed using the same statistical method used for the primary analysis.                                                                                          |
| Analysis based on imputing CV events after study discontinuation | A 2-stage multiple imputation process was used to assess the sensitivity of the primary analysis for any missing CV events due to early study discontinuation.                                                                                                               |
| Analysis based on truncating outliers                            | For patients with >7 events during the DB Period, the first 7 most important events were kept for analysis, with importance ranked in the order of death, CV hospitalization and urgent HF visit. The same model from the primary analysis was applied after the truncation. |

Secondary endpoints were analysed for the overall population and the vutrisiran monotherapy subgroup as summarised in Table 4 below.

Table 4. Secondary endpoints: analysis details

|                  | Secondary Endpoints: Analysis Details                                                                                                                                                                                                                                                                                                                       | Secondary Endpoints: Analysis Details                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Secondary Endpoints: Analysis Details                                                                                     |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|
| Analysis         | Change from baseline in 6-MWT/KCCQ-OS at Month 30                                                                                                                                                                                                                                                                                                           | All-cause Mortality through 42 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Change from baseline in NYHA Class at Month 30 (dichotomized into 2 categories: stable/improved vs worsened)              |
| Primary Analysis | • Performed using a REML based MMRM approach • Model included baseline 6-MWT/KCCQ-OS as a covariate, and treatment, visit, treatment-by-visit interaction, ATTR disease type, and age group as fixed effect terms. • Overall population analysis included baseline tafamidis use and treatment-by- baseline tafamidis use interaction as fixed effect terms | • Survival time was calculated as time from first dose of study drug to last survival follow-up date up to 42 months, regardless of whether the patient entered the OLE Period • Log-rank test, stratified by baseline NT-proBNP group is used to test the difference between vutrisiran and placebo. • Cox PH model with treatment, ATTR disease type, NYHA Class, age group and baseline NT-proBNP as covariates was used to estimate the overall HR and 95% CI. • Adjusted KM curves using inverse probability of | • CMH analysis stratified by baseline NT-proBNP. • Overall population analysis also stratified by baseline tafamidis use. |

<div style=\"page-break-after: always\"></div>

|          | Secondary Endpoints: Analysis Details             | Secondary Endpoints: Analysis Details                                                                                 | Secondary Endpoints: Analysis Details                                                                        |
|----------|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| Analysis | Change from baseline in 6-MWT/KCCQ-OS at Month 30 | All-cause Mortality through 42 months                                                                                 | Change from baseline in NYHA Class at Month 30 (dichotomized into 2 categories: stable/improved vs worsened) |
|          |                                                   | treatment weighting (IPTW) presented • Overall population analysis stratified by baseline tafamidis use (yes vs. no). |                                                                                                              |

Two  pivotal  trials  in  ATTR  amyloidosis  with  cardiomyopathy,  including  ATTR-ACT  and  ATTRibute-CM, indicated that therapeutics with upstream mechanisms of action take approximately 18 months to manifest benefit on mortality. Therefore, the analysis of the secondary endpoint, all-cause mortality, included survival data collected within 6 months after the first dose during the OLE Period (i.e., through 42 months), to improve the precision of estimates and to increase the power to detect a treatment difference.

The missing 6-MWT change from baseline values due to amyloidosis disease progression and death were imputed as the average of 20 random samples with replacement from the worst 10% of observed change from baseline of all patients at the same visit from the same treatment arm and baseline tafamidis use group, capped by 0-baseline distance. After imputation, the change from baseline to Month 30 in 6-MWT was analyzed using a MMRM model. Sensitivity analyses were conducted to assess the impact of missing data and the robustness of the primary analysis using the MMRM model without imputing missing due to death and the pattern mixture model which assumes data is not missing at random.

The overall Type I error rate for the primary endpoints and secondary endpoints was controlled at a 2-sided 0.05 significance level using a prespecified multiplicity testing procedure. The primary endpoint family and the first three secondary endpoint families were tested using a truncated Hochberg test with a truncation fraction of 0.96, and the last secondary endpoint family was tested using a regular Hochberg test. For testing the  primary  endpoint  family,  if  the  larger  p-value  of  the  two  primary  endpoint s  was  ≤0.049,  both  null hypotheses were rejected and the 6-MWT family continued to test; if the larger p-value was &gt;0.049 and the smaller pvalue was ≤0.025, the null hypothesis corresponding to the smaller p -value was rejected and the 6-MWT continued to test defined in the population (at alpha level of 0.001) which was rejected in the primary endpoint testing; if the larger p-value was &gt;0.049 and the smaller p-value was &gt;0.025, both null hypotheses were accepted and the testing procedure was stopped.

<div style=\"page-break-after: always\"></div>

Figure 12. Multiplicity testing procedure for testing primary and secondary endpoints

<!-- image -->

NT-proBNP was prespecified in the SAP as a key factor for adjustment in the outcome endpoint analysis models as it is a well-established risk factor for CV hospitalization and mortality in HF, including ATTR-CM. However, adjustment was not prespecified for  Kaplan-Meier  curves,  as  a  significant  imbalance  was  not anticipated in a randomized study.  After unblinding, due to a significant imbalance in baseline NT-proBNP and troponin I between treatment groups, adjusted Kaplan-Meier curves were generated using the Inverse Probability of Treatment Weighting (IPTW) method for time to event endpoints, including all-cause mortality and time to first CV event or all-cause mortality.  The IPTW-adjusted Kaplan-Meier curve provides a more accurate estimate of survival probabilities by accounting for baseline differences between treatment groups.

## Results

Patient disposition based on the 08 May 2024 data cutoff date, corresponding to the 14 June 2024 database lock date, is presented in Figure 13. Of the 799 patients screened, 655 patients were randomized to either vutrisiran (326 patients) or placebo (329 patients). Of these 655 patients, 1 patient randomized to placebo was not dosed and not included in the FAS (or analysis populations).

<div style=\"page-break-after: always\"></div>

## Participant flow

Figure 13. Disposition of patients

<!-- image -->

Abbreviations: DB=double-blind; OLE=open-label extension.

Note: Patients who discontinued study drug during the DB or OLE Periods could remain in the study to complete safety follow-up.

a One subject who was randomized to placebo but did not receive a dose of study drug is not included in the overall treatment disposition.

Sources: Table 14.1.1.1, Table, 14.1.1.1b, Table 14.1.1.4, and Listing 16.2.1.1

<div style=\"page-break-after: always\"></div>

## Vutrisiran Group

Of the 326 patients in the vutrisiran group, 78 (23.9%) patients discontinued study drug during the DB Period; the most common reasons were death (37 patients), withdrawal by patient (23 patients), and AE (13 patients). Sixty-nine (21.2%) patients stopped study participation during the DB Period; the primary reasons were death (49 patients) and withdrawal by participant (11 patients).

Two hundred and forty-one patients in the vutrisiran group entered the OLE Period. Four (1.2%) patients discontinued study drug during the OLE Period; the primary reasons were death (3 patients) and withdrawal by patient (1 patient). Three (0.9%) patients stopped study participation during the OLE Period; the primary reason for all 3 patients was death.

## Placebo Group

Of the 329 patients in the placebo group, 99 (30.1%) patients discontinued study drug during the DB Period; the most common reasons were death (48 patients), withdrawal by participant (23 patients), and AE (13 patients). Ninety-three (28.3%) patients in the placebo group stopped study participation during the DB Period; the primary reasons were death (63 patients) and withdrawal by participant (15 patients)

Two hundred and twenty-one patients in the placebo group entered the OLE Period. Eight (2.4%) patients discontinued study drug during the OLE Period; the primary reasons were death (6 patients), AE (1 patient), and  withdrawal  by  guardian  (1  patient).  Eight  (2.4%)  patients  in  the  placebo  group  stopped  study participation during the OLE Period; the primary reasons were death (7 patients) and withdrawal by guardian (1 patient).

Patients who discontinued study drug during the DB or OLE Periods could remain in the study to complete safety follow-up.

As of the data cutoff date, 248 patients in the vutrisiran group and 224 patients in the placebo group were still participating in the study.

## Extent of Exposure

## DB Period

In the overall population, the median duration of treatment in the vutrisiran group was 35.78 months (range: 0.6 to 38.7 months), with a cumulative treatment exposure of 833.9 person-years. Two hundred and fiftyseven  (78.8%)  patients  had  vutrisiran  exposure ≥ 30  months,  and  77  (23.6%)  patients  had  vutrisiran exposure ≥ 36 months. The median duration of treatment in the placebo group was 33.77 months (range: 1.1 to 37.3 months), with a cumulative treatment exposure of 822.4 person-years.

In the vutrisiran monotherapy subgroup, the median duration of treatment in the vutrisiran group was 33.28 months (range: 0.6 to 38.2 months), with a cumulative treatment exposure of 472.6 person-years. One hundred and forty-four (73.5%) patients had vutrisiran exposure ≥ 30 months, and 35 (17.9%) patients had vutrisiran exposure ≥ 36 months. The median duration of treatment in the placebo group was 33.15 months (range: 1.1 to 37.0 months), with a cumulative treatment exposure of 474.8 person-years.

## All Vutrisiran Treated Set

For the All Vutrisiran Treated Set, the median duration of vutrisiran exposure was 19.25 months (range: 0.0 to 51.6 months), with a cumulative treatment exposure of 979.7 patient-years. The median duration of treatment  in  the  vutrisiran/vutrisiran  group  was  37.55  months  (range:  0.6  to  51.6  months),  with  a cumulative  treatment  exposure  of  912.3  person-years.  The  median  duration  of  treatment  in  the placebo/vutrisiran  group  was  3.45  months  (range:  0.0  to  15.2  months),  with  a  cumulative  treatment exposure of 67.4 person-years.

<div style=\"page-break-after: always\"></div>

## Recruitment

Patients were randomized and treated at 87 study centers in 26 countries. Countries that randomized ≥ 10 patients  were  US  (165  patients  [25.2%]),  United  Kingdom  (151  patients  [23.1%]),  Spain  (64  patients [9.8%]), Germany (37 patients [5.6%]), France (29 patients [4.4%]), Australia (28 patients [4.3%]), Japan (25  patients  [3.8%]),  Netherlands  (22  patients  [3.4%]),  Portugal  (17  patients  [2.6%]),  Argentina  (16 patients  [2.4%]),  Sweden  (15  patients  [2.3%]),  Norway  (14  patients  [2.1%]),  Denmark  (12  patients [1.8%]), Belgium (11 patients [1.7%]), and Austria (10 patients [1.5%]).

## Conduct of the study

A Data Quality Assurance system was in place with eCRFs, investigators meetings, clinical monitors in place and risk management processes. 12 sites underwent audits for compliance with GCP requirements.

## Protocol Amendments

The protocol was finalized on 22 August 2019. There were 5 global protocol amendments, plus a number of country-specific protocol amendments; the major changes of which are described below:

## Amendment 0.1 (France) 20 May 2020

- -Changes related to Urgent safety measures (USMs) amid the COVID-19 pandemic.

## Amendment 1 (global) 28 May 2020

- -Changes related to Urgent safety measures (USMs) amid the COVID-19 pandemic.
- -Revised primary and secondary objectives and endpoints. The primary composite endpoint of 'allcause mortality and recurrent CV hospitalizations' was changed to 'all-cause mortality and recurrent CV events.' Recurrent CV events include CV hospitalizations and urgent HF visits. The composite secondary endpoint of 'all-cause mortality and recurrent all-cause hospitalizations' was revised to also include urgent HF visits. The secondary endpoint of 'recurrent CV hospitalizations was revised to 'recurrent CV events' to include urgent HF visits.
- -Modified inclusion and exclusion criteria based in part on feedback from regulators and Investigators that the prior criteria would unnecessarily exclude patients with ATTR  amyloidosis with cardiomyopathy for whom the risk benefit profile favors inclusion in the study. The modifications pertained (among others) to documentation of TTR protein in cardiac tissue, allow for lower NTproBNP levels at entry and modification of several exclusion criteria.
- -other changes including exclusion of deaths and hospitalizations due to COVID-19 from all-cause deaths and hospitalizations in the primary analyses of primary and applicable secondary endpoints, and other modifications.

## Amendment 1 (France) 28 May 2020

- -Integration of global amendment 1 into the country specific amendment.

## Amendment 2 (global) 18 February 2021

- -Removed limit of 30% on enrollment of patients receiving tafamidis at study entry.
- -Adjustments to inclusion criteria 4a and 2biv Amendment 3 (global) 13 May 2022
- -and others

<div style=\"page-break-after: always\"></div>

Amendment 3 (global) 13 May 2022

- -Added an Open-label RTE Period to allow a descriptive comparison of 2 vutrisiran dosing regimens administered during this period, 25 mg q3M (the regimen tested during the DB Period) and 50 mg q6M.
- -and others

Amendment 3.1 (United States) 17 May 2022

- -Enabled the collection of clinical data on the use of a single prefilled syringe with a fill volume of 1.0 mL (total dose of 50 mg vutrisiran) for the 50 mg q6M dosing regimen after this presentation of the drug product becomes available for use.
- -and others

Amendment 4 (global) 22 March 2023 and Amendment 4 (United States) 29 March 2023

- -Transitioned all patients in the 50 mg q6M vutrisiran arm of the extension period to receive 25 mg q3M vutrisiran for the remainder of their dosing visits in the study.
- -deletion of the planned interim analysis.
- -and others

## Amendment 5 (global) 12 February 2024

## 2024

- -Expanded  the  analysis  of  the  existing  primary  endpoint  to  include  the  vutrisiran  monotherapy subgroup (defined as the subgroup of patients not on tafamidis at study baseline) in addition to the overall population which was the original analysis.
- -Restructuring the existing secondary and exploratory endpoints.
- -Additional statistical updates
- -and others

Several  Urgent  Safety  Measures  due  to  COVID-19  were  implemented  as  communicated  in  a  Dear Investigator Letter, dated 07 April 2020. These USMs were incorporated into France Amendment 0.1 (dated 20 May 2020) and global Amendment 1 (dated 28 May 2020).

## Baseline data

Baseline demographics were similar for patients in the vutrisiran monotherapy subgroup compared with patients in the overall population. In the overall population, the mean age was 75.4 years (range, 45 to 85 years) and the majority of patients were white (84.4%) and male (92.5%) (Table 5).

Baseline demographic characteristics were similar between the vutrisiran and placebo groups in the overall population and in the vutrisiran monotherapy subgroup.

In the background tafamidis subgroup, the majority of patients, 61.0%, were from the US, whereas in the vutrisiran monotherapy subgroup, only 1.5% were from the US. Other baseline demographics were similar for patients who were on tafamidis at baseline (background tafamidis subgroup) compared with patients who were not on tafamidis at baseline (vutrisiran monotherapy subgroup).

<div style=\"page-break-after: always\"></div>

Baseline disease characteristics are summarized in Table 6.

Baseline disease characteristic were overall balanced between the groups. In the overall population, 578 (88.4%) patients had wtATTR amyloidosis and 76 (11.6%) patients had hATTR amyloidosis. The mean years since diagnosis of ATTR amyloidosis was 1.43 (range, 0.0 to 11.1) years. The mean age of patients at symptom onset was 73.3 (range, 35 to 85) years. Most (77.7%) patients had NYHA class II HF and were classified  as  having  ATTR  amyloidosis  disease  Stage  1  (66.8%)  or  Stage  2  (28.6%).  In  the  overall population,  baseline  disease  characteristics  were  generally  similar  between  the  vutrisiran  and  placebo groups, except for a higher median NT-proBNP level in the vutrisiran group (2020.50 ng/L) compared to the placebo group (1801.00 ng/L), which was primarily driven by an imbalance in the vutrisiran monotherapy subgroup.

In  the  vutrisiran  monotherapy  subgroup,  there  were  some  imbalances  in  parameters  suggestive  of  a somewhat greater disease severity in patients randomized to vutrisiran compared to placebo (NT-proBNP and troponin I, percentage of patients with NT-proBNP &gt;2000 ng/L, ATTR amyloidosis disease Stage and NYHA class, Table 6).

<div style=\"page-break-after: always\"></div>

Table 5. Demographic characteristics for the DB period (full analysis set)

|                              | Overall Population           | Overall Population           | Overall Population           | VutrisiranMonotherapy Subgroup   | VutrisiranMonotherapy Subgroup   | VutrisiranMonotherapy Subgroup   |
|------------------------------|------------------------------|------------------------------|------------------------------|----------------------------------|----------------------------------|----------------------------------|
| Demographic                  | Placebo (N=328)              | Vutrisiran (N=326)           | Total (N=654)                | Placebo (N=199)                  | Vutrisiran (N=196)               | Total (N=395)                    |
| Age at randomization (years) | Age at randomization (years) | Age at randomization (years) | Age at randomization (years) | Age at randomization (years)     | Age at randomization (years)     | Age at randomization (years)     |
| Mean (SD)                    | 75.2 (6.3)                   | 75.5 (7.2)                   | 75.4 (6.7)                   | 75.5 (6.4)                       | 76.3 (6.8)                       | 75.9 (6.6)                       |
| Median (min, max)            | 76.0 (46, 85)                | 77.0 (45, 85)                | 77.0 (45,85)                 | 76.0 (53, 85)                    | 77.5 (46, 85)                    | 77.0 (46, 85)                    |
| Age group (years), n (%)     | Age group (years), n (%)     | Age group (years), n (%)     | Age group (years), n (%)     | Age group (years), n (%)         | Age group (years), n (%)         | Age group (years), n (%)         |
| <65                          | 20 (6.1)                     | 27 (8.3)                     | 47 (7.2)                     | 11 (5.5)                         | 10 (5.1)                         | 21 (5.3)                         |
| 65 to <75                    | 114 (34.8)                   | 96 (29.4)                    | 210 (32.1)                   | 69 (34.7)                        | 63 (32.1)                        | 132 (33.4)                       |
| ≥75                          | 194 (59.1)                   | 203 (62.3)                   | 397 (60.7)                   | 119 (59.8)                       | 123 (62.8)                       | 242 (61.3)                       |
| Sex, n (%)                   | Sex, n (%)                   | Sex, n (%)                   | Sex, n (%)                   | Sex, n (%)                       | Sex, n (%)                       | Sex, n (%)                       |
| Male                         | 306 (93.3)                   | 299 (91.7)                   | 605 (92.5)                   | 183 (92.0)                       | 178 (90.8)                       | 361 (91.4)                       |
| Female                       | 22 (6.7)                     | 27 (8.3)                     | 49 (7.5)                     | 16 (8.0)                         | 18 (9.2)                         | 34 (8.6)                         |
| Race, n (%)                  | Race, n (%)                  | Race, n (%)                  | Race, n (%)                  | Race, n (%)                      | Race, n (%)                      | Race, n (%)                      |
| White                        | 275 (83.8)                   | 277 (85.0)                   | 552 (84.4)                   | 169 (84.9)                       | 169 (86.2)                       | 338 (85.6)                       |
| Black or African American    | 24 (7.3)                     | 23 (7.1)                     | 47 (7.2)                     | 11 (5.5)                         | 10 (5.1)                         | 21 (5.3)                         |
| Asian                        | 19 (5.8)                     | 18 (5.5)                     | 37 (5.7)                     | 15 (7.5)                         | 12 (6.1)                         | 27 (6.8)                         |
| Not reported                 | 8 (2.4)                      | 6 (1.8)                      | 14 (2.1)                     | 2 (1.0)                          | 3 (1.5)                          | 5 (1.3)                          |
| Other                        | 2 (0.6)                      | 2 (0.6)                      | 4 (0.6)                      | 2 (1.0)                          | 2 (1.0)                          | 4 (1.0)                          |
| Ethnicity, n (%)             | Ethnicity, n (%)             | Ethnicity, n (%)             | Ethnicity, n (%)             | Ethnicity, n (%)                 | Ethnicity, n (%)                 | Ethnicity, n (%)                 |
| Not Hispanic or Latino       | 304 (92.7)                   | 298 (91.4)                   | 602 (92.0)                   | 179 (89.9)                       | 171 (87.2)                       | 350 (88.6)                       |
| Hispanic or Latino           | 16 (4.9)                     | 22 (6.7)                     | 38 (5.8)                     | 16 (8.0)                         | 21 (10.7)                        | 37 (9.4)                         |
| Not reported                 | 7 (2.1)                      | 5 (1.5)                      | 12 (1.8)                     | 3 (1.5)                          | 4 (2.0)                          | 7 (1.8)                          |
| Unknown                      | 1 (0.3)                      | 1 (0.3)                      | 2 (0.3)                      | 1 (0.5)                          | 0                                | 1 (0.3)                          |
| Regiona, n (%)               | Regiona, n (%)               | Regiona, n (%)               | Regiona, n (%)               | Regiona, n (%)                   | Regiona, n (%)                   | Regiona, n (%)                   |
| Europe                       | 198 (60.4)                   | 206 (63.2)                   | 404 (61.8)                   | 156 (78.4)                       | 160 (81.6)                       | 316 (80.0)                       |
| US                           | 83 (25.3)                    | 81 (24.8)                    | 164 (25.1)                   | 1 (0.5)                          | 5 (2.6)                          | 6 (1.5)                          |
| Rest of World                | 47 (14.3)                    | 39 (12.0)                    | 86 (13.1)                    | 42 (21.1)                        | 31 (15.8)                        | 73 (18.5)                        |

Abbreviations:DB=double-blind;max=maximum;min=minimum;SD=standard deviation;US=United States.

Note: Baseline is defined as the last non-missing measurement before the first dose in the DB Period.

a Europe includes Austria, Belgium, Croatia, Czech Republic, Denmark, France, Germany, Hungary, Ireland, includes Argentina, Australia, Canada, Israel, Japan, Peru, and South Korea.

Source:Table 14.1.2.1

Table 6. Baseline disease characteristics and ATTR diagnosis during the DB period (full analysis set)

<div style=\"page-break-after: always\"></div>

| Parameter                                                            | Overall Population                                                   | Overall Population                                                   | Overall Population                                                   | Vutrisiran Monotherapy Subgroup                                      | Vutrisiran Monotherapy Subgroup                                      | Vutrisiran Monotherapy Subgroup                                      |
|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
|                                                                      | Placebo (N=328)                                                      | Vutrisiran (N=326)                                                   | Total (N=654)                                                        | Placebo (N=199)                                                      | Vutrisiran (N=196)                                                   | Total (N=395)                                                        |
| ATTR amyloidosis type, n (%)                                         | ATTR amyloidosis type, n (%)                                         | ATTR amyloidosis type, n (%)                                         | ATTR amyloidosis type, n (%)                                         | ATTR amyloidosis type, n (%)                                         | ATTR amyloidosis type, n (%)                                         | ATTR amyloidosis type, n (%)                                         |
| wtATTR amyloidosis                                                   | 289 (88.1)                                                           | 289 (88.7)                                                           | 578 (88.4)                                                           | 174 (87.4)                                                           | 173 (88.3)                                                           | 347 (87.8)                                                           |
| hATTR amyloidosis                                                    | 39 (11.9)                                                            | 37 (11.3)                                                            | 76 (11.6)                                                            | 25 (12.6)                                                            | 23 (11.7)                                                            | 48 (12.2)                                                            |
| Time since ATTR amyloidosis diagnosis (years)                        | Time since ATTR amyloidosis diagnosis (years)                        | Time since ATTR amyloidosis diagnosis (years)                        | Time since ATTR amyloidosis diagnosis (years)                        | Time since ATTR amyloidosis diagnosis (years)                        | Time since ATTR amyloidosis diagnosis (years)                        | Time since ATTR amyloidosis diagnosis (years)                        |
| Mean (SD)                                                            | 1.52 (1.63)                                                          | 1.35 (1.57)                                                          | 1.43 (1.60)                                                          | 1.16 (1.28)                                                          | 1.03 (1.27)                                                          | 1.10 (1.28)                                                          |
| Median (min, max)                                                    | 1.03 (0.0, 10.8)                                                     | 0.86 (0.0, 11.1)                                                     | 0.94 (0.0, 11.1)                                                     | 0.63 (0.0, 6.2)                                                      | 0.50 (0.0, 8.3)                                                      | 0.60 (0.0, 8.3)                                                      |
| Age (years) at ATTR amyloidosis symptom onset, n (%)                 | Age (years) at ATTR amyloidosis symptom onset, n (%)                 | Age (years) at ATTR amyloidosis symptom onset, n (%)                 | Age (years) at ATTR amyloidosis symptom onset, n (%)                 | Age (years) at ATTR amyloidosis symptom onset, n (%)                 | Age (years) at ATTR amyloidosis symptom onset, n (%)                 | Age (years) at ATTR amyloidosis symptom onset, n (%)                 |
| Mean (SD)                                                            | 73.1 (6.7)                                                           | 73.5 (7.5)                                                           | 73.3 (7.1)                                                           | 73.4 (6.7)                                                           | 74.3 (7.3)                                                           | 73.9 (7.0)                                                           |
| Median (min, max)                                                    | 74.0 (44, 85)                                                        | 75.0 (35, 85)                                                        | 74.0 (35, 85)                                                        | 75.0 (52, 85)                                                        | 75.0 (35, 85)                                                        | 75.0 (35, 85)                                                        |
| Baseline tafamidis use n (%)                                         | Baseline tafamidis use n (%)                                         | Baseline tafamidis use n (%)                                         | Baseline tafamidis use n (%)                                         | Baseline tafamidis use n (%)                                         | Baseline tafamidis use n (%)                                         | Baseline tafamidis use n (%)                                         |
| No                                                                   | 199 (60.7)                                                           | 196 (60.1)                                                           | 395 (60.4)                                                           | 199 (100.0)                                                          | 196 (100.0)                                                          | 395 (100.0)                                                          |
| Yes                                                                  | 129 (39.3)                                                           | 130 (39.9)                                                           | 259 (39.6)                                                           | 0                                                                    | 0                                                                    | 0                                                                    |
| Time from start of tafamidis therapy to start of study drug (months) | Time from start of tafamidis therapy to start of study drug (months) | Time from start of tafamidis therapy to start of study drug (months) | Time from start of tafamidis therapy to start of study drug (months) | Time from start of tafamidis therapy to start of study drug (months) | Time from start of tafamidis therapy to start of study drug (months) | Time from start of tafamidis therapy to start of study drug (months) |
| Median (min, max)                                                    | 11.30 (1.1, 65.5)                                                    | 9.18 (1.1, 65.3)                                                     | 10.84 (1.1, 65.5)                                                    | NA                                                                   | NA                                                                   | NA                                                                   |
| NYHA class, n (%)                                                    | NYHA class, n (%)                                                    | NYHA class, n (%)                                                    | NYHA class, n (%)                                                    | NYHA class, n (%)                                                    | NYHA class, n (%)                                                    | NYHA class, n (%)                                                    |
| I                                                                    | 35 (10.7)                                                            | 49 (15.0)                                                            | 84 (12.8)                                                            | 12 (6.0)                                                             | 15 (7.7)                                                             | 27 (6.8)                                                             |
| I                                                                    | 258 (78.7)                                                           | 250 (76.7)                                                           | 508 (77.7)                                                           | 169 (84.9)                                                           | 172 (87.8)                                                           | 341 (86.3)                                                           |
| IⅡI                                                                  | 35 (10.7)                                                            | 27 (8.3)                                                             | 62 (9.5)                                                             | 18 (9.0)                                                             | 9 (4.6)                                                              | 27 (6.8)                                                             |
| NT-proBNP (ng/L)                                                     | NT-proBNP (ng/L)                                                     | NT-proBNP (ng/L)                                                     | NT-proBNP (ng/L)                                                     | NT-proBNP (ng/L)                                                     | NT-proBNP (ng/L)                                                     | NT-proBNP (ng/L)                                                     |
| Median (min, max)                                                    | 1801.00 (317.0, 7988.0)                                              | 2020.50 (322.0, 8892.0)                                              | 1919.50 (317.0, 8892.0)                                              | 1865.00 (335.0, 7988.0)                                              | 2402.00 (370.0, 8892.0)                                              | 2128.00 (335.0, 8892.0)                                              |
| NT-proBNP, n (%)                                                     | NT-proBNP, n (%)                                                     | NT-proBNP, n (%)                                                     | NT-proBNP, n (%)                                                     | NT-proBNP, n (%)                                                     | NT-proBNP, n (%)                                                     | NT-proBNP, n (%)                                                     |
| >2000 ng/L                                                           | 147 (44.8)                                                           | 165 (50.6)                                                           | 312 (47.7)                                                           | 92 (46.2)                                                            | 115 (58.7)                                                           | 207 (52.4)                                                           |

<div style=\"page-break-after: always\"></div>

| Parameter                             | Overall Population                    | Overall Population                    | Overall Population                    | VutrisiranMonotherapy Subgroup        | VutrisiranMonotherapy Subgroup        | VutrisiranMonotherapy Subgroup        |
|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
|                                       | Placebo (N=328)                       | Vutrisiran (N=326)                    | Total (N=654)                         | Placebo (N=199)                       | Vutrisiran (N=196)                    | Total (N=395)                         |
| >3000 ng/L                            | 86 (26.2)                             | 99 (30.4)                             | 185 (28.3)                            | 54 (27.1)                             | 73 (37.2)                             | 127 (32.2)                            |
| Troponin I (ng/L)                     | Troponin I (ng/L)                     | Troponin I (ng/L)                     | Troponin I (ng/L)                     | Troponin I (ng/L)                     | Troponin I (ng/L)                     | Troponin I (ng/L)                     |
| Median (min, max)                     | 65.20 (10.0, 30827.7)                 | 71.90 (10.0, 8712.0)                  | 67.45 (10.0, 30827.7)                 | 62.20 (10.0, 30827.7)                 | 76.25 (10.0, 2304.2)                  | 68.90 (10.0, 30827.7)                 |
| eGFR (mL/min/1.73m2)                  | eGFR (mL/min/1.73m2)                  | eGFR (mL/min/1.73m2)                  | eGFR (mL/min/1.73m2)                  | eGFR (mL/min/1.73m2)                  | eGFR (mL/min/1.73m2)                  | eGFR (mL/min/1.73m2)                  |
| Median (min, max)                     | 65.0 (26, 152)                        | 64.0 (28, 205)                        | 65.0 (26, 205)                        | 65.0 (26, 152)                        | 64.0 (28, 205)                        | 65.0 (26, 205)                        |
| ATTR amyloidosis disease stage, n (%) | ATTR amyloidosis disease stage, n (%) | ATTR amyloidosis disease stage, n (%) | ATTR amyloidosis disease stage, n (%) | ATTR amyloidosis disease stage, n (%) | ATTR amyloidosis disease stage, n (%) | ATTR amyloidosis disease stage, n (%) |
| Stage 1                               | 229 (69.8)                            | 208 (63.8)                            | 437 (66.8)                            | 138 (69.3)                            | 113 (57.7)                            | 251 (63.5)                            |
| Stage 2                               | 87 (26.5)                             | 100 (30.7)                            | 187 (28.6)                            | 55 (27.6)                             | 68 (34.7)                             | 123 (31.1)                            |
| Stage 3                               | 12 (3.7)                              | 18 (5.5)                              | 30 (4.6)                              | 6 (3.0)                               | 15 (7.7)                              | 21 (5.3)                              |

Abbreviations: ATTR=transthyretin-mediated amyloidosis; DB=double-blind; eGFR=estimated glomerular filtration rate; hATTR=hereditary ATTR (amyloidosis); max=maximum; min=minimum; NA=not applicable; NT-proBNP=N-terminal prohormone B-type natriuretic peptide; NYHA=New York Heart Association;

SD=standard deviation; wtATTR=wild-type ATTR (amyloidosis).

Note: Baseline is defined as the last non-missing measurement before the first dose in the DB Period.

Source: Table 14.1.3.1

Baseline disease characteristics were indicative of somewhat greater disease severity among patients not on tafamidis at baseline (vutrisiran monotherapy subgroup) compared with patients who were on tafamidis at baseline (background tafamidis subgroup). Specifically, the proportion of patients in NYHA class I was lower  among  patients  in  the  vutrisiran  monotherapy  subgroup  compared  with  those  in  the  background tafamidis  subgroup  (6.8%  and  22.0%,  respectively),  mean  6-MWT  distance  was  lower  (367.808  and 384.918 meters, respectively), mean KCCQ-OS was lower (70.11 and 76.40, respectively), and median NTproBNP was greater (2128.00 and 1759.00 pg/mL, respectively).

## All Vutrisiran Treated Set

The combination of the vutrisiran/vutrisiran group (N=326) and placebo/vutrisiran group (N=221) comprises the All Vutrisiran Treated Set (N=547).

In the All Vutrisiran Treated Set, 493 (90.1%) patients had wtATTR amyloidosis and 54 (9.9%) patients had hATTR amyloidosis. The majority of patients were NYHA class II (72.8%). In addition, there were 76 (13.9%) patients with NYHA class I and 73 (13.3%) patients with NYHA class III; no patients were class IV. Overall, 48.1% of patients were on tafamidis before their first dose of vutrisiran.

The baseline for the All Vutrisiran Treated Set was defined as the latest assessment prior to the first dose of  vutrisiran.  Thus,  although  disease  severity  was  similar  between  patients  in  the  overall  placebo  and vutrisiran groups at baseline in the DB Period, patients in the placebo/vutrisiran group tended to have more advanced  disease  at  the  time  they  received  their  first  dose  of  vutrisiran  compared  to  patients  in  the vutrisiran/vutrisiran  group,  as  demonstrated  by  an  increased  proportion  of  patients  with  NYHA  class  III (20.8% and 8.3% [overall population] and 23.9% and 4.6% [vutrisiran monotherapy subgroup]).

<div style=\"page-break-after: always\"></div>

## Medical History

## Overall Population

In the overall population, the most frequently reported ( ≥ 50% of patients overall) medical history conditions were in the SOCs of cardiac disorders (99.2%), nervous system disorders (67.7%), metabolism and nutrition disorders and vascular disorders (65.4% each), musculoskeletal and connective tissue disorders (60.6%), and eye disorders (59.3%).

Overall,  35.5%  of  patients  also  had  a  history  of  neuropathy/polyneuropathy.  Of  these,  94.8%  reported sensory neuropathy, 15.5% reported motor neuropathy, and 8.6% reported autonomic neuropathy.

## Vutrisiran Monotherapy Subgroup

In the Vutrisiran Monotherapy Subgroup, the most frequently reported ( ≥ 50% of patients overall) medical history  conditions  were  in  the  SOCs  of  cardiac  disorders  (99.5%),  nervous  system  disorders  (64.3%), vascular disorders (62.5%), metabolism and nutrition disorders (60.3%), musculoskeletal and connective tissue disorders (54.9%), and eye disorders (53.4%),

Overall,  30.1%  of  patients  also  had  a  history  of  neuropathy/polyneuropathy.  Of  these,  93.3%  reported sensory neuropathy, 15.1% reported motor neuropathy, and 10.9% reported autonomic neuropathy.

## Treatment Compliance

## DB Period

In the overall population vutrisiran group, 303 (92.9%) patients had no missed doses of study drug, 16 (4.9%) patients had 1 missed dose, and 7 (2.1%) patients had 2 missed doses. In the overall population placebo group, 311 (94.8%) patients had no missed doses of study drug, 14 (4.3%) patients had 1 missed dose, and 3 (0.9%) patients had 2 missed doses. Treatment compliance was similar for patients in the vutrisiran monotherapy subgroup compared with patients in the overall population.

## All Vutrisiran Treated Set

In the All Vutrisiran Treated Set, 515 (94.1%) patients received all planned doses of study drug, 25 (4.6%) patients had 1 missed dose, and 7 (1.3%) patients had 2 missed doses.

## Protocol Deviations

In  total,  major  protocol  deviations  were  reported  for  157  patients  (87  [26.4%]  placebo,  70  [21.5%] vutrisiran) during the study:

Major protocol deviations by category reported in ≥ 20 patients were:

-  60  major  protocol  deviations  (in  52  patients;  34  [10.3%]  placebo,  18  [5.5%]  vutrisiran)  were  in  the category of Other Protocol Deviation:

-All 60 deviations were related to failure to report SAEs or AEs of clinical interest within 24 hours

- 60 major protocol deviations (in 51 patients; 28 [8.5%] placebo, 23 [7.1%] vutrisiran) were in the category of Informed Consent:

· 25 major protocol deviations (in 24 patients; 12 [3.6%] placebo, 12 [3.7%] vutrisiran) were in the category of Missing Endpoint Assessments.

-All 25 deviations were related to the primary endpoint or secondary endpoint assessments being missed (at baseline or end of DB Period [Month 30]) or that were conducted outside of the analysis window (±3 months).

<div style=\"page-break-after: always\"></div>

o 16 deviations were related to secondary endpoint assessments being missed at baseline or Month 30.

o 9 deviations were related to the duration of the DB Period being truncated at 33 months instead of the planned 36 months.

The remaining major protocol deviations were in the categories of study treatment compliance (15 patients), study procedures assessments (10 patients), eligibility criteria (9 patients), study treatment admin/dispense (9 patients), accidental unblinding (6 patients), and concomitant medication (4 patients)

The remaining deviations were minor.

## Impact of the COVID Pandemic on Study Participation

The impact of the COVID-19 pandemic on study patients was assessed on the basis of missed, delayed or partially completed visits, missed or delayed study drug doses, and visit location changes, such as home health or phone visits.

In the vutrisiran group, 42 (12.9%) patients were reported to have had their study visits or dosing impacted by the COVID-19 pandemic: 39 (12.0%) patients with a missed, delayed, or partially completed visit; 35 (10.7%) patients with any location change; and 11 (3.4%) patients with a missed or delayed dose.

In the placebo group, 49 (14.9%) patients were reported to have had their study visits or dosing impacted by the COVID-19 pandemic: 42 (12.8%) patients with a missed, delayed, or partially completed visit; 32 (9.8%) patients with any location change; and 10 (3.0%) patients with a missed or delayed dose

Impacted visits consisted primarily of partially completed visits, rather than missed or delayed visits, and location changes were mostly home or telehealth visits.

## Numbers analysed

Analysis populations are summarised in Table 7.

Vital status was known for 326 of 326 (100%) vutrisiran patients and for 327 of 328 (99.7%) placebo patients in the overall population at the data cutoff date. The only placebo patient with unknown vital status was censored at approximately Month 30.

<div style=\"page-break-after: always\"></div>

Table 7. Analysis populations

|                                                              | No. of Patients (%)   | No. of Patients (%)   | No. of Patients (%)   |
|--------------------------------------------------------------|-----------------------|-----------------------|-----------------------|
| Study Population                                             | Placebo (N=329)       | Vutrisiran (N=326)    | Overall (N=655)       |
| Full Analysis Set (FAS)                                      | 328 (99.7)            | 326 (100)             | 654 (99.8)            |
| Vutrisiran Monotherapy Subgroup Full Analysis Set (mono-FAS) | 199 (60.5)            | 196 (60.1)            | 395 (60.3)            |
| Safety Analysis Set                                          | 328 (99.7)            | 326 (100)             | 654 (99.8)            |
| Vutrisiran Monotherapy Subgroup Safety Analysis Set          | 199 (60.5)            | 196 (60.1)            | 395 (60.3)            |
| PK Analysis Set                                              | 328 (99.7)            | 326 (100)             | 654 (99.8)            |
| PD Analysis Set                                              | 324 (98.5)            | 317 (97.2)            | 641 (97.9)            |
| All Vutrisiran Treated Set                                   | 221 (67.2)            | 326 (100)             | 547 (83.5)            |
| Vutrisiran Monotherapy Subgroup All Vutrisiran Treated Set   | 88 (26.7)             | 196 (60.1)            | 284 (43.4)            |

Abbreviations: PD=pharmacodynamic; PK=pharmacokinetic.

Source: Table 14.1.1.2

## Outcomes and estimation

## Analysis of efficacy:

The primary analysis complied comparisons in two different populations:

- Target patient population:
- -Overall population: Patients with hATTR or wtATTR amyloidosis with cardiomyopathy regardless of use of tafamidis.
- -Vutrisiran monotherapy subgroup: Patients with hATTR or wtATTR amyloidosis with cardiomyopathy who are tafamidis naïve.

The primary analysis cutoff date was prespecified as the date when all patients had completed at least 33 months of follow-up. Patients enrolled earlier were eligible to enter the OLE Period and received their first OLE dose at Month 36, while those enrolled later received their first OLE dose at Month 33. Two main allcause mortality analyses were conducted using 2 follow-up durations:

Component analysis of all-cause mortality (DB Period; through 36 months):

Survival data were censored at the OLE first dose date for patients who entered the OLE Period, which occurred at approximately 33 or 36 months, depending on the patient's enrollment time. For patients who did not enter the OLE Period, survival data were censored at the earlier of last known alive date or 36 months.

- Secondary endpoint analysis of all-cause mortality (through 42 months): Patients who entered the OLE Period were censored the earlier of last known alive date or 6 months after their first OLE dose, which was approximately 39 or 42 months depending on their first OLE dose date. For patients who did not enter the OLE Period, survival data were censored at the earlier of last known alive date or 42 months.

<div style=\"page-break-after: always\"></div>

Primary Endpoint: Composite Outcome of All-cause Mortality and Recurrent CV Events (CV Hospitalizations and Urgent HF Visits)

Events collected during the DB Period were included for the analyses of the primary endpoints, composite outcome of all-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits).

In the overall population, vutrisiran patients had a statistically significant 28.2% reduction in the risk of allcause mortality and recurrent CV events compared to placebo (hazard ratio: 0.718; 95% CI: 0.555, 0.929; P=0.0118) (Table 8 and Figure 14).

In the vutrisiran monotherapy subgroup, vutrisiran patients had a statistically significant 32.8% reduction in the risk of all-cause mortality and recurrent CV events compared to placebo (hazard ratio: 0.672; 95% CI: 0.487, 0.929; P=0.0162) (Table 9 and Figure 15).

Data in the complementary group of patients on background tafamidis therapy are shown in Table 14.2.1.1 (excerpt) below.

Table 8. Composite outcome of all-cause mortality and frequency of recurrent CV hospitalizations and urgent HF visits over the DB period, modified Andersen-Gill model

|                           | Overall Population   | Overall Population   | Vutrisiran Monotherapy Subgroup   | Vutrisiran Monotherapy Subgroup   |
|---------------------------|----------------------|----------------------|-----------------------------------|-----------------------------------|
| Statistic                 | Placebo (N=328)      | Vutrisiran (N=326)   | Placebo (66I=N)                   | Vutrisiran (N=196)                |
| Total number of events, n | 332                  | 251                  | 211                               | 155                               |
| All-cause mortality, n    | 69                   | 51                   | 46                                | 36                                |
| CV deaths                 | 53                   | 39                   | 34                                | 28                                |
| CV-related                | 37                   | 23                   | 23                                | 18                                |
| Indeterminate             | 12                   | 13                   | 10                                | 10                                |
| Heart transplants         | 4                    | 3                    | 1                                 | 0                                 |
| LVAD placement            | 0                    | 0                    | 0                                 | 0                                 |
| Non-CV deaths             | 16                   | 12                   | 12                                | 8                                 |

<div style=\"page-break-after: always\"></div>

|                                         | Overall Population   | Overall Population   | Vutrisiran Monotherapy Subgroup   | Vutrisiran Monotherapy Subgroup   |
|-----------------------------------------|----------------------|----------------------|-----------------------------------|-----------------------------------|
| Statistic                               | Placebo (N=328)      | Vutrisiran (N=326)   | Placebo (66I=N)                   | Vutrisiran (N=196)                |
| CV events, n                            | 263                  | 200                  | 165                               | 119                               |
| CV hospitalizations                     | 229                  | 178                  | 144                               | 101                               |
| CV-related                              | 224                  | 174                  | 139                               | 97                                |
| Indeterminate                           | ５                    | 4                    | 5                                 | 4                                 |
| Urgent HF visits                        | 34                   | 22                   | 21                                | 18                                |
| Total follow-uptime (years)             | 841.7                | 864.3                | 489.4                             | 495.6                             |
| Patients with ≥1 event, n (%)           | 159 (48.5)           | 125 (38.3)           | 105 (52.8)                        | 76 (38.8)                         |
| All-cause mortality                     | 69 (21.0)            | 51 (15.6)            | 46 (23.1)                         | 36 (18.4)                         |
| CV events                               | 133 (40.5)           | 112 (34.4)           | 87 (43.7)                         | 66 (33.7)                         |
| Hazard ratio(vutrisiranversus placebo)a | 0.718                | 0.718                | 0.672                             | 0.672                             |
| 95% CI                                  | (0.555, 0.929)       | (0.555, 0.929)       | (0.487, 0.929)                    | (0.487, 0.929)                    |
| p-value                                 | 0.0118               | 0.0118               | 0.0162                            | 0.0162                            |

DB=double-blind; HF=heart failure; LVAD=left ventricular assist device; NT-proBNP=N-terminal prohormone B-

Abbreviations: ATTR=transthyretin-mediated amyloidosis; CI=confidence interval; CV=cardiovascular;

type natriuretic peptide; NYHA=NewYork Heart Association.

a Based on the modified Andersen-Gill model including treatment group, log-transformed NT-proBNP, type of ATTR amyloidosis, NYHA class, and age group as covariates. In the vutrisiran monotherapy subgroup, the analysis was based on the subgroup data only. In the overall population, the model was stratified by baseline tafamidis use.

Source: Table 14.2.1.1

<div style=\"page-break-after: always\"></div>

Table 14.2.1.1 (excerpt): Primary analysis of composite all-cause mortality and recurrent cardiovascular (CV) events during the double-blind (DB) period, modified Andersen-Gill model full analysis set

Background Tafamidis Subgroup

Placebo

Vutrisiran

(N=129)

121

23

19

14

2

3

0

4

98

85

85

0

13

352.4

0.343

Statistic

Totalnumber of events，n

All-cause mortality, n

CV deaths

CV-related

Indeterminate

Heart transplants

LVAD placements

Non-CV deaths

CV events， n

CV hospitalizations

CV-related

Indeterminate

Urgent heart failure visits

Total follow-up time (years)

Observed event rate(totalnumber of events/total follow-up years)

|                                                     | Background Tafamidis Subgroup          | Background Tafamidis Subgroup          | Background Tafamidis Subgroup   |
|-----------------------------------------------------|----------------------------------------|----------------------------------------|---------------------------------|
| Statistic                                           | Placebo (N=129)                        | Placebo (N=129)                        | Vutrisiran (N=130)              |
| Number (%) of patients with at least 1 event, n (%) | 54                                     | (41.9)                                 | 49 (37.7)                       |
| All-cause mortality                                 | 23                                     | (17.8)                                 | 15 (11.5)                       |
| CV events                                           | 46                                     | (35.7)                                 | 46 (35.4)                       |
| Hazard ratio(Vutrisiran vs Placebo)[1]              | Hazard ratio(Vutrisiran vs Placebo)[1] | Hazard ratio(Vutrisiran vs Placebo)[1] | 0.785                           |
| 95%CI                                               | 95%CI                                  | 95%CI                                  | 0.511， 1.207                    |
| p-value                                             | p-value                                | p-value                                | 0.2701                          |

(N=130)

96

15

11

5

3

3

0

4

81

77

77

0

4

368.6

0.260

<div style=\"page-break-after: always\"></div>

Figure 14. Mean cumulative function plot of all-cause mortality and recurrent CV events during the DB period (overall population)

<!-- image -->

Abbreviations:CV=cardiovascular;DB=double-blind;HR=hazard ratio.

Source: Figure 14.2.1.1.1.

<div style=\"page-break-after: always\"></div>

Figure 15. Mean cumulative function plot of all-cause mortality and recurrent CV events during the DB period (Vutrisiran monotherapy subgroup)

<!-- image -->

Abbreviations: CV=cardiovascular; DB=double-blind; HR=hazard ratio. Source: Figure 14.2.1.1.2.

## Individual Components of the Primary Endpoint

Component Analysis: All-Cause Mortality

Events reported after study withdrawal were included for the component analysis of all-cause mortality. In the  overall  population,  vutrisiran  treatment  led  to  a  30.6%  reduction  in  the  risk  of  all-cause  mortality compared to placebo (hazard ratio: 0.694; 95% CI: 0.490, 0.982; P=0.0389) (Table 9 and Figure 16).

In the vutrisiran monotherapy subgroup, vutrisiran treatment led numerically to a 29.5% reduction in the risk of all-cause mortality compared to placebo (hazard ratio: 0.705; 95% CI: 0.467, 1.064; P=0.1179) (Table 9 and Figure 17).

<div style=\"page-break-after: always\"></div>

Table 9. Component analysis of the primary endpoint: all-cause mortality during the DB period

|                                                              | Overall Population   | Overall Population   | Vutrisiran Monotherapy Subgroup   | Vutrisiran Monotherapy Subgroup   |
|--------------------------------------------------------------|----------------------|----------------------|-----------------------------------|-----------------------------------|
| Category                                                     | Placebo (N=328)      | Vutrisiran (N=326)   | Placebo (N=199)                   | Vutrisiran (N=196)                |
| All-cause mortality included in the analysis, n (%)          | 75 (22.9)            | 56 (17.2)            | 52 (26.1)                         | 41 (20.9)                         |
| CV-related deaths                                            | 37 (11.3)            | 25 (7.7)             | 23 (11.6)                         | 20 (10.2)                         |
| Indeterminate deaths                                         | 17 (5.2)             | 16 (4.9)             | 15 (7.5)                          | 13 (6.6)                          |
| Non-CV-related deaths                                        | 17 (5.2)             | 12 (3.7)             | 13 (6.5)                          | 8 (4.1)                           |
| Heart transplantations                                       | 4 (1.2)              | 3 (0.9)              | 1 (0.5)                           | 0                                 |
| LVAD placements                                              | 0                    | 0                    | 0                                 | 0                                 |
| Hazard ratio from Cox PH model (vutrisiran/placebo) (95% CI) | 0.694 (0.490, 0.982) | 0.694 (0.490, 0.982) | 0.705 (0.467, 1.064)              | 0.705 (0.467, 1.064)              |
| p-value                                                      | 0.0389               | 0.0389               | 0.1179                            | 0.1179                            |

Figure 16. Adjusted cumulative incidence rate plot of component analysis all-cause mortality during the DB period (overall population)

<!-- image -->

MonthssinceFirstDose

<div style=\"page-break-after: always\"></div>

Figure 17. Adjusted cumulative incidence rate plot of component analysis all-cause mortality during the DB period (Vutrisiran monotherapy subgroup)

<!-- image -->

The prespecified sensitivity analysis of weighted log-rank FH (1,1) test, which allocates more weight to events that occurred at a later time period, also demonstrated a reduction in mortality in the vutrisiran group  compared  to  placebo  in  both  the  overall  population  (P=0.0175)  and  the  vutrisiran  monotherapy subgroup (P=0.0327).

An additional analysis was performed to summarize CV-related mortality and resulted in a similar treatment effect as the all-cause mortality analyses in both the overall population and the vutrisiran monotherapy subgroup.

## Component Analysis: Recurrent CV Events

In the overall population, in the analysis of recurrent CV events, including CV hospitalizations and urgent HF visits, vutrisiran treatment led to a 26.7% reduction in the risk of CV events compared to placebo (relative rate ratio: 0.733; 95% CI: 0.610, 0.882; P=0.0010) (Table 10 and Figure 18).

In  the  vutrisiran  monotherapy  subgroup,  vutrisiran  led  to  a  32.4%  reduction  in  the  risk  of  CV  events compared to placebo (relative rate ratio: 0.676; 95% CI: 0.533, 0.857; P=0.0012) (Table 10 and Figure 19).

<div style=\"page-break-after: always\"></div>

Table 10. Component analysis of the primary endpoint: recurrent CV events during the DB period, Poisson regression model

|                                                                             | Overall Population   | Overall Population   | Vutrisiran Monotherapy Subgroup   | Vutrisiran Monotherapy Subgroup   |
|-----------------------------------------------------------------------------|----------------------|----------------------|-----------------------------------|-----------------------------------|
| Statistic                                                                   | Placebo (N=328)      | Vutrisiran (N=326)   | Placebo (N=199)                   | Vutrisiran (N=196)                |
| Observed event rate among all patients (total events/total follow-up years) | 0.312                | 0.231                | 0.337                             | 0.240                             |
| CV event rate                                                               | 0.288                | 0.211                | 0.306                             | 0.207                             |
| 95% CI                                                                      | 0.253,0.327          | 0.183, 0.244         | 0.260, 0.360                      | 0.171, 0.250                      |
| Relative rate ratio (vutrisiran versus placebo)                             | 0.733                | 0.733                | 0.676                             | 0.676                             |
| 95% CI                                                                      | (0.610, 0.882)       | (0.610, 0.882)       | (0.533, 0.857)                    | (0.533, 0.857)                    |
| p-value                                                                     | 0.0010               | 0.0010               | 0.0012                            | 0.0012                            |

<div style=\"page-break-after: always\"></div>

Figure 18. Mean cumulative function plot of component analysis for recurrent CV events during the DB period (overall population)

<!-- image -->

Abbreviations:CV=cardiovascular;DB=double-blind;RR=rate ratio.

Source: Figure 14.2.3.1.4.1

Figure 19. Mean cumulative function plot of component analysis for recurrent CV events during the DB period (Vutrisiran monotherapy subgroup)

<!-- image -->

Abbreviations:CV=cardiovascular;DB=double-blind;RR=rate ratio.

Source: Figure 14.2.3.1.4.2

Recurrent CV events were also analyzed using a JFM as a sensitivity analysis. [Rondeau 2007] Consistent treatment effects were observed relative to the primary analysis in both populations.

<div style=\"page-break-after: always\"></div>

## Sensitivity and Additional Analyses for the Primary Endpoints

In the win ratio sensitivity analysis, the survival status collected after study discontinuation was included in the hierarchical comparisons. A win ratio of &gt;1 represents a favorable outcome for vutrisiran. The win ratio in the overall population was 1.39 (P=0.0088), indicating a reduction in all-cause mortality and recurrent CV events in the vutrisiran group compared to placebo (Table 11). A consistent effect was observed in the vutrisiran monotherapy subgroup (win ratio: 1.51; P=0.0089). A numerically consistent but smaller effect was also observed for the Background Tafamidis  Subgroup with a win ratio of 1.21; P= 0.3627 (Table 14.2.2.1.1, appendix of the study report). In patients with high NT-proBNP at baseline (NT-proBNP &gt; 3000 ng/L) the win ratio was only 1.12 in the vutrisiran monotherapy group and even smaller than 1 (0.83) in the background Tafamidis groups.

Table 11. Sensitivity analysis of composite all-cause mortality, frequency of CV events during the DB period, stratified win ratio

|                                         | Overall Population Total   | Vutrisiran Monotherapy Subgroup Total   |
|-----------------------------------------|----------------------------|-----------------------------------------|
| Statistic                               | (N=654)                    | (N=395)                                 |
| Number of vutrisiran patients           | 326                        | 196                                     |
| Number of placebo patients              | 328                        | 199                                     |
| Number of vutrisiran-placebo pairs      | 32,697                     | 21,777                                  |
| All-cause mortalitya                    |                            |                                         |
| Number (%) of pairs favoring vutrisiran | 6090 (18.6)                | 4259 (19.6)                             |
| Number (%) of pairs favoring placebo    | 4028 (12.3)                | 3016 (13.8)                             |
| Number (%) of tied pairs                | 22,579 (69.1)              | 14,502 (66.6)                           |
| Frequency of CV eventsa                 |                            |                                         |
| Number (%) of pairs favoring vutrisiran | 6239 (19.1)                | 4499 (20.7)                             |
| Number (%) of pairs favoring placebo    | 4018 (12.3)                | 2342 (10.8)                             |
| Number (%) of tied pairs                | 12,322 (37.7)              | 7661 (35.2)                             |
| Win ratio                               | 1.39                       | 1.51                                    |
| 95% CI                                  | 1.09, 1.78                 | 1.11, 2.05                              |
| p-value                                 | 0.0088                     | 0.0089                                  |

Abbreviations: CI=confidence interval; CV=cardiovascular; DB=double-blind.

a Percentages were based on the number of vutrisiran-placebo pairs.

Source: Table 14.2.2.1.1

Similarly, all other sensitivity and additional analyses performed for the primary endpoints were consistent and supported the primary analysis results of the vutrisiran treatment effect compared to placebo. This pertains to sensitivity analyses based on: - Data through 42 months, - Imputing CV events after study withdrawal, - Truncating outliers (For patients with more than 7 events, the first 7 most important events were kept for analysis, with importance ranked in the order of death, CV hospitalization and urgent HF visit), - HT/LVAD placement not treated as all cause mortality; data censored at the date of such procedure, - SGLT2 inhibitor drop-in due to cardiac disease progression treated as a CV event, and additional analyses based on: - Use of CV events per investigator assessment instead of CEC adjudication, - For the monotherapy subgroup, events beyond 9 months of initiation of tafamidis censored.

<div style=\"page-break-after: always\"></div>

Subgroup Analysis: Composite Outcome of All-cause Mortality and Recurrent CV Events (CV Hospitalizations and Urgent HF Visits)

The effect of vutrisiran treatment on the composite outcome of all-cause mortality and recurrent CV events was consistent across allmost prespecified subgroups, including age, baseline tafamidis use (in the overall population), NYHA class, and baseline NT-proBNP in both the overall population (Figure 20) and the vutrisiran monotherapy subgroup (Figure 21). For patients with hATTR the analyses indicated efficacy of vutrisiran in the vutrisiran monotherapy subgroup but not in the overall population. The data suggest even a numerically negative effect of vutrisiran in patients with hATTR when pretreated with tafamidis.

Figure 20. Forest plot of prespecified subgroup analyses of composite all-cause mortality and recurrent CV events during the DB period, modified Andersen-Gill model (overall population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 21. Forest plot of prespecified subgroup analyses of composite all-cause mortality and recurrent CV  events during the DB  period, modified Andersen-Gill  model (Vutrisiran monotherapy subgroup)

<!-- image -->

Subgroup analyses including race, ethnicity, sex, region, baseline 6-MWT, KCCQ-OS, and eGFR are summarized in Table 14.5.3.1.1 and Table 14.5.3.1.3 and presented in Figure 14.5.3.1.1. below, In the vutrisiran monotherapy subgroup, additional subgroup analyses were also conducted for race, ethnicity, sex, baseline 6-MWT, KCCQ-OS, and eGFR.

<div style=\"page-break-after: always\"></div>

Figure 14.5.3.1.1

(DB) Period, Modified Andersen-Gill Model

Forest Plot of Subgroup Analyses of Composite All-cause Mortality and Recurrent CV Events During the Double-blind

Full Analysis Set

Favors Vutrisiran

Favors Placebo

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 14.5.3.4.1 Forest Plot of Subgroup Analyses of All-cause Mortality During the DB and 6 Months of OLE Period FullAnalysisSet

<!-- image -->

Figure 14.5.3.4.2 Forest Plot of Subgroup Analyses of All-cause Mortality During the DB and 6 Months of OLE Period VutrisiranMonotherapySubgroupFAs

<!-- image -->

## Secondary endpoints

## 6-MWT

## Primary Analysis

In both the overall population and the vutrisiran monotherapy subgroup, baseline 6-MWT values were similar between treatment groups (Table 12). At Month 30, vutrisiran led to a statistically significant improvement in  6-MWT compared to placebo in the overall population (least square [LS] mean difference: 26.46 m; P=7.976E-05) (Figure 22), with consistent results observed in the vutrisiran monotherapy subgroup (32.09 m; P = 0.0005, Figure 23).

<div style=\"page-break-after: always\"></div>

In the Background Tafamidis Subgroup the least square [LS] mean difference (SEM) at month 30 was 18.44 (9.15), P = 0.0450 (Table 14.2.1.2 of the study report).

## 6-MWT Binary Analysis

In the binary analysis in the overall population, 41.2% (95% CI: 34.9, 47.4) of patients in the vutrisiran group achieved improvement ( ≥ 0 m change from baseline) in 6-MWT at Month 30 compared to 27.8% (21.9, 33.7) of patients in the placebo group (Odds ratio (95% CI): 1.8 (1.2, 2.7), Adjusted difference (95% CI): 13.3 (4.7, 21.9), p-value 0.0024. Consistent results were observed in the vutrisiran monotherapy subgroup.

Prespecified  sensitivity  analyses  indicated  a  consistent  estimate  of  the  treatment  effect.  The  effect  of vutrisiran  treatment  on  6-MWT  was  consistent  across  all  prespecified  subgroups  in  both  the  overall population (including baseline tafamidis use) and the vutrisiran monotherapy subgroup.

Table 12. Change from baseline to month 30 in 6-MWT, MMRM model

| Visit                                                |                                                 | Overall Population   | Overall Population   | Vutrisiran Monotherapy Subgroup   | Vutrisiran Monotherapy Subgroup   |
|------------------------------------------------------|-------------------------------------------------|----------------------|----------------------|-----------------------------------|-----------------------------------|
| Visit                                                | Statistic                                       | Placebo (N=328)      | Vutrisiran (N=326)   | Placebo (N=199)                   | Vutrisiran (N=196)                |
| Baseline                                             | n                                               | 328                  | 325                  | 199                               | 196                               |
| Baseline                                             | Mean (SD)                                       | 377.14 (96.29)       | 371.97 (103.71)      | 372.84 (98.08)                    | 362.70 (102.74)                   |
| Observed change from baseline to Month 30            | n                                               | 223                  | 238                  | 124                               | 130                               |
| Observed change from baseline to Month 30            | Median                                          | -30.65               | -7.50                | -47.33                            | -13.05                            |
| Observed change from baseline to Month 30            | Q1, Q3                                          | -82.55, 4.77         | -55.00, 18.00        | -91.92, -2.35                     | -69.04, 17.41                     |
| Change from baseline to Month 30 with imputed values | n                                               | 285                  | 294                  | 166                               | 170                               |
| Change from baseline to Month 30 with imputed values | Mean (SD)                                       | -68.00 (84.84)       | -46.10 (82.67)       | -86.56 (85.39)                    | -60.59 (89.91)                    |
| Change from baseline to Month 30 with imputed values | LS mean (SEM)                                   | -71.88 (4.79)        | -45.42 (4.62)        | -91.78 (6.39)                     | -59.69 (6.60)                     |
| Change from baseline to Month 30 with imputed values | LS mean (SEM) difference (vutrisiran - placebo) | 26.46 (6.66)         | 26.46 (6.66)         | 32.09 (9.19)                      | 32.09 (9.19)                      |
| Change from baseline to Month 30 with imputed values | 95% CI                                          | 13.38, 39.55         | 13.38, 39.55         | 14.03, 50.15                      | 14.03, 50.15                      |
| Change from baseline to Month 30 with imputed values | p-value                                         | 7.976E-05            | 7.976E-05            | 0.0005                            | 0.0005                            |

<div style=\"page-break-after: always\"></div>

Figure 22. LS mean (±SEM) change from baseline in 6-MWT by visit during the DB period, MMRM (overall population)

<!-- image -->

Abbreviations: 6-MWT=6-minute walk test; DB=double-blind; LS mean=least square mean; MMRM=mixed effects model repeated measures; SEM=standard error of the mean.

Source: Figure 14.2.1.2.1

Figure 23. LS mean (±SEM) change from baseline in 6-MWT by visit during the DB period, MMRM (Vutrisiran monotherapy subgroup)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## KCCQ-OS

The KCCQ is a self-administered questionnaire that measures patients' perception of health status, including HF symptoms, impact on physical and social function, and how their HF impacts quality of life within a 2week recall period. Higher KCCQ scores indicate better health status.

In both the overall population and the vutrisiran monotherapy subgroup, baseline KCCQ-OS values were similar  between  treatment  groups  (Table  13).  At  Month  30,  vutrisiran  led  to  a  statistically  significant improvement in KCCQ-OS compared to placebo in the overall population (LS mean difference: 5.80 points; P=0.0008) (Figure 24), with consistent results observed in the vutrisiran monotherapy subgroup (Figure 25).

In the binary analysis in the overall population, 45.2% (95% CI: 39.1, 51.4) of patients in the vutrisiran group achieved improvement ( ≥ 0-point increase from baseline) in KCCQ-OS score at Month 30 compared to 32.1% (26.1,  38.0)  of  patients  in  the  placebo  group  (p-value:  0.0028),  Adjusted  difference  (vutrisiran placebo) (95% CI): 13.2 (4.6, 21.8).

Consistent results were observed in the vutrisiran monotherapy subgroup: 49.6 % (41.3, 58.0) vs. 26.7 % (19.1, 34.3) (p-value: 0.0002). Adjusted difference (vutrisiran placebo) (95% CI): 22.9 (11.7, 34.2).

Domains of the KCCQ-OS reflect the severity of physical and social limitations, the frequency and severity of symptoms, and the quality of life impacts associated with cardiomyopathy. Results across all KCCQ-OS domains were consistent with the primary analysis and showed a treatment effect in favor of vutrisiran compared to placebo in both the overall population and the vutrisiran monotherapy subgroup (not shown here).

The effect of vutrisiran treatment on KCCQ-OS was largely consistent across all prespecified subgroups in both the overall population (including baseline tafamidis use) and the vutrisiran monotherapy subgroup but showed some variability (Figure 26 and Figure 27).

<div style=\"page-break-after: always\"></div>

Table 13. Change from baseline to month 30 in KCCQ-QS score, MMRM model

| Visit                                                |                                                 | Overall Population   | Overall Population   | Vutrisiran Monotherapy Subgroup   | Vutrisiran Monotherapy Subgroup   |
|------------------------------------------------------|-------------------------------------------------|----------------------|----------------------|-----------------------------------|-----------------------------------|
| Visit                                                | Statistic                                       | Placebo (N=328)      | Vutrisiran (N=326)   | Placebo (N=199)                   | Vutrisiran (N=196)                |
|                                                      | n                                               | 327                  | 325                  | 198                               | 195                               |
|                                                      | Mean (SD)                                       | 72.26 (19.92)        | 72.96 (19.44)        | 69.93 (20.80)                     | 70.29 (20.21)                     |
| Observed change from baseline to Month 30            | n                                               | 234                  | 252                  | 131                               | 139                               |
| Observed change from baseline to Month 30            | Median                                          | -6.25                | -1.30                | -8.65                             | -0.26                             |
| Observed change from baseline to Month 30            | Q1, Q3                                          | -17.71, 3.13         | -11.07, 8.14         | -20.05, 1.56                      | -13.80, 11.77                     |
| Change from baseline to Month 30 with imputed values | n                                               | 298                  | 306                  | 175                               | 180                               |
| Change from baseline to Month 30 with imputed values | Mean (SD)                                       | -15.39 (22.15)       | -9.34 (21.44)        | -19.50 (23.37)                    | -10.25 (23.49)                    |
| Change from baseline to Month 30 with imputed values | LS mean (SEM)                                   | -15.49 (1.26)        | -9.68 (1.19)         | -19.47 (1.73)                     | -10.78 (1.66)                     |
| Change from baseline to Month 30 with imputed values | LS mean (SEM) difference (vutrisiran - placebo) | 5.80 (1.73)          | 5.80 (1.73)          | 8.69 (2.40)                       | 8.69 (2.40)                       |
| Change from baseline to Month 30 with imputed values | 95% CI                                          | (2.40, 9.20)         | (2.40, 9.20)         | (3.98, 13.40)                     | (3.98, 13.40)                     |
| Change from baseline to Month 30 with imputed values | p-value                                         | 0.0008               | 0.0008               | 0.0003                            | 0.0003                            |

1

1

<div style=\"page-break-after: always\"></div>

Figure 24. LS mean (±SEM) change from baseline in KCCQ-OS by visit during the DB period, MMRM (overall population)

<!-- image -->

Abbreviations: DB=double-blind; KCCQ-OS=Kansas City Cardiomyopathy Questionnaire Overall Summary; LS mean=least square mean; MMRM=mixed effects model repeated measures; SEM=standard error of the mean. Source: Figure 14.2.1.3.1

Figure 25. LS mean (±SEM) change from baseline in KCCQ-OS score by visit during the DB period, MMRM model (Vutrisiran monotherapy subgroup)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 26. Forest plot of prespecified subgroup analyses of change from baseline to month 30 in KCCQ-OS score (overall population)

<!-- image -->

Favors Placebo

Favors Vutrisiran

Figure 27. Forest plot of prespecified subgroup analyses of change from baseline to month 30 in KCCQ-OS (Vutrisiran monotherapy subgroup)

<!-- image -->

## All-Cause Mortality

With the variable follow-up design of this study, patients enrolled in the OLE Period received their first OLE dose at either Month 33 or Month 36, depending on their enrollment time. The analysis of all-cause mortality as a secondary endpoint included all vital status collected through 42 months. Vital status collected after study withdrawal was also included in the analyses. Vital status was collected for all but 1 patient, who was censored at approximately 30 months. As of the data cutoff date of the primary analysis, patients who were alive but had not yet reached 42 months or completed 6 months of the OLE Period were censored at their last known alive date.

Vutrisiran patients had a statistically significant 35.5% reduction in the risk of all-cause mortality compared to placebo in the overall population (hazard ratio: 0.645; 95% CI: 0.463, 0.898; P=0.0098; 95% CI: 0.440, 0.973; P=0.0454) (Table 14).

FavorsPlacebo

Favors Vutrisiran

<div style=\"page-break-after: always\"></div>

Table 14. Analysis of all-cause mortality through 42 months

|                                                              | Overall Population   | Overall Population   | Vutrisiran Monotherapy Subgroup   | Vutrisiran Monotherapy Subgroup   |
|--------------------------------------------------------------|----------------------|----------------------|-----------------------------------|-----------------------------------|
| Category                                                     | Placebo (N=328)      | Vutrisiran (N=326)   | Placebo (N=199)                   | Vutrisiran (N=196)                |
| All-cause mortality included in the analysis, n (%)          | 85 (25.9)            | 60 (18.4)            | 58 (29.1)                         | 43 (21.9)                         |
| CV-related deaths, n (%)                                     | 39 (11.9)            | 26 (8.0)             | 25 (12.6)                         | 20 (10.2)                         |
| Indeterminate deaths, n (%)                                  | 21 (6.4)             | 19 (5.8)             | 18 (9.0)                          | 15 (7.7)                          |
| Non-CV-related deaths, n (%)                                 | 21 (6.4)             | 12 (3.7)             | 14 (7.0)                          | 8 (4.1)                           |
| Heart transplantation, n (%)                                 | 4 (1.2)              | 3 (0.9)              | 1 (0.5)                           | 0                                 |
| LVAD placement, n (%)                                        | 0                    | 0                    | 0                                 | 0                                 |
| CV-related mortality, n (%)a                                 | 64 (75.3)            | 48 (80.0)            | 44 (75.9)                         | 35 (81.4)                         |
| Hazard ratio from Cox PH model (vutrisiran/placebo) (95% CI) | 0.645 (0.463, 0.898) | 0.645 (0.463, 0.898) | 0.655 (0.440, 0.973)              | 0.655 (0.440, 0.973)              |
| p-value                                                      | 0.0098               | 0.0098               | 0.0454                            | 0.0454                            |

The prespecified sensitivity analysis of weighted log-rank FH (1,1) test, which allocates more weight on events that occurred at a later time period, also demonstrated a reduction in mortality in both the overall population (P=0.0028) and the vutrisiran monotherapy subgroup (P=0.0079).

The analysis of CV-related mortality through 42 months showed a similar numerical treatment effect as allcause mortality in both the overall population and the vutrisiran monotherapy subgroup (p &gt; 0.05 for both groups, data not shown here).

## All-Cause Mortality Subgroup Analysis

The  effect  of  vutrisiran  treatment  on  all-cause  mortality  was  overall  consistent  across  all  prespecified subgroups in both the overall population (including baseline tafamidis use; and the vutrisiran monotherapy subgroup (data not shown here). Mortality was numerically only slightly reduced in hATTR patients in the overall population (HR (95% CI) 0.891 (0.390, 2.033) due to the difference in the vutrisiran monotherapy population (0.672 (0.254, 1780)).

## NYHA Class

In both the overall population and the vutrisiran monotherapy subgroup, most patients had NYHA class II HF at baseline (Table 6). At Month 30, vutrisiran led to a statistically significantly greater proportion of patients  who  showed stability  (no  change  in  class)  or  improvement  compared  to  placebo  in  the  overall population (adjusted difference: 8.7%, 95% CI: 1.3, 16.1; P=0.0217), with consistent results observed in the vutrisiran monotherapy subgroup.

<div style=\"page-break-after: always\"></div>

Table 15. Analysis of stable or improved NYHA class at month 30, CMH method with multiple imputation for missing data

|                                                                             | Overall Population   | Overall Population   | Vutrisiran Monotherapy Subgroup   | Vutrisiran Monotherapy Subgroup   |
|-----------------------------------------------------------------------------|----------------------|----------------------|-----------------------------------|-----------------------------------|
| Statistics at Month 30                                                      | Placebo (N=328)      | Vutrisiran (N=326)   | Placebo (N=199)                   | Vutrisiran (N=196)                |
| Observed, n (%)                                                             |                      |                      |                                   |                                   |
| Stable or improved from baseline                                            | 181 (55.2)           | 206 (63.2)           | 98 (49.2)                         | 117 (59.7)                        |
| Worsened from baseline or death                                             | 118 (36.0)           | 100 (30.7)           | 78 (39.2)                         | 62 (31.6)                         |
| Missing                                                                     | 29 (8.8)             | 20 (6.1)             | 23 (11.6)                         | 17 (8.7)                          |
| With imputation                                                             |                      |                      |                                   |                                   |
| % stable or improved from baseline                                          | 60.5                 | 67.8                 | 56.4                              | 66.3                              |
| % worsened from baseline                                                    | 39.5                 | 32.2                 | 43.6                              | 33.7                              |
| Difference in % stable or improved (vutrisiran - placebo)                   | 7.4                  | 7.4                  | 9.9                               | 9.9                               |
| Adjusted difference in % stable or improved (vutrisiran - placebo) (95% CI) | 8.7 (1.3, 16.1)      | 8.7 (1.3, 16.1)      | 12.5 (2.7, 22.2)                  | 12.5 (2.7, 22.2)                  |
| p-value                                                                     | 0.0217               | 0.0217               | 0.0121                            | 0.0121                            |

A  sensitivity  analysis  of  the  change  from  baseline  in  NYHA  class  treated  as  a  continuous  variable  and analyzed using MMRM model showed consistent results.

The effect of vutrisiran treatment on NYHA class was consistent across all prespecified subgroups in both the overall population (including baseline tafamidis use) and the vutrisiran monotherapy subgroup (data not shown  here).  Only  a  very  small  numerical  difference  favouring  vutrisiran  was  observed  in  patients  on tafamidis at baseline (% difference (95% CI): 3.0 (-8.4, 14.4)).

## Exploratory endpoints

Time to First CV Event (including CV Hospitalizations and Urgent HF Visits) or All-Cause Mortality

Kaplan-Meier curves illustrating time to first CV event or all-cause mortality showed curves diverging after approximately  6  months  of  treatment  in  both  the  overall  population  (Figure  28)  and  in  the  vutrisiran monotherapy subgroup (Figure 29).

In the overall population, vutrisiran treatment led to a 28.4% reduction in the risk of first CV event or allcause mortality compared to placebo (hazard ratio: 0.716; 95% CI: 0.566, 0.905; P=0.0062)

In the vutrisiran monotherapy subgroup, vutrisiran treatment led to a 35.6% reduction in the risk of first CV  event  or  all-cause  mortality  compared  to  placebo  (hazard  ratio:  0.644;  95%  CI:  0.479,  0.867; P=0.0043).

<div style=\"page-break-after: always\"></div>

Figure 28. Adjusted Kaplan-Meier plot of time to first CV event or all-cause mortality during the DB period (overall population)

<!-- image -->

Figure 29. Adjusted Kaplan-Meier plot of time to first CV event or all-cause mortality during the DB period (Vutrisiran monotherapy subgroup)

<!-- image -->

Consistent results were also obtained for the following exploratory analyses (data not shown here):

- -Time to First CV Event (including CV Hospitalization, Urgent HF Visit and Any Initiation of SGLT2 Inhibitor due to Cardiac Disease Progression), or All-Cause Mortality
- -Time to First Oral Diuretic Intensification, First CV Event (including CV Hospitalization and Urgent HF Visit), or All-Cause Mortality
- -Time to Second CV Event (including CV Hospitalizations and Urgent HF Visits) or All-Cause Mortality
- -Composite Outcome of All-Cause Mortality and Recurrent All-Cause Hospitalizations and Urgent HF Visits.

<div style=\"page-break-after: always\"></div>

## -Cardiac Biomarkers

- -NT-proBNP Change from Baseline
- -Serum levels of NT-proBNP were measured during the DB Period.
- -At Month 30, vutrisiran led to a 32% relative reduction in the fold increase in NT-proBNP compared to placebo in the overall population (adjusted geometric mean fold change ratio [vutrisiran/placebo]: 0.68; P=3.440E-12) (Table 16). Median change from baseline in NT-proBNP levels indicated relative stability  in  vutrisiran  patients  with  an  8.98%  increase  while  levels  in  placebo  patients  indicated worsening with a 51.62% increase.
- -Vutrisiran led to a 43% relative reduction in the fold increase in NT-proBNP compared to placebo in the vutrisiran monotherapy subgroup (adjusted geometric mean fold change ratio [vutrisiran/placebo]: 0.57; P=4.339E-12) (Table 16).
- -Adjusted median NT-proBNP values over time are shown in Figure 30 for the overall population and for the vutrisiran monotherapy group.
- -In a binary analysis in the overall population, 41.6% of patients in the vutrisiran group remained stable or had decreases ( ≤ 0 ng/L change from baseline) in NT-proBNP levels at Month 30 compared to  24.9% in the placebo group (odds ratio: 2.2; 95% CI: 1.5, 3.3). In a binary analysis in the vutrisiran monotherapy subgroup, 36.4% of patients in the vutrisiran group remained stable or had decreases in NT-proBNP levels compared to 14.3% of patients in the placebo group (odds ratio: 3.4; 95% CI: 1.8, 6.6).
- -The effect of vutrisiran treatment on NT-proBNP was consistent across most subgroups in both the overall population and the vutrisiran monotherapy population. However, only a small numerical difference was observed in patients with Tafamidis at baseline. At month 30 NT-proBNP values were similar (Mean (SD) placebo: 2753.22 (2522.64), n = 104 vs. vutrisiran 2521.62 (3472.60, n = 114), change in NT proBNP from baseline was 710.03 (1913.38) in the placebo arm vs. 579.45 (3039.67) in the vutrisiran arm, accounting for an adjusted geometric mean fold-change (95% CI) of 1.29 (1.18, 1.42) vs. 1.06 (0.94, 1.17). (Table 14.2.4.7.1. Appendix to the study report).

<div style=\"page-break-after: always\"></div>

Table 16. Analysis of change from baseline to month 30 in NT-proBNP (ng/L), MMRM model

|                                                                    | Overall Population   | Overall Population   | Vutrisiran Monotherapy Subgroup   | Vutrisiran Monotherapy Subgroup   |
|--------------------------------------------------------------------|----------------------|----------------------|-----------------------------------|-----------------------------------|
| Statistic                                                          | Placebo (N=328)      | Vutrisiran (N=326)   | Placebo (N=199)                   | Vutrisiran (N=196)                |
| n                                                                  | 328                  | 326                  | 199                               | 196                               |
| Median                                                             | 1801.00              | 2020.50              | 1865.00                           | 2402.00                           |
| Geometric mean (SEM)a                                              | 1773.67 (72.59)      | 1979.81 (79.36)      | 1833.38 (98.61)                   | 2213.21 (121.30)                  |
| n                                                                  | 203                  | 223                  | 99                                | 109                               |
| Median                                                             | 2846.00              | 1837.00              | 3778.00                           | 2148.00                           |
| Geometric mean (SEM)a                                              | 2697.60 (170.14)     | 1981.23 (125.47)     | 3707.84 (320.80)                  | 2337.38 (228.48)                  |
| n                                                                  | 203                  | 223                  | 99                                | 109                               |
| Median change from baseline                                        | 753.00               | 118.00               | 1713.00                           | 203.00                            |
| Adjusted geometric  mean fold-changeb                              | 1.75                 | 1.19                 | 2.28                              | 1.30                              |
| 95% CI                                                             | 1.62, 1.89           | 1.11, 1.28           | 2.04, 2.55                        | 1.17, 1.45                        |
| Ratio of adjusted geometric mean fold change (vutrisiran/placebo)b | 0.68                 | 0.68                 | 0.57                              | 0.57                              |
| 95% CI                                                             | 0.61, 0.76           | 0.61, 0.76           | 0.49, 0.66                        | 0.49, 0.66                        |
| p-value                                                            | 3.440E-12            | 3.440E-12            | 4.339E-12                         | 4.339E-12                         |

<div style=\"page-break-after: always\"></div>

Figure 30. Adjusted geometric mean fold-change of NT-proBNP (ng/L) during the DB period, MMRM model (overall population)

<!-- image -->

Figure 31. Adjusted geometric mean fold-change of NT-proBNP (ng/L) during the DB period, MMRM model (Vutrisiran monotherapy subgroup)

<!-- image -->

## -Troponin I

- -At Month 30, vutrisiran led to a 32% relative reduction in the fold increase in troponin I compared to placebo in the overall population (adjusted geometric mean fold change ratio [vutrisiran/placebo]: 0.68; P=1.566E-14). A median percent increase (worsening) in troponin I levels relative to baseline was observed for the placebo group (21.70%) compared to a median percent decrease (improving) for the vutrisiran group (-9.86%) (Table 14.2.4.8).

<div style=\"page-break-after: always\"></div>

- -Vutrisiran led to a 45% relative reduction in the fold increase in troponin I compared to placebo in the vutrisiran monotherapy subgroup (adjusted geometric mean fold change ratio [vutrisiran/placebo]:  0.55;  P=9.684E-17).  A  median  percent  increase  (worsening)  in  troponin  I levels relative to baseline was observed for the placebo group (51.30%) compared to a median percent decrease (improving) for the vutrisiran group (-4.62%) stable or had decreases ( ≤ 0 ng/L change from baseline) in troponin I levels at Month 30 compared to 33.3% of patients in the placebo group (odds ratio: 2.9; 95% CI: 1.9, 4.2) (Table 14.2.4.8.3 of the study report, data not shown here).
- -In a binary analysis in the vutrisiran monotherapy subgroup, 49.3% of patients in the vutrisiran group remained stable or had decreases in troponin I levels compared to 15.3% of patients in the placebo group (odds ratio: 5.4; 95% CI: 2.9, 10.2) (Table 14.2.4.8.3 of the study report, data not shown here).
- -The effect of vutrisiran treatment on troponin I was consistent across most subgroups in both the overall population (including baseline tafamidis use; Table 14.2.4.8.1 and Figure 14.2.4.8.6) and the vutrisiran monotherapy subgroup.
- -However, no notable difference was observed in patients with Tafamidis at baseline. At month 30 troponin values were similar (Mean (SD) placebo, n = 100: 73.26 (56.50) vs. vutrisiran, n = 114: 76.81 (94.60).
- -At month 30 change in Troponin I from baseline was Mean (SD) -6.56 (64.09) vs. -7.94 (99.96) accounting for an adjusted geometric mean fold-change (95% CI) of 0.96 (0.88, 1.04) vs. 0.86 (0 0.79, 0.94) (Table 14.2.4.8.1. Appendix to the study report).
- -Echocardiographic parameters
- -Echocardiographic parameters were assessed during the study and analyzed by a central reader to evaluate changes in cardiac structure and function.
- -In  both  the  overall  population  and  vutrisiran  monotherapy  subgroup  some  improvements  were observed  with  vutrisiran  compared  to  placebo  for  prespecified  echocardiographic  parameters  of mean LV wall thickness and average peak longitudinal strain and additional parameters of cardiac structure (LV mass) and function (LV ejection fraction) at Month 30 as presented in Table 17.

<div style=\"page-break-after: always\"></div>

Table 17. Analysis of change from baseline to month 30 in echocardiographic parameters, MMRM model

| Visit                                |                                                  | Overall Population                   | Overall Population                   | Vutrisiran Monotherapy Subgroup      | Vutrisiran Monotherapy Subgroup      |
|--------------------------------------|--------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| Actual/Change                        | Statistic                                        | Placebo (N=328)                      | Vutrisiran (N=326)                   | Placebo (N=199)                      | Vutrisiran (N=196)                   |
| Mean LV Wall Thickness (cm)          | Mean LV Wall Thickness (cm)                      | Mean LV Wall Thickness (cm)          | Mean LV Wall Thickness (cm)          | Mean LV Wall Thickness (cm)          | Mean LV Wall Thickness (cm)          |
| Baseline                             | n                                                | 324                                  | 321                                  | 197                                  | 191                                  |
| Baseline                             | Mean (SD)                                        | 1.82 (0.27)                          | 1.82 (0.26)                          | 1.83 (0.29)                          | 1.82 (0.27)                          |
| Change from baseline to Month 30     | n                                                | 219                                  | 236                                  | 120                                  | 127                                  |
| Change from baseline to Month 30     | LS mean (SEM)                                    | 0.09 (0.01)                          | 0.05 (0.01)                          | 0.11 (0.02)                          | 0.04 (0.02)                          |
| Change from baseline to Month 30     | LS mean (SEM) difference (vutrisiran-placebo)    | -0.04 (0.02)                         | -0.04 (0.02)                         | -0.08 (0.03)                         | -0.08 (0.03)                         |
| Change from baseline to Month 30     | 95% CI                                           | -0.08, -0.00                         | -0.08, -0.00                         | -0.14, -0.02                         | -0.14, -0.02                         |
| Change from baseline to Month 30     | p-value                                          | 0.0343                               | 0.0343                               | 0.0080                               | 0.0080                               |
| Average Peak Longitudinal Strain (%) | Average Peak Longitudinal Strain (%)             | Average Peak Longitudinal Strain (%) | Average Peak Longitudinal Strain (%) | Average Peak Longitudinal Strain (%) | Average Peak Longitudinal Strain (%) |
| Baseline                             | n                                                | 328                                  | 324                                  | 199                                  | 194                                  |
| Baseline                             | Mean (SD)                                        | -13.96 (3.48)                        | -13.99 (3.46)                        | -14.25 (3.52)                        | -14.04 (3.44)                        |
| Change from baseline to Month 30     | n                                                | 227                                  | 244                                  | 125                                  | 132                                  |
| Change from baseline to Month 30     | LS mean (SEM)                                    | 2.18 (0.19)                          | 0.95 (0.17)                          | 2.37 (0.26)                          | 1.07 (0.26)                          |
| Change from baseline to Month 30     | LS mean (SEM) difference (vutrisiran-placebo)    | -1.23 (0.26)                         | -1.23 (0.26)                         | -1.30 (0.36)                         | -1.30 (0.36)                         |
| Change from baseline to Month 30     | 95% CI                                           | -1.73, -0.73                         | -1.73, -0.73                         | -2.01, -0.59                         | -2.01, -0.59                         |
| Change from baseline to Month 30     | p-value                                          | 2.021E-6                             | 2.021E-6                             | 0.0004                               | 0.0004                               |
| LV Mass, Estimated (g)               | LV Mass, Estimated (g)                           | LV Mass, Estimated (g)               | LV Mass, Estimated (g)               | LV Mass, Estimated (g)               | LV Mass, Estimated (g)               |
| Baseline                             | n                                                | 318                                  | 320                                  | 193                                  | 190                                  |
| Baseline                             | Mean (SD)                                        | 350.64 (93.22)                       | 351.83 (87.67)                       | 356.17 (99.53)                       | 355.06 (90.94)                       |
| Change from baseline to Month 30     | n                                                | 207                                  | 228                                  | 112                                  | 123                                  |
| Change from baseline to Month 30     | LS mean (SEM)                                    | 42.76 (5.41)                         | 23.90 (4.72)                         | 48.58 (7.80)                         | 17.71 (7.00)                         |
| Change from baseline to Month 30     | LS mean (SEM) difference (vutrisiran -- placebo) | -18.86 (7.17)                        | -18.86 (7.17)                        | -30.87 (10.48)                       | -30.87 (10.48)                       |

<div style=\"page-break-after: always\"></div>

|                                  |                                                 | Overall Population       | Overall Population       | Vutrisiran Monotherapy Subgroup   | Vutrisiran Monotherapy Subgroup   |
|----------------------------------|-------------------------------------------------|--------------------------|--------------------------|-----------------------------------|-----------------------------------|
| Visit Actual/Change              | Statistic                                       | Placebo (N=328)          | Vutrisiran (N=326)       | Placebo (N=199)                   | Vutrisiran (N=196)                |
|                                  | 95% CI                                          | -32.96, -4.76            | -32.96, -4.76            | -51.50, -10.24                    | -51.50, -10.24                    |
|                                  | p-value                                         | 0.0088                   | 0.0088                   | 0.0035                            | 0.0035                            |
| LV Ejection Fraction (%)         | LV Ejection Fraction (%)                        | LV Ejection Fraction (%) | LV Ejection Fraction (%) | LV Ejection Fraction (%)          | LV Ejection Fraction (%)          |
| Baseline                         | n                                               | 318                      | 309                      | 192                               | 182                               |
| Baseline                         | Mean (SD)                                       | 55.93 (12.35)            | 55.64 (12.74)            | 55.68 (12.05)                     | 54.80 (12.64)                     |
| Change from baseline to Month 30 | n                                               | 209                      | 225                      | 115                               | 117                               |
| Change from baseline to Month 30 | LS mean (SEM)                                   | -6.15 (0.66)             | -4.12 (0.56)             | -5.89 (0.93)                      | -3.62 (0.75)                      |
|                                  | LS mean (SEM) difference (vutrisiran - placebo) | 2.03 (0.86)              | 2.03 (0.86)              | 2.27 (1.19)                       | 2.27 (1.19)                       |
|                                  | 95% CI                                          | 0.34, 3.73               | 0.34, 3.73               | -0.07, 4.61                       | -0.07, 4.61                       |
|                                  | p-value                                         | 0.0190                   | 0.0190                   | 0.0577                            | 0.0577                            |

- -eGFR
- -Vutrisiran was associated with lower decline from baseline in eGFR compared to placebo (LS mean [SEM]  difference:  2.2  [±1.3]  mL/min/1.73m2,  P=0.0876)  in  the  overall  population.  Consistent results  were  observed  in  the  vutrisiran  monotherapy  subgroup  and  in  patients  on  background tafamidis therapy (LS mean [SEM] difference mL/min/1.73m2: 2.5 (1.8) p= 0.1654, and 2.0 (1.8), p= 0.2763 respectively).
- -ATTR Amyloidosis Disease Stage
- -ATTR amyloidosis disease staging is commonly used in clinical practice to stratify patients with ATTR amyloidosis with cardiomyopathy (both hATTR and wtATTR) into prognostic categories using the serum  biomarkers  NT-proBNP  and  eGFR.[Gillmore  2018]  Stage  1  indicates  lower  risk,  Stage  2 indicates intermediate risk, and Stage 3 indicates higher risk. More than half of patients in both treatment groups had ATTR amyloidosis disease Stage 1 (63.8%, vutrisiran group; 69.8%, placebo group) at baseline.
- -In the overall population, 77.3% of patients in the vutrisiran group showed no progression in ATTR amyloidosis stage at Month 30 compared to 61.2% of patients in the placebo group (adjusted difference: 16.1; 95% CI: 8.1, 24.2; P=7.889E-05). Consistent results were observed in the vutrisiran monotherapy subgroup and in patients on background tafamidis therapy (adjusted difference: 14.8 (3.7, 26.0), p = 0.0112, and 17.8 (6.3, 29.3), p = 0.0030, respectively).
- -Quality of Life

<div style=\"page-break-after: always\"></div>

- -EQ-5D-5L
- -At Month 30, vutrisiran improved patients' self-reported general health-related quality of life, as assessed by the change from baseline in EQ-5D-5L index score, compared to placebo in the overall population (LS mean [SEM] difference: 0.0308 [±0.0111]; P=0.0056), with consistent results observed in the vutrisiran monotherapy subgroup. Consistent results were observed for the EQ5D-5L visual analog scale.

## Norfolk QoL-DN Questionnaire

At  Month  30,  vutrisiran  improved  patients'  self-reported  outcomes  with  respect  to  the  impact  of polyneuropathy on quality of life, as assessed by the Norfolk QoL-DN questionnaire, compared to placebo in the overall population (LS mean [SEM] difference: -5.3 (±1.4); P=0.0001, MMRM model). The effect size was larger in the vutrisiran monotherapy group (-7.5 (±1.9); P=0.0001) and smaller in the Background Tafamidis Group (-2.6 (±1.9); P= 0.1654). Baseline values for the vutrisiran monotherapy groups were 19.6 (19.5) and 19.2 (18.7) (vutrisiran and placebo (SD), in the background tafamidis group 14.3 (15.0) and 14.9 (15.2), and in 17.5 (18.0) and 17.5 (17.5), respectively in the overall population.

In  a  subset  of  patients  with  a  history  of  neuropathy,  vutrisiran  also  improved  patients'  self-reported outcomes with respect to the impact of polyneuropathy on quality of life compared to placebo in the overall population (LS mean [SEM] difference: -4.6 [±2.3]; P=0.0473). The effect size was larger in the vutrisiran monotherapy group (-9.5 (±3.5); P= 0.0089), No effect was observed in the Background Tafamidis Group (-0.8 (±3,1); P= 0. 8041)

- -Baseline values for the vutrisiran monotherapy groups were 25.0 (19.9) and 27.5 (22.2) (vutrisiran and placebo (SD), in the background tafamidis group 17.5 (17.5) and 21.2 (16.5), and 21.1 (19.0) and 24.7 (20.0), respectively in the overall population.

## Ancillary analyses

Regarding analyses for individual components, in subgroups and sensitivity analyses see above.

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 18. Summary of efficacy for HELIOS-B trial

| Title: HELIOS-B: A Phase 3, Randomised, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)   | Title: HELIOS-B: A Phase 3, Randomised, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                      | Study number: ALN-TTRSC02-003 EudraCT number: 2019-003153-28                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Design                    | Phase 3, global, randomised (1:1), double-blind (DB), placebo-controlled study designed to evaluate the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of vutrisiran in patients with hATTR and wtATTR amyloidosis with cardiomyopathy, who were either not on tafamidis at baseline (vutrisiran monotherapy subgroup) or were receiving concomitant tafamidis at baseline per the inclusion criteria (background tafamidis subgroup). Patients were stratified by baseline tafamidis use, ATTR disease type (hATTR vs wtATTR), and NYHA class I-II and age <75 years vs. all other.   | Phase 3, global, randomised (1:1), double-blind (DB), placebo-controlled study designed to evaluate the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of vutrisiran in patients with hATTR and wtATTR amyloidosis with cardiomyopathy, who were either not on tafamidis at baseline (vutrisiran monotherapy subgroup) or were receiving concomitant tafamidis at baseline per the inclusion criteria (background tafamidis subgroup). Patients were stratified by baseline tafamidis use, ATTR disease type (hATTR vs wtATTR), and NYHA class I-II and age <75 years vs. all other.   | Phase 3, global, randomised (1:1), double-blind (DB), placebo-controlled study designed to evaluate the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of vutrisiran in patients with hATTR and wtATTR amyloidosis with cardiomyopathy, who were either not on tafamidis at baseline (vutrisiran monotherapy subgroup) or were receiving concomitant tafamidis at baseline per the inclusion criteria (background tafamidis subgroup). Patients were stratified by baseline tafamidis use, ATTR disease type (hATTR vs wtATTR), and NYHA class I-II and age <75 years vs. all other.   |
|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                           | Duration of main phase: Duration of Run-in phase: Duration of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Open-label Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | up to 36 months (completed) not applicable up to 24 months (ongoing)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Hypothesis                | Superiority of vutrisiran over placebo for clinical efficacy endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Superiority of vutrisiran over placebo for clinical efficacy endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Superiority of vutrisiran over placebo for clinical efficacy endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Treatments groups         | Overall population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Overall population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Overall population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Treatments groups         | Vutrisiran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Vutrisiran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Treatment: vutrisiran SC injection 25 mg every 3 months (q3M) Duration: up to 36 months Number randomised: 326                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Treatments groups         | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Treatment: sodium chloride 0.9% w/v SC injection q3M Duration: up to 36 months Number randomised: 329                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Treatments groups         | Vutrisiran Monotherapy Subgroup (defined as the group of patients not on tafamidis at study baseline)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Vutrisiran Monotherapy Subgroup (defined as the group of patients not on tafamidis at study baseline)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Vutrisiran Monotherapy Subgroup (defined as the group of patients not on tafamidis at study baseline)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Treatments groups         | Vutrisiran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Vutrisiran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | N=196                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Treatments groups         | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | N=199                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Endpoints and definitions | Primary endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | All-cause mortality and recurrent CV events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Composite outcome of all-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) in the overall population Composite outcome of all-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) in the vutrisiran monotherapy subgroup (defined as the group of patients not on tafamidis at study baseline)                                                                                                                                                                                                                                            |
| Endpoints and definitions | Secondary endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 6-MWT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Change from baseline in 6-minute walk test (6-MWT) at Month 30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Endpoints and definitions | (each defined in both the overall population and the vutrisiran monotherapy subgroup):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | KCCQ-OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Change from baseline in Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS) at Month 30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Endpoints and definitions | (each defined in both the overall population and the vutrisiran monotherapy subgroup):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | All-cause mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | All-cause mortality through 42 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Endpoints and definitions | (each defined in both the overall population and the vutrisiran monotherapy subgroup):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | NYHA Class                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Change from baseline in New York Heart Association (NYHA) class at Month 30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| Database lock                                   | Primary analysis database lock: 14 June 2024                                                                                                                                                                                                             | Primary analysis database lock: 14 June 2024                                                                                                                                                                                                             | Primary analysis database lock: 14 June 2024                                                                                                                                                                                                             | Primary analysis database lock: 14 June 2024                                                                                                                                                                                                             | Primary analysis database lock: 14 June 2024                                                                                                                                                                                                             |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Results and Analysis                            | Results and Analysis                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                     |
| Analysis description Primary Analysis           | Analysis description Primary Analysis                                                                                                                                                                                                                    | Analysis description Primary Analysis                                                                                                                                                                                                                    | Analysis description Primary Analysis                                                                                                                                                                                                                    | Analysis description Primary Analysis                                                                                                                                                                                                                    | Analysis description Primary Analysis                                                                                                                                                                                                                    |
| Analysis population and time point description  | Full analysis set (FAS): all randomised patients who received any amount of study drug. Corresponds to 'Overall population'. Vutrisiran monotherapy subgroup full analysis set: All patients in the FAS who were not on tafamidis at the study baseline. | Full analysis set (FAS): all randomised patients who received any amount of study drug. Corresponds to 'Overall population'. Vutrisiran monotherapy subgroup full analysis set: All patients in the FAS who were not on tafamidis at the study baseline. | Full analysis set (FAS): all randomised patients who received any amount of study drug. Corresponds to 'Overall population'. Vutrisiran monotherapy subgroup full analysis set: All patients in the FAS who were not on tafamidis at the study baseline. | Full analysis set (FAS): all randomised patients who received any amount of study drug. Corresponds to 'Overall population'. Vutrisiran monotherapy subgroup full analysis set: All patients in the FAS who were not on tafamidis at the study baseline. | Full analysis set (FAS): all randomised patients who received any amount of study drug. Corresponds to 'Overall population'. Vutrisiran monotherapy subgroup full analysis set: All patients in the FAS who were not on tafamidis at the study baseline. |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                          | Overall population                                                                                                                                                                                                                                       | Overall population                                                                                                                                                                                                                                       | Vutrisiran Monotherapy Subgroup                                                                                                                                                                                                                          | Vutrisiran Monotherapy Subgroup                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                          | Placebo                                                                                                                                                                                                                                                  | Vutrisiran                                                                                                                                                                                                                                               | Placebo                                                                                                                                                                                                                                                  | Vutrisiran                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                       | 328                                                                                                                                                                                                                                                      | 326                                                                                                                                                                                                                                                      | 199                                                                                                                                                                                                                                                      | 196                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | Composite endpoint of All-cause mortality and recurrent CV events (total number of events)                                                                                                                                                               | 332                                                                                                                                                                                                                                                      | 251                                                                                                                                                                                                                                                      | 211                                                                                                                                                                                                                                                      | 155                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | 6-MWT (observed median change from baseline at Month 30, meters)                                                                                                                                                                                         | -30.65                                                                                                                                                                                                                                                   | -7.50                                                                                                                                                                                                                                                    | -47.33                                                                                                                                                                                                                                                   | -13.05                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | Q1, Q3                                                                                                                                                                                                                                                   | -82.55, 4.77                                                                                                                                                                                                                                             | -55.00, 18.00                                                                                                                                                                                                                                            | -91.92, -2.35                                                                                                                                                                                                                                            | -69.04, 17.41                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | KCCQ-OS (observed median change from baseline at Month 30)                                                                                                                                                                                               | -6.25                                                                                                                                                                                                                                                    | -1.30                                                                                                                                                                                                                                                    | -8.65                                                                                                                                                                                                                                                    | -0.26                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | Q1, Q3                                                                                                                                                                                                                                                   | -17.71, 3.13                                                                                                                                                                                                                                             | -11.07, 8.14                                                                                                                                                                                                                                             | -20.05, 1.56                                                                                                                                                                                                                                             | -13.80, 11.77                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | All-cause mortality                                                                                                                                                                                                                                      | 85 (25.9%)                                                                                                                                                                                                                                               | 60 (18.4%)                                                                                                                                                                                                                                               | 58 (29.1%)                                                                                                                                                                                                                                               | 43 (21.9%)                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | (number of events [%]) NYHA class                                                                                                                                                                                                                        | 60.5                                                                                                                                                                                                                                                     | 67.8                                                                                                                                                                                                                                                     | 56.4                                                                                                                                                                                                                                                     | 66.3                                                                                                                                                                                                                                                     |
| Effect estimate per comparison                  | Primary endpoint All-cause mortality and recurrent CV events                                                                                                                                                                                             | Overall population                                                                                                                                                                                                                                       | Overall population                                                                                                                                                                                                                                       | Overall population                                                                                                                                                                                                                                       | Overall population                                                                                                                                                                                                                                       |
| Effect estimate per comparison                  | Primary endpoint All-cause mortality and recurrent CV events                                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                                        | Comparison groups                                                                                                                                                                                                                                        | Vutrisiran vs. placebo                                                                                                                                                                                                                                   | Vutrisiran vs. placebo                                                                                                                                                                                                                                   |
| Effect estimate per comparison                  | Primary endpoint All-cause mortality and recurrent CV events                                                                                                                                                                                             | Hazard ratio                                                                                                                                                                                                                                             | Hazard ratio                                                                                                                                                                                                                                             | 0.718                                                                                                                                                                                                                                                    | 0.718                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                            | 95% CI                                                | (0.555, 0.929)                  |
|----------------------------|-------------------------------------------------------|---------------------------------|
|                            | P-value (LWYY method)                                 | 0.0118                          |
|                            | Vutrisiran monotherapy subgroup                       | Vutrisiran monotherapy subgroup |
|                            | Comparison groups                                     | Vutrisiran vs. placebo          |
|                            | Hazard ratio                                          | 0.672                           |
|                            | 95% CI                                                | (0.487, 0.929)                  |
|                            | P-value (LWYY method)                                 | 0.0162                          |
| Secondary endpoint 6-MWT   | Overall population                                    | Overall population              |
|                            | Comparison groups                                     | Vutrisiran vs. placebo          |
|                            | LS mean difference at Month 30 (vutrisiran - placebo) | 26.46                           |
|                            | 95% CI                                                | 13.38, 39.55                    |
|                            | P-value (MMRM model)                                  | 7.976E-05                       |
|                            | Vutrisiran monotherapy subgroup                       | Vutrisiran monotherapy subgroup |
|                            | Comparison groups                                     | Vutrisiran vs. placebo          |
|                            | LS mean difference at Month 30 (vutrisiran - placebo) | 32.09                           |
|                            | 95% CI                                                | 14.03, 50.15                    |
|                            | P-value (MMRM model)                                  | 0.0005                          |
| Secondary endpoint KCCQ-OS | Overall population                                    | Overall population              |
|                            | Comparison groups                                     | Vutrisiran vs. placebo          |
|                            | LS mean difference at Month 30 (vutrisiran - placebo) | 5.80                            |
|                            | 95% CI                                                | (2.40, 9.20)                    |
|                            | P-value (MMRM model)                                  | 0.0008                          |
|                            | Vutrisiran monotherapy subgroup                       | Vutrisiran monotherapy subgroup |
|                            | Comparison groups                                     | Vutrisiran vs. placebo          |
|                            | LS mean difference at Month 30 (vutrisiran - placebo) | 8.69                            |
|                            | 95% CI                                                | (3.98, 13.40)                   |
|                            | P-value (MMRM model)                                  | 0.0003                          |
| Secondary endpoint         | Overall population                                    | Overall population              |
| All-cause mortality        | Comparison groups                                     | Vutrisiran vs. placebo          |
|                            | Hazard ratio (Cox PH model)                           | 0.645                           |
|                            | 95% CI                                                | (0.463, 0.898)                  |
|                            | P-value (log-rank test)                               | 0.0098                          |

<div style=\"page-break-after: always\"></div>

|       | Vutrisiran monotherapy subgroup                                    | Vutrisiran monotherapy subgroup   |
|-------|--------------------------------------------------------------------|-----------------------------------|
|       | Comparison groups                                                  | Vutrisiran vs. placebo            |
|       | Hazard ratio (Cox PH model)                                        | 0.655                             |
|       | 95% CI                                                             | (0.440, 0.973)                    |
|       | P-value (log-rank test)                                            | 0.0454                            |
|       | Overall population                                                 |                                   |
|       |                                                                    | Vutrisiran vs. placebo            |
|       | Difference in %stable or improved at Month 30                      | 8.7                               |
|       | 95% CI                                                             | (1.3, 16.1)                       |
|       | P-value (Cochran-Mantel- Haenszel method with multiple             | 0.0217                            |
|       | Vutrisiran monotherapy                                             |                                   |
|       | Comparison groups                                                  | Vutrisiran vs. placebo            |
|       | Difference in %stable or improved at Month 30                      | 12.5                              |
|       | 95%                                                                | (2.7, 22.2)                       |
|       | P-value (Cochran-Mantel- Haenszel method with multiple imputation) | 0.0121                            |
| Notes |                                                                    |                                   |
|       | CI                                                                 | CI                                |
|       | imputation)                                                        | imputation)                       |
|       |                                                                    | subgroup                          |

## Analysis performed across trials (pooled analyses and meta-analysis)

The primary evidence for efficacy in this application is based on a single pivotal Phase 3 study in ATTR amyloidosis patients with cardiomyopathy.

No formal pooling or other comparisons of efficacy data across studies were performed to support this application.

<div style=\"page-break-after: always\"></div>

## Clinical studies in special populations

Table 19. Clinical studies in special populations

|                       | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|-----------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| HELIOS-B Study        | HELIOS-B Study                                    | HELIOS-B Study                                    | HELIOS-B Study                                  |
| Overall               | 210/654 = 32.1%                                   | 367/654 = 56.1%                                   | 30/654 = 4.6%                                   |
| Vutrisiran            | 96/326 = 29.4%                                    | 188/326 = 57.7%                                   | 15/326 = 4.6%                                   |
| Placebo               | 114/328 = 34.8%                                   | 179/328 = 54.6%                                   | 15/328 = 4.6%                                   |
| Non-Controlled trials | N/A                                               | N/A                                               | N/A                                             |

## Supportive study(ies)

N/A

## 2.4.3. Discussion on clinical efficacy

Vutrisiran is an RNAi therapeutic comprised of a synthetic, chemically modified, double-stranded small interfering RNA (siRNA) that specifically targets variant and wtTTR and silences TTR messenger RNA (mRNA). This is accomplished by incorporation of vutrisiran siRNA into the cellular multiprotein enzyme cleavage complex known as the RNA induced silencing complex (RISC). Reduction of both variant and wild type TTR production in the liver, which are the fundamental pathogenic proteins causing hATTR amyloidosis, will reduce ongoing deposition of amyloid deposits and potentially allow for clearance of existing deposits and consequently, halting or reversing disease progression.

In amyloidosis with polyneuropathy previous clinical studies with mRNA silencing agents, such as patisiran, and the antisense oligonucleotide (ASO) inotersen, and with vutrisiran demonstrated that TTR reduction in patients with hATTR can have beneficial effects, measured by clinical endpoints evaluating disease manifestations and patient-reported outcomes. Amvuttra has been approved for the treatment of hATTR amyloidosis with in adult patients with stage 1 or stage 2 polyneuropathy.

Within this procedure the MAH applies for an extension of the indication as follows:

Amvuttra is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN).

Amvuttra is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

## Design and conduct of clinical studies

The clinical development program of vutrisiran to support an indication for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) included one pivotal phase 3 trial, the study ALN-TTRSC02-003 (HELIOS B). It is an ongoing, Phase 3, multicenter, multinational,

<div style=\"page-break-after: always\"></div>

randomized,  double-blind,  placebo-controlled  study  in  hATTR  amyloidosis  patients  with  cardiomyopathy (Primary analysis completed, Data cutoff: 08 May 2024).

The clinical development program to support the indication and the design of the Phase 3 HELIOS-B study were discussed with the European Union (EU) European Medicines Agency EMA in June 2019 (EMEA/H/SA/ 3876/2/2019/PA/II),  and  subsequently  advice  was  given  in  November  2023  in  a  pre-submission teleconference with the CHMP Rapporteur and Co-Rapporteur.

The data are assessed in the context of data submitted at the time of the initial MAA: A safety and clinical pharmacology study assessing PD in healthy subjects (Study 001) and an open-label on-going Phase 3 study in adult patients with hATTR amyloidosis with polyneuropathy (ALN-TTRSC02-002, HELIOS-A).

## Design

HELIOS-B is an ongoing, global, Phase 3, randomized, double blind study designed to evaluate efficacy, safety, PK, and PD of vutrisiran in adult patients with hATTR amyloidosis with cardiomyopathy.

The study consisted of the following periods:

- -Screening Period:
- Double blind (DB) treatment period
- Open-label treatment extension period up to 2 years
- Follow-up period up to 1 year after last dose of study drug (up to 18 months for women of child-bearing potential).

After  screening,  eligible  patients  were  randomized  in  a  1:1  ratio  to  receive  blinded  doses  of  25  mg  of vutrisiran or placebo administered as an SC injection q3M (every 12 weeks ±7 days) for up to 36 months in the DB Period.

During the OLE Period, all patients received open-label doses of 25 mg q3M vutrisiran administered as SC injections.

Between Protocol Amendment 3 (13 May 2022, start) and Protocol Amendment 4 (22 March 2023, end) an Open-label Randomized Treatment Extension (RTE) Period was added wherein patients were randomized 1:1 to receive treatment with either 25 mg q3M vutrisiran or 50 mg once every 6 months (q6M) vutrisiran with all patients receiving 25 mg q3M vutrisiran thereafter.

Patients who were on tafamidis at baseline (background tafamidis subgroup) as per inclusion criteria were encouraged, if considered appropriate, to remain on tafamidis for the duration of the study. Initiating onlabel  use  of  tafamidis  in  previously  naïve  patients  during  the  study  (tafamidis  drop-in)  was  allowed.  In addition to study drug, all patients were instructed to take the recommended daily allowance of vitamin A during their DB, OLE, and Follow-up Periods.

## Endpoints

Two primary efficacy endpoints were predefined:

- Composite outcome of all-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) in the overall population
- Composite outcome of all-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) in the vutrisiran monotherapy subgroup (defined as the group of patients not on tafamidis at study baseline)

<div style=\"page-break-after: always\"></div>

The following (confirmatory) secondary endpoints were defined in both the overall population and the vutrisiran monotherapy subgroup:

· Change from baseline in 6-MWT · Change from baseline in the KCCQ-OS · All-cause mortality · Change from baseline in NYHA class

## Additional secondary endpoints covered among others

· Composite outcome of all-cause mortality and recurrent all-cause hospitalizations and urgent HF visits · Time to first CV event (including CV hospitalizations and urgent HF visits) or all-cause mortality

Change from baseline in · ECHO parameters, · NT-proBNP · Troponin I · eGFR · ATTR amyloidosis disease stage · EuroQoL-5 Dimensions-5 Levels questionnaire, and · Norfolk QoL-DN

In  addition,  assessment  of PD (change from baseline in serum TTR levels) plasma PK exposure and frequency and titers of ADA was investigated.

The choice of the primary and secondary endpoint is overall acceptable

## Conduct

The rate of reported protocol violations was within the expected range, partly related to COVID-19 pandemia. Quality control measures were in place. No serious GCP issues were identified with the potential to affect the integrity of the study or with an impact of the conclusions on the benefit risk balance.  Analyses covering the impact of the COVID19-pandemic were provided. Overall treatment compliance was high.

- Via Amendment 1 the primary endpoint was amended in order to include not only CV hospitalizations but also urgent HF visits (UHV) without hospitalization. This is acceptable in case of stringent definition of the events, e.g., in line with Hicks et al 2018 and in case they are adjudicated.

- Via global amendment 5 (12 February 2024) an additional primary analysis in patients not on tafamidis at study baseline was added. Based on the information provided that Applicant had no information at that time point allowing a reasonable guess on treatment assignment at that stage.

## Study size

Patients  were  randomized  and  treated  at  87  study  centers  worldwide  in  26  countries  with  a  sufficient representation of patients from the EU. 799 patients were screened, 655 were randomized. Of the 326 patients in the vutrisiran group, 78 (23.9%) patients discontinued study drug during the DB Period. Of the 329 patients in the placebo group, 99 (30.1%) patients discontinued study drug during the DB Period. 241 (vutrisiran) and 221 patients (placebo) entered the OLE period, 4 and 8 patients, respectively discontinued vutrisiran therapy during the OLC period that was ongoing with 248 and 224 patients respectively at the time of the data base lock.

## Study population

Subjects were well representative for patients with hATTRwt and hATTRv amyloidosis and mild to moderate symptomatic cardiomyopathy. Baseline disease characteristic were overall balanced between the groups. In the overall population, 578 (88.4%) patients had wtATTR amyloidosis and 76 (11.6%) patients had hATTR amyloidosis. The mean years since diagnosis of ATTR amyloidosis was 1.43 (range, 0.0 to 11.1) years. The mean age of patients at symptom onset was 73.3 (range, 35 to 85) years. Most (77.7%) patients had NYHA class II HF and were classified as having ATTR amyloidosis disease Stage 1 (66.8%) or Stage 2 (28.6%). In the overall population, baseline disease characteristics were generally similar between the vutrisiran and placebo  groups,  except  for  a  higher  median  NT-proBNP  level  in  the  vutrisiran  group  (2020.50  ng/L) compared to the placebo group (1801.00 ng/L), which was primarily driven by an imbalance in the vutrisiran monotherapy  subgroup.  Baseline  disease  characteristics  were  indicative  of  somewhat  greater  disease

<div style=\"page-break-after: always\"></div>

severity among patients not on tafamidis at baseline (vutrisiran monotherapy subgroup) compared with patients who were on tafamidis at baseline (background tafamidis subgroup).

Overall, 35.5% of patients also had a history of neuropathy/polyneuropathy.

## Statistical methods

The definition of the analysis sets is overall appropriate. For the SAF Patients who were randomized to placebo group but received any amount of vutrisiran during the DB Period were grouped into the vutrisiran arm. This is not an issue if it happens to single patients. In a case where a larger group of patients in the placebo group receives single doses of vutrisiran, the AE rate may be diluted. This was not a relevant issue in HELIOS-B.

The primary efficacy analyses were prespecified for two populations, all patients included and patients on vutrisiran  monotherapy  (no  tafamidis  at  baseline).  This  is  endorsed.  Analyses  for  patients  on  tafamidis background therapy are provided in the Attachment to the clinical study report separately. Reporting the results in this subgroup in the Body CSR and in the summary of efficacy/overview key documents also would have made the assessment of the data easier.

Estimands were specified in the SAP in alignment with the primary and key secondary objectives. Generally, as the study design and analysis should be aligned to the estimand, it is preferred when estimands are also specified in the protocol.

As  part  of  the  primary  estimand  definition,  it  was  specified  that  the  intercurrent  events  treatment discontinuation  and  initiation  of  alternative  therapies  (including  tafamidis  drop-in  in  the  vutrisiran monotherapy subgroup) were to be accounted for by the treatment policy strategy, which is appropriate. Heart  transplantation  and  LVAD  placement  were  treated  as  CV-related  death,  i.e.,  accounted  for  by  a composite strategy, which is also acceptable. Study discontinuation was considered as an intercurrent event by the applicant that was accounted for by the hypothetical strategy, however, it is not an intercurrent event in itself (see ICH E9 (R1)) but a reason for missing data.

For addressing the effect on 6-MWT and KCCQ-OS after 30 months of treatment, treatment discontinuation and initiation of alternative therapies was also accounted for by a treatment policy strategy. Death (including heart transplant and LVAD placement) was aimed to be accounted for by a composite strategy, which is in principle  acceptable.  However,  it  is  not  straightforward  what  is  the  appropriate  implementation  of  a composite  strategy,  particularly  whether  the  imputation  based  on  10%  worst  values  in  the  respective treatment arm is  appropriately  aligned  with  considering  a  patient  a  treatment  failure.  Therefore,  1)  an analysis assigning worst possible values to deaths (i.e., imputing a value of 0 for patients who die) and 2) a rank-based analysis in analogy to the sensitivity analysis for the primary endpoint (i.e., assigning worst ranks to patients with shortest survival time) was provided.

The randomisation stratification factors were appropriately taken into account in the analysis.

The analysis of the composite primary endpoint based on the modified Andersen-Gill model incorporating mortality as terminal event and hospitalisations as recurrent event may bear considerable problems with interpretation, as the two events included are of different severity, and mortality is a competing event for hospitalisation. However, it is acknowledged that a rank-based analysis was also provided as well as an analysis of the single components. Overall, the primary analysis in combination with these analyses are considered  sufficient  for  providing  a  complete  picture.  In  alignment  with  the  treatment  policy  strategy, patients  were  aimed  to  be  followed  irrespectively  of  treatment  discontinuation,  which  is  appreciated. However, the analysis is based on the non-informative censoring assumption for patients who nevertheless discontinued the study, which is questionable as it assumes a continued benefit from treatment for patients in the active arm. It is acknowledged that a sensitivity analysis imputing CV events after discontinuation

<div style=\"page-break-after: always\"></div>

was provided but as the imputation model considered treatment arm, it is still based on the assumption of similar CV risk for patients in the active arm who discontinued treatment than for patients on treatment. Additional  analyses  assuming a similar CV event rate as in the placebo arm were be provided showing robustness of the results

Included survival data collected within 6 months after the first dose during the OLE Period in the analysis of all-cause mortality is acceptable, as even if the assumption of no effect on mortality during this time was not fulfilled, it would be a conservative analysis.

For the continuous secondary endpoints 6-MWT and KCCQ-OS, the MMRM model that was primarily used may also not be plausible for patients who discontinued the study as it is based on the missing at random assumption. The pattern mixture model (copy reference) that was provided as sensitivity analysis may be in better alignment with the targeted estimand as it assumes similar outcomes than in patients who are not on active treatment and should be the basis for reporting results.

As a significant imbalance in baseline NT-proBNP and troponin I between treatment groups was observed after unblinding, adjusted Kaplan-Meier curves were generated for time to event endpoints, including allcause mortality and time to first CV event or all-cause mortality. However, although the argument that the analysis models that were the basis for hypothesis tests and estimation of treatment effects are adjusted for  these  factors  is  acknowledged,  results  should  still  be  primarily  reported  based  on  the  pre-specified methods to avoid any data-driven decisions.

The multiplicity strategy ensured control of the study-wise type 1 error for the hypothesis tests for the primary  and  key  secondary  endpoints  based  on  the  overall  population  and  the  Vutrisiran  Monotherapy Subgroup. However, as the effects in the overall population may be driven by the monotherapy subgroup, it is agreed that the analysis in the background tafamidis subgroup is also important.

## Efficacy data and additional analyses

## Primary Endpoint: Composite Outcome of All-cause Mortality and Recurrent CV Events (CV Hospitalizations and Urgent HF Visits)

In the overall population, vutrisiran patients had a statistically significant 28.2% reduction in the risk of allcause mortality and recurrent CV events compared to placebo (hazard ratio: 0.718; 95% CI: 0.555, 0.929; P=0.0118).

In the vutrisiran monotherapy subgroup, vutrisiran patients had a statistically significant 32.8% reduction in the risk of all-cause mortality and recurrent CV events compared to placebo (hazard ratio: 0.672; 95% CI: 0.487, 0.929; P=0.0162).

There was a time delay of about 9 months and about 15 - 18 months before a treatment effect was observed for the overall population and the vutrisiran monotherapy population, respectively. Both, mortality events and HFH/UHVs events contributed consistently to the result. Heart transplant events added only to a minor degree to the mortality, consistent with 'true' death events, no LVAD placement was noted. Inclusion of the letter two events did not have a relevant impact on the overall result.

A consistent numerical result was also noted in patients receiving background tafamidis therapy with a HR of  0.785,  p  =  0.27  favouring  vutrisiran  over  placebo  (not  part  of  the  primary  analysis)  with  consistent numerical imbalances for both components of the composite endpoint. The data on the administration in combination with tafamidis are difficult to interpret. There may be some overlap in efficacy between onset of an effect of tafamidis after treatment initiation and onset of efficacy of vutrisiran. No conclusions are possible on whether there is benefit in coadministration of both drugs over administration of vutrisiran or

<div style=\"page-break-after: always\"></div>

tafamidis alone. The data do also not provide information on whether efficacy of vutrisiran is higher than efficacy of tafamidis.

## Individual Components of the Primary Endpoint

## All-Cause Mortality

Events reported after study withdrawal were included for the component analysis of all-cause mortality. In the  overall  population,  vutrisiran  treatment  led  to  a  30.6%  reduction  in  the  risk  of  all-cause  mortality compared to placebo (hazard ratio: 0.694; 95% CI: 0.490, 0.982; P=0.0389).

In the vutrisiran monotherapy subgroup, vutrisiran treatment led numerically to a 29.5% reduction in the risk of all-cause mortality compared to placebo (hazard ratio: 0.705; 95% CI: 0.467, 1.064; P=0.1179).

There was a delay by about 18 - 24 months until an effect on mortality was observed. Of note, also the rate of non-CV deaths was lower in patients receiving vutrisiran.

## Recurrent CV Events

In the overall population, in the analysis of recurrent CV events, including CV hospitalizations and urgent HF visits, vutrisiran treatment led to a 26.7% reduction in the risk of CV events compared to placebo (relative rate ratio: 0.733; 95% CI: 0.610, 0.882; P=0.0010).

In  the  vutrisiran  monotherapy  subgroup,  vutrisiran  led  to  a  32.4%  reduction  in  the  risk  of  CV  events compared to placebo (relative rate ratio: 0.676; 95% CI: 0.533, 0.857; P=0.0012).

There was a delay by about 9 - 15 months for the treatment effect to emerge.

## Sensitivity and Additional Analyses for the Primary Endpoints

In the win ratio sensitivity analysis, the survival status collected after study discontinuation was included in the hierarchical comparisons. A win ratio of &gt;1 represents a favorable outcome for vutrisiran. The win ratio in the overall population was 1.39 (P=0.0088), indicating a reduction in all-cause mortality and recurrent CV events in the vutrisiran group compared to placebo. A consistent effect was observed in the vutrisiran monotherapy subgroup (win ratio: 1.51; P=0.0089).

All  other  sensitivity  and  additional  analyses  presented  for  the  primary  endpoints  were  consistent  and supported the primary analysis results of the vutrisiran treatment effect compared to placebo. This pertains to sensitivity analyses based on: - Data through 42 months, - Imputing CV events after study withdrawal, Truncating outliers (For patients with more than 7 events, the first 7 most important events were kept for analysis, with importance ranked in the order of death, CV hospitalization and urgent HF visit), - HT/LVAD placement not treated as all cause mortality; data censored at the date of such procedure, - SGLT2 inhibitor drop-in due to cardiac disease progression treated as a CV event, and additional analyses based on: - Use of CV events per investigator assessment instead of CEC adjudication, - For the monotherapy subgroup, events beyond 9 months of initiation of tafamidis censored.

## Subgroup Analysis: Composite Outcome of All-cause Mortality and Recurrent CV Events (CV Hospitalizations and Urgent HF Visits)

The effect of vutrisiran treatment on the composite outcome of all-cause mortality and recurrent CV events was consistent across allmost prespecified subgroups, including age, baseline tafamidis use (in the overall population),  NYHA  class,  and  baseline  NT-proBNP  in  both  the  overall  population  (Figure  20)  and  the vutrisiran monotherapy subgroup (Figure 20 and Figure 21). Analyses by Region showed consistent results for the EU population vs. other regions.

<div style=\"page-break-after: always\"></div>

For patients with hATTR the analyses indicated efficacy of vutrisiran in the vutrisiran monotherapy subgroup but not in the overall population. The data suggest even a numerically negative effect of vutrisiran in patients with hATTR when pretreated with tafamidis. This was further clarified  by the Applicant.

## Secondary endpoints

## 6-MWT

At Month 30, vutrisiran led to a statistically significant improvement in 6-MWT compared to placebo in the overall  population  (least  square  [LS]  mean  difference:  26.46  m;  P=7.976E-05),  with  consistent  results observed in the vutrisiran monotherapy subgroup (32.09 m; P = 0.0005). In the Background Tafamidis Subgroup the least square [LS] mean difference (SEM) at month 30 was 18.44 (9.15), P = 0.0450. The difference  by  32  and  26  m  in  the  vutrisiran  monotherapy  and  the  overall  group,  respectively  is  at  the threshold of what has been accepted in the past as being clinically relevant. There was a delay by about 12 - 18 months before a larger treatment effect was observed. This is consistent with published results for acoramidis (delay by about 12 months), but not for Tafamidis (no relevant delay, Gillmore et al., 2024; Maurer et al., 2018).  Irrespectively, in the context of the totality of data, the result is supportive for the assumption of a clinically relevant efficacy.

## KCCQ-OS

At Month 30, vutrisiran led to a statistically significant improvement in KCCQ-OS compared to placebo in the overall population (LS mean difference: 5.80 points; P=0.0008). The difference was larger (8.7 points (in the vutrisiran monotherapy group and small (LSMean difference 1.7) in the Background Tafamidis group.

The overall treatment effect can be considered a small but clinically relevant difference in the overall group and in the vutrisiran monotherapy group, whereas the difference in the background tafamidis group was below the generally accepted threshold of 5.

Results across all KCCQ-OS domains, reflecting the severity of physical and social limitations, the frequency and severity of symptoms, and the quality of life impacts associated with cardiomyopathy were consistent with the primary analysis and showed a treatment effect in favor of vutrisiran compared to placebo in both the overall population and the vutrisiran monotherapy subgroup.

The effect of vutrisiran treatment on KCCQ-OS was largely consistent across most prespecified subgroups in both the overall population (including baseline tafamidis use) and the vutrisiran monotherapy subgroup. Analyses for 6-MWD and KCCQ did not indicate athat an effect on polyneuropathy had a relevant impact on the overall results

## All-Cause Mortality

The  Applicant  has  counted  death  cases  that  occurred  in  the  placebo  arm  after  switching  to  open  label vutrisiran treatment up to month 42 as death cases on placebo. The approach is based on the assumption of a time delay of more than 12 months until an effect of vutrisiran on mortality emerges. With the variable follow-up design of this study, patients enrolled in the OLE Period received their first OLE dose at either Month 33 or Month 36, depending on their enrollment time. The analysis of all-cause mortality as a secondary endpoint  included  all  vital  status  collected  through  42  months.  The  approach  can  be  supported  for exploratory but not for a confirmatory purpose. However, since the results are consistent with the component analysis of mortality during the DB phase, the acceptability of the approach is more of theoretical nature.

Vutrisiran patients had a statistically significant 35.5% reduction in the risk of all-cause mortality compared to placebo in the overall population (hazard ratio: 0.645; 95% CI: 0.463, 0.898; P=0.0098; 95% CI: 0.440, 0.973; P=0.0454.

<div style=\"page-break-after: always\"></div>

The analysis of CV-related mortality through 42 months showed a similar numerical treatment effect as allcause mortality in both the overall population and the vutrisiran monotherapy subgroup. (p &gt; 0.05 for both groups. The effect of vutrisiran treatment on all-cause mortality was overall consistent across all prespecified subgroups in both the overall population and the vutrisiran monotherapy subgroup. Only a small effect on mortality  was  observed  in  patients  with  hATTR,  mainly  due  to  the  result  in  the  vutrisiran  monotherapy population. An integrated discussion of the totality of data available for hATTR patients indicated efficacy of vutrisiran monotherapy also in this population whereas efficacy of vutrisiran in hATTR patients an tafamidis background therapy is in question.

## NYHA Class

At Month 30, vutrisiran led to a statistically significantly greater proportion of patients who showed stability (no change in class) or improvement compared to placebo in the overall population (adjusted difference: 8.7%,  95%  CI:  1.3,  16.1;  P=0.0217),  with  consistent  results  observed  in  the  vutrisiran  monotherapy subgroup and only a smaller effect in patients at background tafamidis therapy.

## Exploratory endpoints

## Time to First CV Event (including CV Hospitalizations and Urgent HF Visits) or All-Cause Mortality

In the overall population, vutrisiran treatment led to a 28.4% reduction in the risk of first CV event or allcause mortality compared to placebo (hazard ratio: 0.716; 95% CI: 0.566, 0.905; P=0.0062)

In the vutrisiran monotherapy subgroup, vutrisiran treatment led to a 35.6% reduction in the risk of first CV  event  or  all-cause  mortality  compared  to  placebo  (hazard  ratio:  0.644;  95%  CI:  0.479,  0.867; P=0.0043).

Kaplan-Meier curves illustrating time to first CV event or all-cause mortality showed curves diverging after approximately 6 months of treatment in both the overall population and in the vutrisiran monotherapy subgroup.

Consistent results were also obtained for the following exploratory analyses (data not shown here):

- -Time to First CV Event (including CV Hospitalization, Urgent HF Visit and Any Initiation of SGLT2 Inhibitor due to Cardiac Disease Progression), or All-Cause Mortality
- -Time to First Oral Diuretic Intensification, First CV Event (including CV Hospitalization and Urgent HF Visit), or All-Cause Mortality
- -Time to Second CV Event (including CV Hospitalizations and Urgent HF Visits) or All-Cause Mortality
- -Composite Outcome of All-Cause Mortality and Recurrent All-Cause Hospitalizations and Urgent HF Visits

Considering clinical and methodological issues hampering a straightforward interpretation of recurrent event analysis in diseases with high mortality, the first event analysis, even if only predefined as an exploratory analysis by the MAH, is considered of major importance. The results were consistent with the  primary  analysis  and  supported  the  robustness  and  assumption  of  the  clinical  relevance  of  the primary results in both main populations analysed.

## Cardiac Biomarkers

## NT-proBNP Change from Baseline

Serum levels of NT-proBNP were measured during the DB Period.

<div style=\"page-break-after: always\"></div>

At  Month 30, vutrisiran led to a 32% relative reduction in the fold increase in NT-proBNP compared to placebo in the overall population (adjusted geometric mean fold change ratio [vutrisiran/placebo]: 0.68; P=3.440E-12). Median change from baseline in NT-proBNP levels indicated relative stability in vutrisiran patients with an 8.98% increase while levels in placebo patients indicated worsening with a 51.62% increase.

Vutrisiran led to a 43% relative reduction in the fold increase in NT-proBNP compared to placebo in the vutrisiran monotherapy subgroup (adjusted geometric mean fold change ratio [vutrisiran/placebo]: 0.57; P=4.339E-12).

The effect of vutrisiran treatment on NT-proBNP was consistent across most subgroups in both the overall population  and  the  vutrisiran  monotherapy  population.  However,  only  a  small  numerical  difference  was observed in patients with Tafamidis at baseline.

## Troponin I

Results for Troponin I were similar to the results as reported for NT-proBNP

## Echocardiographic parameters

Echocardiographic  parameters  showed  some  improvement  in  change  from  baseline  to  month  30  when comparing vutrisiran and placebo. There was an LS mean (SEM) difference in mean LV wall thickness by 0.4 (0.2) mm and 0.8 (0.3) mm in the overall and the vutrisiran monotherapy population. Small differences were also seen for LV ejection fraction that decreased with placebo and with vutrisiran. There were LS mean (SEM) differences in the change of the ejection fraction by (absolute) 2.03 (0.86) and 2.27 (1.19) % (overall group and vutrisiran monotherapy group, respectively), in LV mass by -18.86 (7.17) and -30.87 (10.48) and in average peak longitudinal strain (%) by -1.23 (0.26) and -1.30 (0.36) respectively. Per se, these differences are considered at the most moderate.

## eGFR

Vutrisiran was associated with lower decline from baseline in eGFR compared to placebo (LS mean [SEM] difference:  2.2  [±1.3]  mL/min/1.73m2,  P=0.0876)  in  the  overall  population.  Consistent  results  were observed in the vutrisiran monotherapy subgroup and in patients on background tafamidis therapy (LS mean [SEM] difference mL/min/1.73m2: 2.5 (1.8) p= 0.1654, and 2.0 (1.8), p= 0.2763 respectively). The results are reassuring. Since the underlying form of amyloidosis has in impact on whether the kidney is a target organ of the disease, data on kidney function over time by differentiating between wtATTR and hATTR were requested. The data indicated a small numerical imbalance in favour of vutrisiran becoming visible after 24 months.

## ATTR Amyloidosis Disease Stage

Categorizing patients by NAC stage is clinically in use for its prognostic value. In the overall population, 77.3% of patients in the vutrisiran group showed no progression in ATTR amyloidosis stage at Month 30 compared  to  61.2%  of  patients  in  the  placebo  group  (adjusted  difference:  16.1;  95%  CI:  8.1,  24.2; P=7.889E-05). Consistent results were observed in the vutrisiran monotherapy subgroup and in patients on background tafamidis therapy (adjusted difference: 14.8 (3.7, 26.0), p = 0.0112, and 17.8 (6.3, 29.3), p = 0.0030, respectively). The result of more patients showing no progression in ATTR NAC stage at month 30 are supportive for the overall conclusion on a beneficial treatment effect.

## EQ-5D-5L

At Month 30, vutrisiran improved patients' self-reported general health-related quality of life, as assessed by the change from baseline in EQ-5D-5L index score, compared to placebo in the overall population (LS mean [SEM] difference: 0.0308 [±0.0111]; P=0.0056), with consistent results observed in the vutrisiran

<div style=\"page-break-after: always\"></div>

monotherapy subgroup. The treatment effect is below of what has been described as a clinically MID values by simulations (Nathan S. McClure NS et al., Value in health 2017; 20: 644-650)

## Norfolk QoL-DN Questionnaire

EMA has accepted the Norfolk QoL-DN as a validated tool to assess patients' self-reported outcomes with respect to the impact of polyneuropathy on quality of life to be used as a key secondary endpoint in the initial  MAA  for  vutrisiran  in  patients  with  hATTR  polyneuropathy  and  in  other  studies  in  hATTR  with polyneuropathy.

At Month 30, vutrisiran the result in the Norfolk QoL-DN questionnaire, compared to placebo in the overall population (LS mean [SEM] difference: -5.3 (±1.4); P=0.0001, MMRM model). The effect size was larger in the vutrisiran monotherapy group (-7.5 (±1.9); P=0.0001) and smaller in the Background Tafamidis Group (-2.6 (±1.9); P= 0.1654).

In  a  subset  of  patients  with  a  history  of  neuropathy,  vutrisiran  also  improved  the  score  with  vutrisiran compared to placebo in the overall population (LS mean [SEM] difference: -4.6 [±2.3]; P=0.0473). The effect size was larger in the vutrisiran monotherapy group (-9.5 (±3.5); P= 0.0089). No effect was observed in the Background Tafamidis Group (-0.8 (±3,1); P= 0. 8041).

Considering the different patient population in HELIOS-A (ATTR amyloidosis with PN9 and HELIOS-B (ATTR amyloidosis with CM), it is expected that the effect size in HELIOS-B was smaller as compared to the effect size  of  -21.0  (3.1,8)  in  the  indirect  comparison  between  HELIOS  A  and  APOLLO  placebo.  EPAR EMA/CHMP/689555/2022. Since no published values for an MID are known, the relevance of the finding is not entirely clear.

## Additional expert consultation

## N/A

## Assessment of paediatric data on clinical efficacy

No data in the paediatric population were submitted as part of the application.

A product-specific paediatric investigational plan waiver was granted by the EMA Paediatric Committee for vutrisiran  (EMEA-002425-PIP01-18  -  P/0015/2019),  as  ATTR  amyloidosis  occurs  almost  exclusively  in adults. The waiver covers all subsets of the paediatric population (0 to 18 years).

## 2.4.4. Conclusions on the clinical efficacy

Transthyretin  amyloidosis  including  hATTR  and  wtATTR  is  a  rare,  progressive  and  fatal  disease  which manifests as destabilization of the tetrameric structure of the TTR protein. Vutrisiran is an siRNA molecule that uses RNA interference mechanisms to target and silence the expression of wild type and variant TTR mRNA and inhibit the synthesis of the TTR protein.

Large reductions in TTR and a clinically relevant and statistically significant reduction in the primary composite endpoint of all-cause mortality and CV events (CV hospitalizations and UHVs) have been observed in the overall population and in patients not treated with tafamidis at baseline. The results are supported by clinically relevant and statistically significant improvements in the following confirmatory secondary endpoints: 6-MWT at month 30, KCCQ-OS at month 30, All-cause mortality by month 42 and

<div style=\"page-break-after: always\"></div>

NYHA class at month 30 in both populations. The population reflects the target indication as proposed in the indication applied for.

## 2.5. Clinical safety

## Introduction

The MAH is seeking to extend the indication for the medicinal product AMVUTTRA (vutrisiran) to include the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTRCM), based on the results of the HELIOS-B study.

## Patient exposure

During the DB period of the HELIOS-B study, 326 patients were treated with vutrisiran and 328 patients were treated with placebo. At the time of the primary analysis, all active patients had completed the DB period.

The median duration of treatment in the vutrisiran group was 35.78 months (range:  0.6 to 38.7 months), with  a  cumulative  treatment  exposure  of  833.9  patient  years  (Table  20).  Two  hundred  and  fifty-seven (78.8%) patients had vutrisiran exposure ≥ 30 months, and 77 (23.6%) patients had vutrisiran exposure ≥ 36 months. The median duration of treatment in the placebo group was 33.77 months (range:  1.1 to 37.3 months), with a cumulative treatment exposure of 822.4 patient-years. The proportion of patients who received at least 12 doses was 75.8% and 69.5% in the vutrisiran and placebo groups, respectively. Overall, a total of 3601 doses of vutrisiran and 3573 doses of placebo were administered during the DB Period.

Table 20. Overall exposure to study drug during the DB period of the HELIOS-B study (safety analysis set)

| Parameter                                           | Placebo (N=328)                            | Vutrisiran (N=326)                         |
|-----------------------------------------------------|--------------------------------------------|--------------------------------------------|
| Duration of study drug exposure (months) a          |                                            |                                            |
| Mean (SD)                                           | 30.09 (9.32)                               | 30.70 (9.58)                               |
| Median (min, max)                                   | 33.77 (1.1, 37.3)                          | 35.78 (0.6, 38.7)                          |
| Cumulative study drug exposure, patient-years a     | 822.4                                      | 833.9                                      |
| Duration of study drug exposure (cumulative), n (%) |                                            |                                            |
| ≥1 day                                              | 328 (100.0)                                | 326 (100.0)                                |
| ≥6 months                                           | 314 (95.7)                                 | 312 (95.7)                                 |
| ≥12 months                                          | 301 (91.8)                                 | 293 (89.9)                                 |
| ≥18 months                                          | 279 (85.1)                                 | 278 (85.3)                                 |
| ≥24 months                                          | 262 (79.9)                                 | 267 (81.9)                                 |
| ≥30 months                                          | 241 (73.5)                                 | 257 (78.8)                                 |
| ≥36 months                                          | 63 (19.2)                                  | 77 (23.6)                                  |
| Total number of doses received per patient          | Total number of doses received per patient | Total number of doses received per patient |

<div style=\"page-break-after: always\"></div>

| Parameter                             | Placebo (N=328)   | Vutrisiran (N=326)   |
|---------------------------------------|-------------------|----------------------|
| Mean (SD)                             | 10.9 (3.3)        | 11.0 (3.4)           |
| Median (min, max)                     | 12.0 (1, 13)      | 13.0 (1, 13)         |
| Cumulative number of doses received   | 3573              | 3601                 |
| Total number of doses received, n (%) |                   |                      |
| ≥1                                    | 328 (100.0)       | 326 (100.0)          |
| ≥5                                    | 301 (91.8)        | 293 (89.9)           |
| ≥9                                    | 265 (80.8)        | 266 (81.6)           |
| ≥12                                   | 228 (69.5)        | 247 (75.8)           |

Abbreviations:  DB=double-blind; max=maximum; min=minimum; SD=standard deviation.

a Individual duration of exposure (in days) was calculated as the earliest date of (the end of study, data cutoff date, 84 days after the last dose of study drug), minus the date of the first dose of study drug plus 1. Duration of exposure in months or years = duration of exposure (days) divided by 30.4375 and 365.25, respectively.

## Adverse events

During the DB period of the HELIOS-B study, 322 (98.8%) patients in the vutrisiran group and 323 (98.5%) patients in the placebo group had at least 1 AE (Table 21). AEs considered related to study drug by the Investigator were reported in 41 (12.6%) patients in the vutrisiran group and 46 (14.0%) patients in the placebo group. The majority of the AEs were mild or moderate in intensity. Severe AEs were reported in 158 (48.5%) patients in the vutrisiran group and 194 (59.1%) patients in the placebo group. The proportion of patients with severe AEs considered related to study drug by the Investigator was low in the 2 groups (1 [0.3%] vutrisiran; 2 [0.6%] placebo).

Serious  adverse  events  (SAEs)  were  reported  in  201  (61.7%)  patients  in  the  vutrisiran  group  and  220 (67.1%) patients in the placebo group. The percentage of patients with SAEs considered related to study drug by the Investigator was low in both groups (2 [0.6%] vutrisiran; 1 [0.3%] placebo). AEs leading to discontinuation of study drug were reported in 10 (3.1%) patients in the vutrisiran group and 13 (4.0%) patients in the placebo group. No AEs leading to discontinuation of study drug were considered related to study drug in the vutrisiran group.

Fatal AEs were reported in 49 (15.0%) patients in the vutrisiran group and 63 (19.2%) patients in the placebo group. No deaths were assessed as related to study drug by the Investigator.

Table 21. Overview of AEs during the DB period of the HELIOS-B study (safety analysis set)

|                       | Placebo (N=328; PY=822.4)   | Placebo (N=328; PY=822.4)   | Vutrisiran (N=326; PY=833.9)   | Vutrisiran (N=326; PY=833.9)   |
|-----------------------|-----------------------------|-----------------------------|--------------------------------|--------------------------------|
| Category              | n (%)                       | Events/ER                   | n (%)                          | Events/ER                      |
| At least 1 AE         | 323 (98.5)                  | 4549/553.1                  | 322 (98.8)                     | 3542/424.7                     |
| Related to study drug | 46 (14.0)                   | 77/9.4                      | 41 (12.6)                      | 57/6.8                         |
| At least 1 serious AE | 220 (67.1)                  | 629/76.5                    | 201 (61.7)                     | 528/63.3                       |
| Related to study drug | 1 (0.3)                     | 1/0.1                       | 2 (0.6)                        | 2/0.2                          |
| At least 1 severe AE  | 194 (59.1)                  | 515/62.6                    | 158 (48.5)                     | 366/43.9                       |

<div style=\"page-break-after: always\"></div>

|                                                          | Placebo (N=328; PY=822.4)   | Placebo (N=328; PY=822.4)   | Vutrisiran (N=326; PY=833.9)   | Vutrisiran (N=326; PY=833.9)   |
|----------------------------------------------------------|-----------------------------|-----------------------------|--------------------------------|--------------------------------|
| Category                                                 | n (%)                       | Events/ER                   | n (%)                          | Events/ER                      |
| Related to study drug                                    | 2 (0.6)                     | 3/0.4                       | 1 (0.3)                        | 1/0.1                          |
| At least 1 AE leading to study drug interruption         | 8 (2.4)                     | 9/1.1                       | 8 (2.5)                        | 10/1.2                         |
| Related to study drug                                    | 0                           | 0                           | 2 (0.6)                        | 2/0.2                          |
| At least 1 AE leading to discontinuation from study drug | 13 (4.0)                    | 18/2.2                      | 10 (3.1)                       | 10/1.2                         |
| Related to study drug                                    | 1 (0.3)                     | 1/0.1                       | 0                              | 0                              |
| Deaths a                                                 | 63 (19.2)                   | NA                          | 49 (15.0)                      | NA                             |

Abbreviations:  AE=adverse event; DB=double-blind; ER=exposure-adjusted event rate per 100 patient-years, calculated as events/PY*100; NA=not applicable; PY=patient-years; SAE=serious adverse event.

a All fatal SAEs are summarized regardless of treatment-emergent classification. Deaths that occurred after the end of study visit or after the data cutoff date are not included.

## Common Adverse Events

AEs that were reported in ≥ 10% of patients during the DB period of the HELIOS-B study in any group are presented by Preferred Term in Table 22. The most commonly reported AEs ( ≥ 20% of patients) in the Placebo and Vutrisiran group were cardiac failure (39.0% vs. 31.0%), COVID-19 (30.2% vs. 26.7%), and atrial fibrillation (20.7% vs. 21.2%). The majority of AEs in the vutrisiran group occurred at a similar or lower frequency than in the placebo group. No AE had an incidence of ≥ 3% higher in the vutrisiran group compared to the placebo group.

Table 22. AEs in ≥10% of patients in the placebo and Vutrisiran group by preferred term during the DB period of the HELIOS-B study (safety analysis set)

|                         | Placebo (N=328; PY=822.4)   | Placebo (N=328; PY=822.4)   | Vutrisiran (N=326; PY=833.9)   | Vutrisiran (N=326; PY=833.9)   |
|-------------------------|-----------------------------|-----------------------------|--------------------------------|--------------------------------|
| Preferred Term          | n (%)                       | Events/ER                   | n (%)                          | Events/ER                      |
| At least 1 AE           | 323 (98.5)                  | 4549/553.1                  | 322 (98.8)                     | 3542/424.7                     |
| Cardiac failure         | 128 (39.0)                  | 255/31.0                    | 101 (31.0)                     | 173/20.7                       |
| COVID-19                | 99 (30.2)                   | 109/13.3                    | 87 (26.7)                      | 93/11.2                        |
| Atrial fibrillation     | 68 (20.7)                   | 92/11.2                     | 69 (21.2)                      | 107/12.8                       |
| Gout                    | 51 (15.5)                   | 77/9.4                      | 48 (14.7)                      | 81/9.7                         |
| Dyspnoea                | 51 (15.5)                   | 66/8.0                      | 43 (13.2)                      | 49/5.9                         |
| Fall                    | 69 (21.0)                   | 111/13.5                    | 42 (12.9)                      | 64/7.7                         |
| Back pain               | 32 (9.8)                    | 38/4.6                      | 39 (12.0)                      | 45/5.4                         |
| Arthralgia              | 39 (11.9)                   | 46/5.6                      | 33 (10.1)                      | 49/5.9                         |
| Constipation            | 43 (13.1)                   | 55/6.7                      | 33 (10.1)                      | 35/4.2                         |
| Oedema peripheral       | 25 (7.6)                    | 28/3.4                      | 33 (10.1)                      | 41/4.9                         |
| Urinary tract infection | 38 (11.6)                   | 49/6.0                      | 33 (10.1)                      | 46/5.5                         |

<div style=\"page-break-after: always\"></div>

|                | Placebo (N=328; PY=822.4)   | Placebo (N=328; PY=822.4)   | Vutrisiran (N=326; PY=833.9)   | Vutrisiran (N=326; PY=833.9)   |
|----------------|-----------------------------|-----------------------------|--------------------------------|--------------------------------|
| Preferred Term | n (%)                       | Events/ER                   | n (%)                          | Events/ER                      |
| Dizziness      | 43 (13.1)                   | 52/6.3                      | 32 (9.8)                       | 36/4.3                         |
| Fatigue        | 45 (13.7)                   | 58/7.1                      | 28 (8.6)                       | 33/4.0                         |

Abbreviations:  AE=adverse event; COVID-19=Coronavirus disease 2019; DB=double-blind; ER=exposure-adjusted event rate per 100 patient-years, calculated as number of events/PY*100; MedDRA=Medical Dictionary for Regulatory Activities; PY=patient-years. Note:  Adverse events were coded using MedDRA version 23.0. Preferred terms are ordered by descending frequency in vutrisiran column.

## Adverse Events Related to Study Drug

Related AEs were reported in 41 (12.6%) patients in the vutrisiran group and 46 (14.0%) patients in the placebo group during the DB period of the HELIOS-B study. The only related AE reported in ≥ 1% of patients in either group was injection site reaction (ISR; 7 [2.1%] patients in the vutrisiran group and 8 [2.4%] patients in the placebo group). None of the related ISRs were severe or serious or led to discontinuation of study drug.

## Serious adverse event/deaths/other significant events

## Deaths

Deaths were reported in 49 patients (15.0%) in the vutrisiran group and 63 patients (19.2%) in the placebo group during the DB period of the HELIOS-B study. None of the deaths were considered related to study drug by the Investigator. The majority of deaths were CV in nature and consistent with those expected in this patient population.

## Serious Adverse Events (SAEs)

The most frequently reported SAEs ( ≥ 5%) in either treatment group were cardiac failure (11.7% vutrisiran, 17.4%  placebo),  atrial  fibrillation  (8.0%  vutrisiran,  6.1%  placebo),  and  cardiac  failure  acute  (4.0% vutrisiran, 5.5% placebo).

Only 2 (0.6%) patients in the vutrisiran group (PT: hematuria and cough in 1 patient each) and 1 (0.3%) patient in the placebo group (PT: syncope) had SAEs assessed as related to study drug by the Investigator. All of these events resolved during the study.

Table 23. SAEs in ≥2% of patients in the placebo and Vutrisiran group by preferred term during the DB period of the HELIOS-B study (safety analysis set)

|                       | Placebo (N=328; PY=822.4)   | Placebo (N=328; PY=822.4)   | Vutrisiran (N=326; PY=833.9)   | Vutrisiran (N=326; PY=833.9)   |
|-----------------------|-----------------------------|-----------------------------|--------------------------------|--------------------------------|
| Preferred Term        | n (%)                       | Events/ER                   | n (%)                          | Events/ER                      |
| At least 1 SAE        | 220 (67.1)                  | 629/76.5                    | 201 (61.7)                     | 528/63.3                       |
| Cardiac failure       | 57 (17.4)                   | 94/11.4                     | 38 (11.7)                      | 70/8.4                         |
| Atrial fibrillation   | 20 (6.1)                    | 27/3.3                      | 26 (8.0)                       | 29/3.5                         |
| Cardiac failure acute | 18 (5.5)                    | 21/2.6                      | 13 (4.0)                       | 16/1.9                         |
| Pneumonia             | 10 (3.0)                    | 11/1.3                      | 12 (3.7)                       | 13/1.6                         |
| Acute kidney injury   | 10 (3.0)                    | 13/1.6                      | 11 (3.4)                       | 12/1.4                         |

<div style=\"page-break-after: always\"></div>

|                            | Placebo (N=328; PY=822.4)   | Placebo (N=328; PY=822.4)   | Vutrisiran (N=326; PY=833.9)   | Vutrisiran (N=326; PY=833.9)   |
|----------------------------|-----------------------------|-----------------------------|--------------------------------|--------------------------------|
| Preferred Term             | n (%)                       | Events/ER                   | n (%)                          | Events/ER                      |
| Osteoarthritis             | 8 (2.4)                     | 10/1.2                      | 10 (3.1)                       | 10/1.2                         |
| Atrial flutter             | 9 (2.7)                     | 9/1.1                       | 9 (2.8)                        | 10/1.2                         |
| Syncope                    | 7 (2.1)                     | 8/1.0                       | 8 (2.5)                        | 10/1.2                         |
| Ventricular tachycardia    | 8 (2.4)                     | 9/1.1                       | 8 (2.5)                        | 9/1.1                          |
| Fall                       | 8 (2.4)                     | 8/1.0                       | 6 (1.8)                        | 6/0.7                          |
| Cardiac failure congestive | 15 (4.6)                    | 21/2.6                      | 4 (1.2)                        | 4/0.5                          |
| Cardiogenic shock          | 7 (2.1)                     | 8/1.0                       | 4 (1.2)                        | 4/0.5                          |
| Chest pain                 | 7 (2.1)                     | 8/1.0                       | 4 (1.2)                        | 5/0.6                          |
| Bradycardia                | 7 (2.1)                     | 8/1.0                       | 3 (0.9)                        | 3/0.4                          |
| Hyponatraemia              | 7 (2.1)                     | 7/0.9                       | 3 (0.9)                        | 3/0.4                          |

Abbreviations:  DB=double-blind; ER=exposure-adjusted event rate per 100 patient-years, calculated as number of events/PY*100; MedDRA=Medical Dictionary for Regulatory Activities; PY=patient-years; SAE=serious adverse event. Note:  Adverse events were coded using MedDRA version 23.0. Preferred terms are ordered by descending frequency in vutrisiran column.

## Adverse Events of Special Interest

## Injection site reactions (ISRs)

Treatment-related ISRs were reported in 7 (2.1%) patients in the vutrisiran group and 8 (2.4%) patients in the placebo group (Table 24). All ISRs were non-serious, transient, and considered mild in severity; no ISR led to study drug discontinuation.

<div style=\"page-break-after: always\"></div>

Table 24. Treatment related ISRs during the DB period (safety analysis set)

| Category                                 | Placebo (N=328, PY=822.4)   | Placebo (N=328, PY=822.4)   | Vutrisiran (N=326, PY=833.9)   | Vutrisiran (N=326, PY=833.9)   |
|------------------------------------------|-----------------------------|-----------------------------|--------------------------------|--------------------------------|
| Preferred Term                           | n (%)                       | Events/ER                   | n (%)                          | Events/ER                      |
| Number of patients with at least 1 ISR a | 8 (2.4)                     | 9/1.1                       | 7 (2.1)                        | 7/0.8                          |
| Total number of doses                    | 3573                        | N/A                         | 3601                           | N/A                            |
| Total number (%) of doses with ISRs b    | 9 (0.3)                     | N/A                         | 7 (0.2)                        | N/A                            |
| ISR signs and symptoms c                 |                             |                             |                                |                                |
| Injection site erythema                  | 1 (0.3)                     | 2/0.2                       | 2 (0.6)                        | 2/0.2                          |
| Injection site haematoma                 | 0                           | 0                           | 1 (0.3)                        | 1/0.1                          |
| Injection site induration                | 0                           | 0                           | 1 (0.3)                        | 1/0.1                          |
| Injection site pain                      | 3 (0.9)                     | 3/0.4                       | 3 (0.9)                        | 3/0.4                          |
| Injection site paraesthesia              | 1 (0.3)                     | 1/0.1                       | 0                              | 0                              |
| Injection site pruritus                  | 2 (0.6)                     | 2/0.2                       | 0                              | 0                              |
| Injection site rash                      | 0                           | 0                           | 1 (0.3)                        | 1/0.1                          |
| Injection site swelling                  | 1 (0.3)                     | 1/0.1                       | 0                              | 0                              |

Abbreviations:  AE=adverse event; CRF=case report form; DB=double blind; ER=exposure adjusted event rate per 100 patient years; HLT=high level term; ISR=injection site reactions; MedDRA=Medical Dictionary for Regulatory Activities; N/A=not applicable; PY=patient years.

a Includes related AEs considered as injection site reactions by the Investigator (with sign/symptoms collected on a separate CRF page). The subject is counted once for the event if a patient experienced more than 1 event from the same injection.

b   % of doses with ISRs=(Total number of doses with ISRs/Total number of doses)×100.

c   The number of AEs under this section counts individual sign/symptom. AEs mapped to the MedDRA HLT of injection site reactions (sign/symptom not collected) are summarized according to their preferred terms. An ISR may consist of 1 or more signs or symptoms. Thus, sum of ISR signs and symptoms in this section may be larger than number of ISRs.

## Cardiac Events

As patients with ATTR amyloidosis commonly have cardiomyopathy and other cardiac manifestations, the proportion of patients reporting cardiac events was evaluated, including a summary of patients with AEs and SAEs in the Cardiac disorders SOC and the Cardiac arrhythmia high-level group term (HLGT) and high-level terms (HLTs), and by performing an analysis of AEs mapping to the SMQs.

Overall, the type and nature of cardiac events reported in the vutrisiran group were consistent with those expected in the patient population and consistent with the underlying disease.

AEs in the Cardiac disorders SOC were reported during the DB period of the HELIOS-B study in 227 (69.6%) patients of the vutrisiran group and in 242 (73.8%) patients of the placebo group (Table 25).

The percentage of patients with SAEs in the Cardiac disorders SOC was similar between the two treatment groups (35.6% vutrisiran, 37.8% placebo). None of the SAEs were considered related to the study drug.

The  percentage  of  patients  with  AEs  within  the  Cardiac  failure  SMQ  was  lower  in  the  vutrisiran  group compared to the placebo group when using narrow terms (39.0% vutrisiran, 51.5% placebo) and when using both broad and narrow terms (49.4% vutrisiran, 59.8% placebo). The percentage of patients with AEs within the Cardiac arrythmia HLGT was lower in the vutrisiran group (42.9%) compared to the placebo group (46.3%). The percentage of patients with AEs within the Torsade de pointes/QT prolongation SMQ was

<div style=\"page-break-after: always\"></div>

similar between the vutrisiran (16.9%) and placebo (17.7%) groups (Table 25). No confirmed events of Torsade de pointes were reported.

Table 25. Summary of cardiac events during the DB period (safety analysis set)

|                                            | Placebo (N=328; PY=822.4)   | Placebo (N=328; PY=822.4)   | Vutrisiran (N=326; PY=833.9)   | Vutrisiran (N=326; PY=833.9)   |
|--------------------------------------------|-----------------------------|-----------------------------|--------------------------------|--------------------------------|
| Category                                   | n (%)                       | Events/ER                   | n (%)                          | Events/ER                      |
| AEs in the Cardiac disorders SOC           | 242 (73.8)                  | 687/83.5                    | 227 (69.6)                     | 535/64.2                       |
| SAEs in the Cardiac disorders SOC          | 124 (37.8)                  | 259/31.5                    | 116 (35.6)                     | 196/23.5                       |
| Cardiac Failure SMQ (narrow) AEs           | 169 (51.5)                  | 353/42.9                    | 127 (39.0)                     | 232/27.8                       |
| Cardiac Failure SMQ (broad and narrow) AEs | 196 (59.8)                  | 424/51.6                    | 161 (49.4)                     | 299/35.9                       |
| Cardiac arrhythmia HLGT AEs                | 152 (46.3)                  | 271/33.0                    | 140 (42.9)                     | 253/30.3                       |
| Cardiac conduction disorders               | 34 (10.4)                   | 37/4.5                      | 18 (5.5)                       | 24/2.9                         |
| Rate and rhythm disorders NEC              | 34 (10.4)                   | 41/5.0                      | 25 (7.7)                       | 27/3.2                         |
| Supraventricular arrhythmias               | 98 (29.9)                   | 156/19.0                    | 96 (29.4)                      | 162/19.4                       |
| Ventricular arrhythmias and cardiac arrest | 30 (9.1)                    | 37/4.5                      | 31 (9.5)                       | 40/4.8                         |
| Torsade de Pointes/QT Prolongation SMQ AEs | 58 (17.7)                   | 82/10.0                     | 55 (16.9)                      | 69/8.3                         |

Abbreviations:  AE=adverse event; DB=double-blind; ER=exposure-adjusted event rate per 100 patient-years, calculated as number of events/PY*100; HLGT=high level group term; HLT=high level term; MedDRA=Medical Dictionary for Regulatory Activities; NEC=not elsewhere classified; PT=preferred term; PY=patient-years; SAE=serious adverse event; SMQ=standardized MedDRA queries; SOC=system organ class.

Notes:  If a patient had more than 1 event in a given SOC, HLGT, HLT, or SMQ, that patient is counted once for the SOC, HLGT, HLT, or SMQ. If a patient had more than 1 event with a given PT, that patient is counted only once for that PT. For the total number of events, a patient can be counted more than once if the patient has multiple events. Adverse events were coded using MedDRA version 23.0.

## Hepatic Events

As vutrisiran is directed to the liver, the frequency of hepatic events was evaluated by performing an analysis of AEs mapping to the Standardized MedDRA Query (SMQ) Drug-related Hepatic Disorders.

The proportion of hepatic AEs during the DB period of the HELIOS-B study was similar between the vutrisiran (56 [17.2%] patients) and placebo group (62 [18.6%] patients) (. Most of the hepatic AEs were within the Investigations SOC and occurred at a similar frequency between the vutrisiran and placebo group.

The majority of the hepatic AEs were mild or moderate in severity and considered not related to study drug. Hepatic SAEs  were  reported in 2 patients in the vutrisiran group (hepatic failure and  alanine aminotransferase [ALT] increased [1 patient each]) and 5 patients in the placebo group (hepatic function abnormal, hepatic encephalopathy, ischaemic hepatitis, hepatic enzyme increased [1 patient each]; ascites and hepatocellular carcinoma, both in the same patient). All SAEs were considered severe except for the event of ascites. No hepatic SAE was considered related to the study drug. The only SAE (PT: hepatocellular carcinoma) leading to discontinuation of study drug was reported in 1 patient in the placebo group.

Overall, the frequency of hepatic AEs was low, with no imbalances between vutrisiran and placebo groups in the HELIOS-B study.

<div style=\"page-break-after: always\"></div>

Table 26. Drug-related hepatic disorders (SMQ) in ≥1% of patients in either group during the DB period (safety analysis set)

| SOC                                               | Placebo (N=328; PY=822.4)   | Placebo (N=328; PY=822.4)   | Vutrisiran (N=326; PY=833.9)   | Vutrisiran (N=326; PY=833.9)   |
|---------------------------------------------------|-----------------------------|-----------------------------|--------------------------------|--------------------------------|
| Preferred Term                                    | n (%)                       | Events/ER                   | n (%)                          | Events/ER                      |
| At least 1 Drug-related Hepatic Disorder (SMQ) AE | 62 (18.6)                   | 90/10.9                     | 56 (17.2)                      | 87/10.4                        |
| Hepatobiliary disorders                           | 21 (6.4)                    | 21/2.6                      | 19 (5.8)                       | 22/2.6                         |
| Hepatic function abnormal                         | 5 (1.5)                     | 5/0.6                       | 3 (0.9)                        | 4/0.5                          |
| Investigations                                    | 41 (12.5)                   | 58/7.1                      | 40 (12.3)                      | 61/7.3                         |
| Aspartate aminotransferase increased              | 5 (1.5)                     | 5/0.6                       | 4 (1.2)                        | 9/1.1                          |
| Blood alkaline phosphatase increased              | 6 (1.8)                     | 7/0.9                       | 6 (1.8)                        | 6/0.7                          |
| Blood bilirubin increased                         | 5 (1.5)                     | 5/0.6                       | 4 (1.2)                        | 4/0.5                          |
| Gamma-glutamyltransferase increased               | 11 (3.4)                    | 12/1.5                      | 10 (3.1)                       | 12/1.4                         |
| Hepatic enzyme increased                          | 7 (2.1)                     | 7/0.9                       | 3 (0.9)                        | 3/0.4                          |
| Liver function test abnormal                      | 8 (2.4)                     | 8/1.0                       | 6 (1.8)                        | 6/0.7                          |
| Liver function test increased                     | 3 (0.9)                     | 3/0.4                       | 7 (2.1)                        | 7/0.8                          |
| Transaminases increased                           | 5 (1.5)                     | 5/0.6                       | 5 (1.5)                        | 5/0.6                          |
| Gastrointestinal disorder                         | 8 (2.4)                     | 8/1.0                       | 3 (0.9)                        | 3/0.4                          |
| Ascites                                           | 8 (2.4)                     | 8/1.0                       | 2 (0.6)                        | 2/0.2                          |

Abbreviations:  AE=adverse event; DB=double-blind; MedDRA=Medical Dictionary for Regulatory Activities; PY=patient-years; SMQ=standardized MedDRA queries; SOC=system organ class.

## Liver Function Parameters

Table 27 summarizes central and local laboratory results for worst post-baseline liver function tests (LFT) for vutrisiran and placebo patients. The majority of patients, 72.6% in the placebo group and 66.0% in the vutrisiran treatment group had liver function tests (LFT) within normal ranges.

The proportion of patients with ALT elevations (&gt;ULN and ≤ 3 × ULN) during the DB period of the HELIOS B study was higher in the vutrisiran group 97 patients (29.8%) compared with 78 patients (23.8%) in the placebo group. The potential risk for ALT increase is currently not reflected in the SPC. The MAH was asked and agreed to include this information in section 4.4 or 4.8 of the SPC.

In addition, 3 (0.9%) patients in the vutrisiran group and 0 patients in the placebo group met biochemical Hy's law criteria (ALT or AST &gt;3×ULN and concurrent total bilirubin &gt;2×ULN) based on central and local laboratory results (Table 27 and refer to Study 003 CSR 1, Section 12.3.3.2). All elevations were attributed to concurrent conditions and the applicant just referred to full narratives for these patients (Study 003 CSR 1, Section 14.3.3) without providing further explanation. In the view of CHMP involvement of vutrisiran on elevated liver  function  tests  (LFT)  cannot  be  excluded  with  certainty  and  therefore  this  was  adequately reflected in the SPC.

<div style=\"page-break-after: always\"></div>

Table 27. Summary of worst post-baseline LFT results during the DB period (central and local laboratories, safety analysis set)

|                                           |                                              | n (%)           | n (%)              |
|-------------------------------------------|----------------------------------------------|-----------------|--------------------|
| Parameter                                 | Criterion                                    | Placebo (N=328) | Vutrisiran (N=326) |
| ALT                                       | ≤ULN                                         | 238 (72.6)      | 215 (66.0)         |
| ALT                                       | >ULN and ≤3×ULN                              | 78 (23.8)       | 97 (29.8)          |
| ALT                                       | >3×ULN and ≤5×ULN                            | 4 (1.2)         | 5 (1.5)            |
| ALT                                       | >5×ULN and ≤10×ULN                           | 3 (0.9)         | 3 (0.9)            |
| ALT                                       | >10×ULN and ≤20×ULN                          | 1 (0.3)         | 2 (0.6)            |
| ALT                                       | >20×ULN                                      | 1 (0.3)         | 0                  |
| ALT                                       | Missing                                      | 3 (0.9)         | 4 (1.2)            |
| AST                                       | ≤ULN                                         | 204 (62.2)      | 198 (60.7)         |
| AST                                       | >ULN and ≤3×ULN                              | 109(33.2)       | 114 (35.0)         |
| AST                                       | >3×ULN and ≤5×ULN                            | 7 (2.1)         | 5 (1.5)            |
| AST                                       | >5×ULN and ≤10×ULN                           | 3 (0.9)         | 3 (0.9)            |
| AST                                       | >10×ULN and ≤20×ULN                          | 1 (0.3)         | 1 (0.3)            |
| AST                                       | >20×ULN                                      | 1 (0.3)         | 1 (0.3)            |
| AST                                       | Missing                                      | 3 (0.9)         | 4 (1.2)            |
| ALT or AST                                | ≤ULN                                         | 180 (54.9)      | 169 (51.8)         |
| ALT or AST                                | >ULN and ≤3×ULN                              | 131 (39.9)      | 142 (43.6)         |
| ALT or AST                                | >3×ULN and ≤5×ULN                            | 8 (2.4)         | 5 (1.5)            |
| ALT or AST                                | >5×ULN and ≤10×ULN                           | 3 (0.9)         | 3 (0.9)            |
| ALT or AST                                | >10×ULN and ≤20×ULN                          | 2 (0.6)         | 2 (0.6)            |
| ALT or AST                                | >20×ULN                                      | 1 (0.3)         | 1 (0.3)            |
| ALT or AST                                | Missing                                      | 3 (0.9)         | 4 (1.2)            |
| Total bilirubin                           | ≤ULN                                         | 190 (57.9)      | 201 (61.7)         |
| Total bilirubin                           | >ULN and ≤1.5×ULN                            | 77 (23.5)       | 82 (25.2)          |
| Total bilirubin                           | >1.5×ULN and ≤2×ULN                          | 39 (11.9)       | 18 (5.5)           |
| Total bilirubin                           | >2×ULN and ≤3×ULN                            | 15 (4.6)        | 18 (5.5)           |
| Total bilirubin                           | >3×ULN and ≤5×ULN                            | 4 (1.2)         | 3 (0.9)            |
| Total bilirubin                           | >5×ULN                                       | 0               | 0                  |
| Total bilirubin                           | Missing                                      | 3 (0.9)         | 4 (1.2)            |
| ALP                                       | >1.5×ULN                                     | 88 (26.8)       | 77 (23.6)          |
| ALT or AST and concurrent total bilirubin | ALT or AST >3×ULN and total bilirubin >2×ULN | 0               | 3 (0.9)            |

Abbreviations:  ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; DB=double-blind; LFT=liver function test; OLE=open-label extension; ULN=upper limit of normal. Note:  Includes central lab assessments from the scheduled and unscheduled visits through the first dose in the OLE Period for patients who entered OLE, or the earlier of (84 days after the last dose of study drug, early study discontinuation) for patients who discontinued DB treatment.

Source:  Study 003 CSR 1, Table 36.

<div style=\"page-break-after: always\"></div>

## Renal Events

As patients with ATTR amyloidosis often have renal involvement and/or heart failure that can result in renal failure and end stage renal disease, the frequency of patients with AEs mapping to the Acute renal failure SMQ was evaluated.

Overall,  the  types  of  renal  AEs  reported  were  consistent  with  those  expected  in  patients  with  ATTR amyloidosis, and there were no safety concerns considered related to vutrisiran.

The proportion of patients with renal AEs during the DB period of the HELIOS-B study was similar between the vutrisiran (55 [16.9%] patients) and placebo group (57 [17.4%] patients) (Table 28).

Most of the AEs occurred at a similar frequency in the vutrisiran and placebo groups. Renal events reported in ≥ 2% of patients in either group included acute kidney injury (32 [9.8%] vutrisiran, 27 [8.2%] placebo) followed by renal impairment (7 [2.1%] vutrisiran, 18 [5.5%] placebo). The majority of AEs were mild or moderate in severity. One patient in the vutrisiran group (renal impairment) and 3 patients in the placebo group (renal impairment, albuminuria, and protein urine present [1 patient each]) had renal AEs that were considered related to study drug; all were non-serious and mild/moderate in severity.

Renal SAEs were reported in a similar proportion of patients in the placebo and vutrisiran groups. No renal SAE was considered related to the study drug.

Table 28. Renal AEs during the DB period of the HELIOS-B study (safety analysis set)

| SOC                                          | Placebo (N=328; PY=822.4)   | Placebo (N=328; PY=822.4)   | Vutrisiran (N=326; PY-833.9)   | Vutrisiran (N=326; PY-833.9)   |
|----------------------------------------------|-----------------------------|-----------------------------|--------------------------------|--------------------------------|
| Preferred Term                               | n (%)                       | Events/ER                   | n (%)                          | Events/ER                      |
| At least 1 AE in the Acute Renal Failure SMQ | 57 (17.4)                   | 80/9.7                      | 55 (16.9)                      | 66/7.9                         |
| Investigations                               | 9 (2.7)                     | 11/1.3                      | 6 (1.8)                        | 8/1.0                          |
| Creatinine renal clearance decreased         | 2 (0.6)                     | 2/0.2                       | 3 (0.9)                        | 4/0.5                          |
| Blood creatinine increased                   | 2 (0.6)                     | 2/0.2                       | 2 (0.6)                        | 2/0.2                          |
| Glomerular filtration rate decreased         | 5 (1.5)                     | 5/0.6                       | 1 (0.3)                        | 1/0.1                          |
| Protein urine present                        | 1 (0.3)                     | 1/0.1                       | 1 (0.3)                        | 1/0.1                          |
| Blood urea increased                         | 1 (0.3)                     | 1/0.1                       | 0                              | 0                              |
| Renal and urinary disorders                  | 53 (16.2)                   | 69/8.4                      | 50 (15.3)                      | 58/7.0                         |
| Acute kidney injury                          | 27 (8.2)                    | 36/4.4                      | 32 (9.8)                       | 37/4.4                         |
| Renal impairment                             | 18 (5.5)                    | 21/2.6                      | 7 (2.1)                        | 7/0.8                          |
| Proteinuria                                  | 2 (0.6)                     | 2/0.2                       | 5 (1.5)                        | 5/0.6                          |
| Renal failure                                | 5 (1.5)                     | 5/0.6                       | 5 (1.5)                        | 5/0.6                          |
| Albuminuria                                  | 5 (1.5)                     | 5/0.6                       | 2 (0.6)                        | 2/0.2                          |
| Renal tubular dysfunction                    | 0                           | 0                           | 2 (0.6)                        | 2/0.2                          |

Abbreviations:  AE=adverse event; DB=double-blind; ER=exposure adjusted event rate per 100 years;

MedDRA=Medical Dictionary for Regulatory Activities; PY=patient years; PY=patient years; SMQ=standardized MedDRA queries; SOC=system organ class.

Adverse events were coded using MedDRA version 23.0.

<div style=\"page-break-after: always\"></div>

Note:  Preferred terms are sorted by decreasing frequency in the vutrisiran column.

## Malignancies

Overall, the malignancies observed across studies showed no pattern and were similar in the nature and types of malignancies reported in the general population of this age. During the DB period of the HELIOS-B study, a total of 30 (9.2%) patients in the vutrisiran group reported any AE of malignant or unspecified tumors SMQ compared to 45 (13.7%) patients in the placebo group; none were considered related to the study drug.

## Laboratory findings

There were no clinically relevant differences between vutrisiran and placebo regarding changes over time in laboratory parameters (including hematologic measures and blood-chemistry evaluations) except for alanine aminotransferase (ALT) elevations.

The proportion of patients with ALT elevations (&gt;ULN and ≤ 3 × ULN) during the DB period of the HELIOS B study was higher in the vutrisiran group 97 patients (29.8%) compared with 78 patients (23.8%) in the placebo group. The potential risk for ALT increase is currently not reflected in the SPC. The MAH was asked to include this information in section 4.8 of the SPC.

In addition, 3 (0.9%) patients in the vutrisiran group and 0 patients in the placebo group met biochemical Hy's law criteria (ALT or AST &gt;3×ULN and concurrent total bilirubin &gt;2×ULN) based on central and local laboratory results (Table 20 and refer to Study 003 CSR 1, Section 12.3.3.2). The involvement of vutrisiran on elevated liver function tests (LFT) cannot be excluded with certainty and therefore this was  adequately reflected in the SPC. The information in 4.8. of the SmPC is under 'Description of selected adverse reactions, Liver function tests'.

## Vital Signs, Physical Examination and ECG

No clinically relevant changes in vital signs, physical examination or electrocardiograms were observed in either group, and the percentage of patients with abnormalities was similar between the vutrisiran and placebo groups in the HELIOS-B study

## Safety in special populations

The safety profile of vutrisiran in HELIOS-B was consistent with the safety profile characterized in HELIOSA and in subsequent post-marketing use. With regard to special populations please refer to current product information (SmPC/PL) of commercial vutrisiran (AMVUTTRA®).

## Elderly

## Section 4.2:

No dose adjustment is required in patients ≥ 65 years of age (see section 5.2).

## Section 5.2:

There were no significant differences in steady state pharmacokinetic parameters or TTR reduction between patients &lt; 65 years old and ≥ 65 years old.

## Renal impairment

Section 4.2:

<div style=\"page-break-after: always\"></div>

No dose adjustment is necessary in patients with mild or moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 to &lt; 90 mL/min/1.73 m2). Vutrisiran has not been studied in patients with severe renal impairment or end-stage renal disease and should only be used in these patients if the anticipated clinical benefit outweighs the potential risk (see section 5.2).

## Section 5.2:

Population pharmacokinetic and pharmacodynamic analyses indicated no impact of mild or moderate renal impairment (eGFR ≥ 30 to &lt; 90 mL/min/1.73 m2) on vutrisiran exposure or TTR reduction compared to subjects with normal renal function. Vutrisiran has not been studied in patients with severe renal impairment or end-stage renal disease.

## Hepatic impairment

## Section 4.2:

No dose adjustment is necessary in patients with mild hepatic impairment (total bilirubin ≤ 1 x upper limit of normal (ULN) and aspartate aminotransferase (AST) &gt; 1 x ULN, or total bilirubin &gt; 1.0 to 1.5 x ULN and any AST). Vutrisiran has not been studied in patients with moderate or severe hepatic impairment and should only be used in these patients if the anticipated clinical benefit outweighs the potential risk (see section 5.2).

## Section 5.2:

Population pharmacokinetic and pharmacodynamic analyses indicated no impact of mild hepatic impairment (total bilirubin ≤ 1 x ULN and AST &gt; 1 x ULN, or total bilirubin &gt; 1.0 to 1.5 x ULN and any AST) on vutrisiran exposure  or  TTR  reduction  compared  to  patients  with  normal  hepatic  function.  Vutrisiran  has  not  been studied in patients with moderate or severe hepatic impairment.

## Paediatric population

## Section 4.2:

The safety and efficacy of Amvuttra in children or adolescents &lt; 18 years of age have not been established. No data are available.

A product-specific paediatric investigational plan waiver was granted by the EMA Paediatric Committee for vutrisiran (EMEA-002425-PIP01-18 - P/0015/2019), as ATTR amyloidosis occurs almost exclusively in adults. The waiver covers all subsets of the paediatric population (0 to 18 years)

## Safety related to drug-drug interactions and other interactions

For interaction with other medicinal products and other forms of interaction, see section 4.5 of the SmPC (attached in the ANNEX 3 below).

## Discontinuation due to adverse events

The percentage of patients with an AE leading to discontinuation of study drug was 3.1% in the vutrisiran group and 4.0% in the placebo group. No AEs leading to discontinuation of study drug were considered related to study drug in the vutrisiran group.

## Post marketing experience

According to the 4th Periodic Benefit-Risk Evaluation Report (PBRER) for AMVUTTRA (vutrisiran), covering the reporting interval 13 June 2023 through 12 June 2024 (i.e., the data lock point [DLP] of this report), cumulatively, 13,387 prefilled syringes of AMVUTTRA have been sold worldwide, corresponding to an estimated 3346.5 patient-years exposure, and it was estimated that 3034 patients had been treated with

<div style=\"page-break-after: always\"></div>

AMVUTTRA. Based on the evaluation of the post-marketing safety data received, the benefit-risk profile of AMVUTTRA in its approved indication remained positive. Also, based on the evaluation of the cumulative safety data and the benefit-risk analysis, no additional changes to the vutrisiran CCDS, the AMVUTTRA EU RMP, or other product documents were warranted. No change in the PSUR frequency, which is 1 year, has been proposed.

## 2.5.1. Discussion on clinical safety

The safety profile of vutrisiran in HELIOS-B was consistent with the profile characterized in HELIOS-A and in subsequent post-marketing use.

- -In general, the treatment emergent AEs and SAEs observed were consistent with those expected in the patient population and underlying disease.
- -The percentage of patients with treatment-related AEs (12.6% vutrisiran, 14.0% placebo) or AEs leading to study drug discontinuation (3.1% vutrisiran, 4.0% placebo) tended to be lower in the vutrisiran group than in the placebo group. The percentage of patients with SAEs considered related to study drug by the Investigator was low in both groups (2 [0.6%] vutrisiran; 1 [0.3%] placebo).
- -Fewer cases of deaths were reported in the vutrisiran group (15.0%) than in the placebo group (19.2%) during the DB period of the HELIOS-B study. None of the deaths were considered related to study drug by the Investigator.
- -Overall, no safety concerns regarding cardiac events were observed. The type and nature of cardiac events reported in the vutrisiran group were consistent with those expected in the patient population and underlying disease. Compared to placebo, fewer patients in the vutrisiran group reported AEs within the  Cardiac  disorders  SOC  (69.6%  vutrisiran,  73.8%  placebo),  the  Cardiac  failure  SMQ  (49.4% vutrisiran, 59.8% placebo), and the Cardiac arrhythmia HLGT (42.9% vutrisiran, 46.3% placebo). The percentage of patients with AEs within the Torsade de pointes/QT prolongation SMQ was similar between treatment groups (16.9% vutrisiran, 17.7% placebo). No confirmed events of Torsade de pointes were reported.
- -Regarding hepatic events, the proportion of hepatic AEs during the DB period of the HELIOS-B study was similar between the vutrisiran (56 [17.2%] patients) and placebo group (62 [18.6%] patients). Most of the hepatic AEs were within the Investigations SOC and occurred at a similar frequency between the vutrisiran and placebo group.

The proportion of patients with ALT elevations (&gt;ULN and ≤3×ULN) during the DB period of the HELIOS B study was higher in the vutrisiran group 97 patients (29.8%) compared with 78 patients (23.8%) in the placebo group. The potential risk for ALT increase was included in section 4.8 of the SmPC.

- -Regarding renal events, overall, the types of renal AEs reported were consistent with those expected in patients with ATTR amyloidosis, and there were no safety concerns considered related to vutrisiran. Renal SAEs were reported in a similar proportion of patients in the placebo and vutrisiran groups. No renal SAE was considered related to the study drug.

The MAH proposed to delete the following AEs (from SmPC section 4.8) that were initially included based on  results  of  HELIOS  A:  Dyspnoea,  arthralgia,  Blood  Alkaline  Phosphatase  increased  and  pain  in extremity. Regarding dyspnoea, pain in extremity and arthralgia the proposal can be followed. Since the data from HELIOS-B are not considered sufficient to overrule the signal identified in HELIOS-A, ALP increases should not be deleted from section 4.8 of the SmPC.

<div style=\"page-break-after: always\"></div>

## Additional expert consultations

N/A

## Assessment of paediatric data on clinical safety

A product-specific paediatric investigational plan waiver was granted by the EMA Paediatric Committee for vutrisiran (EMEA-002425-PIP01-18 - P/0015/2019), as ATTR amyloidosis occurs almost exclusively in adults. The waiver covers all subsets of the paediatric population (0 to 18 years).

## 2.5.2. Conclusions on clinical safety

In general, the safety profile of vutrisiran in the HELIOS-B study was similar with the HELIOS-A safety profile and consistent with the profile to that demonstrated in the post-marketing exposure. Based on the results of the HELIOS-B study, the overall safety profile of vutrisiran (AMVUTTRA®) for the proposed new additional wild-type or hereditary ATTR-CM indication is positive.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

According to the EURD list the current PSUR frequency is 1 year. In the last PSUSA (EMEA/H/C/PSUSA/00011021/202406) no change has been proposed.

## 2.6. Risk management plan

The MAH submitted/was requested to submit an updated RMP version1.2 with this application.

The (main) proposed RMP changes were the following:

Reference is made to the PRAC Rapp RMP assessment report regarding  RMP part I. T

## Safety concerns

A summary of the safety concerns is provided in Table 29.

Table 29. Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                             |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | • None                                                                                                                                                 |
| Important potential risk     | • Clinical consequences of vitamin A deficiency, including delayed symptoms • Hypersensitivity reactions                                               |
| Missing information          | • Longer-term safety (>2 years) • Use in patients with moderate or severe hepatic impairment • Use in pregnant women and effects on pregnancy outcomes |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

The MAH did not propose changes to the current routine pharmacovigilance activities.

A targeted follow-up questionnaire will be implemented for reports of vitamin A deficiency/ocular toxicity in order to collect additional information on these events; these data will be analysed and presented in the Periodic Safety Update Reports (PSURs) to further characterise the clinical consequences, noted as important potential risk in the RMP.

The MAH did not propose new additional pharmacovigilance activities.

The MAH proposed some further changes to the information of the two post-approval studies:

## Ongoing and Planned Additional Pharmacovigilance Activities

| Study Number Short Name Status                                                                                                                                                                                                  | Summary of Objectives                                                                                                                                                                                                                                                                         | Safety Concerns Addressed                                                                                                                                                                                                                            | Milestones (required by regulators)                                                                                                                                                                                        | Due Dates                                                                                                                                                                                                                  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                      | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                                                                                    | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                                           | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 |
| • Not applicable                                                                                                                                                                                                                | • Not applicable                                                                                                                                                                                                                                                                              | • Not applicable                                                                                                                                                                                                                                     | • Not applicable                                                                                                                                                                                                           | • Not applicable                                                                                                                                                                                                           |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances      | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                                                                    | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                           | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| • Not applicable Category 3 - Required additional pharmacovigilance activities                                                                                                                                                  | • Not applicable Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                | • Not applicable Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                       | • Not applicable Category 3 - Required additional pharmacovigilance activities                                                                                                                                             | • Not applicable Category 3 - Required additional pharmacovigilance activities                                                                                                                                             |
| HELIOS-A Randomised Treatment Extension The HELIOS-A-RTE a study is a Phase 3 global, open-label study to evaluate the safety and efficacy of ALN- TTRSC02 in patients with hATTR Amyloidosis. (Ongoing)                        | The aim of the study is to collect further longer- term safety and efficacy data on vutrisiran in patients with hATTR amyloidosis with polyneuropathy.                                                                                                                                        | • Longer-term safety (>2 years) a • Clinical consequences of vitamin A deficiency, including delayed symptoms • Hypersensitivity reactions                                                                                                           | Final CSR (planned)                                                                                                                                                                                                        | 31/12/ 2025                                                                                                                                                                                                                |
| ALN-TTRSC02-005 Study 005: Prospective observational study to monitor and assess the safety of Amvuttra ® [vutrisiran] in a real- world cohort of hATTR ATTR amyloidosis patients (Planned; protocol to be submitted) (Ongoing) | The primary objective of this study is to characterise the long-term (>2 years) safety of vutrisiran under real-world conditions, including determining the incidence of selected events (eg, hypersensitivity reactions and clinical consequences of vitamin A deficiency, including delayed | • Clinical consequences of vitamin A deficiency, including delayed symptoms • Hypersensitivity Reactions reactions • Longer term safety (>2 years) • Use in patients with moderate or severe hepatic impairment • Use in pregnancy and pregnancy and | Final Protocol                                                                                                                                                                                                             | Final protocol submission date: XX June 2023 Submitted on 19/12/2022 Protocol Amendment Submission: After regulatory approval of type II variation to expand Amvuttra indication.                                          |
| ALN-TTRSC02-005 Study 005: Prospective observational study to monitor and assess the safety of Amvuttra ® [vutrisiran] in a real- world cohort of hATTR ATTR amyloidosis patients (Planned; protocol to be submitted) (Ongoing) | The primary objective of this study is to characterise the long-term (>2 years) safety of vutrisiran under real-world conditions, including determining the incidence of selected events (eg, hypersensitivity reactions and clinical consequences of vitamin A deficiency, including delayed | • Clinical consequences of vitamin A deficiency, including delayed symptoms • Hypersensitivity Reactions reactions • Longer term safety (>2 years) • Use in patients with moderate or severe hepatic impairment • Use in pregnancy and pregnancy and | Start of vutrisiran data collection                                                                                                                                                                                        | As soon as the Study 005 protocol is agreed by regulatory authorities Actual Start of Data Collection:                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Study Number Short Name Status   | Summary of Objectives                                                                                                                                                                                                                    | Safety Concerns Addressed   | Milestones (required by regulators)   | Due Dates                                                                                                                                                                                                                                                                             |
|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                  | symptoms) in hATTR ATTR amyloidosis patients                                                                                                                                                                                             | infant outcomes •           |                                       | 10/04/2024                                                                                                                                                                                                                                                                            |
|                                  | exposed to vutrisiran, as well as provide comparative safety data from patients including untreated patients and patients treated with other therapies for hATTR ATTR amyloidosis excluding patisiran, following local standard of care. | infant outcomes •           | Interim updates                       | Interim Report 1: Q4 31/12/ 2025 Interim Report 2: Q4 31/12/ 2027 Interim Report 3: Q4 31/12/ 2029 Interim Report 4: Q4 31/12/ 2031 Interim Report 5 & End of data Collection: Q4 31/12/ 2033Report of Study Results: Study progress reports reports will be provided with each PBRER |
|                                  | exposed to vutrisiran, as well as provide comparative safety data from patients including untreated patients and patients treated with other therapies for hATTR ATTR amyloidosis excluding patisiran, following local standard of care. | infant outcomes •           | Final Report                          | Final study report: Q4 31/12/ 2034                                                                                                                                                                                                                                                    |

Abbreviations: ATTR=hereditary or wild-type Transthyretin amyloidosis ; CSR=clinical study report; EC=European Commission; hATTR amyloidosis=hereditary transthyretin mediated amyloidosis; NYHA=New York Heart Association ; PAM=post-authorisation measure; PBRER=periodic benefit risk evaluation report; RTE=Randomised Treatment Extension; TBD=to be determined.

a  HELIOS-A Protocol Amendment 3, in place at the time of database lock for this document as of 17 July 2020 included an 18-month extension period (for a total study duration of 36 months); as of 19 February 2021,).  Protocol Amendment 4 lengthened the extension period to a maximum of 36 months (for a total study duration of up to 54 months ).  Protocol Amendment 5 further lengthened the extension period to a maximum of 42 months extension period (for a total study duration of up to 78 months).

The MAH submitted a separate document entitled:

## \"ABSTRACT for Study ALN-TTRSC02-005 Protocol Amendment 1\"

Summary as provided by the MAH of key changes in the proposed protocol amendment 1 compared to current protocol:

- Inclusion of patients with wild-type ATTR amyloidosis so that the patient population studied is expanded from hATTR amyloidosis to ATTR (including both hATTR and wtATTR) amyloidosis.
- Expansion of planned sample size to account for patients with ATTR-CM.
- Addition of sub-population of interest 'Patients with NYHA Class IV heart failure'.
- Addition of data analysis for patients with ATTR-CM including descriptive and comparative analysis if feasible, e.g., overlapping propensity score.
- Addition of milestones of submission of protocol amendment 1 and of start of data collection in patients with ATTR-CM. Addition of option to end data collection earlier if accrual target is met.

The PRAC having considered the data submitted, is of the opinion that the proposed post-authorisation PhV development plan is sufficient to identify and characterise the risks of the product.

The PRAC also considered that routine PhV remains sufficient to monitor the effectiveness of the risk minimisation measures.

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

Routine risk minimisation activities as described in RMP Part V.1 are considered sufficient to to minimise the risks of the medicinal product. No additional risk minimisation measures are proposed.

A summary of PV activities and risk minimisation activities is provided in Table 30.

Table 30.  Summary  table  of  pharmacovigilance  activities  and  risk  minimisation  activities  by safety concern

| Safety Concern                                                            | Risk Minimisation Measures                                                                                                                                                                                                                                  | Pharmacovigilance Activities                                                                                                                                                                                                                                                                            |
|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risk:                                                 | Important Potential Risk:                                                                                                                                                                                                                                   | Important Potential Risk:                                                                                                                                                                                                                                                                               |
| Clinical consequences of vitamin A deficiency, including delayed symptoms | Routine risk minimisation measures: • The secondary pharmacologic effect on serum vitamin A levels is described in SmPC sections 4.4, 4.6, 5.1, and 5.3, and PIL Section 2. • Legal status: Prescription-only Additional risk minimisation measures: • None | Routine PV activities beyond adverse reactions reporting and signal detection: • Specific targeted follow-up of vitamin A deficiency/ocular toxicity Additional PV activities: • Evaluation of data from the HELIOS-A Randomised Treatment Extension (HELIOS-A RTE) • Evaluation of data from Study 005 |
| Hypersensitivity reactions                                                | Routine risk minimisation measures: • SmPC Section 4.3 and PIL Section 2 • Legal status: Prescription-only Additional risk minimisation measures: • None                                                                                                    | Routine PV activities beyond adverse reactions reporting and signal detection: • None Additional PV activities: • Evaluation of data from the HELIOS-A RTE • Evaluation of data from Study 005                                                                                                          |
| Missing Information:                                                      | Missing Information:                                                                                                                                                                                                                                        | Missing Information:                                                                                                                                                                                                                                                                                    |
| Longer-term safety (>2 years)                                             | Routine risk minimisation measures: • SmPC Section 4.8 Additional risk minimisation measures: • None                                                                                                                                                        | Routine PV activities beyond adverse reactions reporting and signal detection: • None Additional PV activities: • Evaluation of data from the HELIOS-A RTE • Evaluation of data from Study 005                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                             | Risk Minimisation Measures                                                                                                             | Pharmacovigilance Activities                                                                                                                        |
|------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Use in patients with moderate or severe hepatic impairment | Routine risk minimisation measures: • SmPC sections 4.2 and 5.2 Additional risk minimisation measures: • None                          | Routine PV activities beyond adverse reactions reporting and signal detection: • None Additional PV activities: • Evaluation of data from Study 005 |
| Use in pregnant women and effects on pregnancy outcomes    | Routine risk minimisation measures: • SmPC sections 4.4, 4.6, and 5.3, and PIL Section 2 Additional risk minimisation measures: • None | Routine PV activities beyond adverse reactions reporting and signal detection: • None Additional PV activities: • Evaluation of data from Study 005 |

Abbreviations:  PIL=Patient Information Leaflet; PV=Pharmacovigilance; RTE=Randomised Treatment Extension; SmPC=Summary of Product Characteristics.

## Overall conclusion on the RMP

The PRAC considered that the risk management plan version 1.5 is acceptable. In addition, minor revisions were recommended to be taken into account with the next RMP update. One additional administrative change has been made and the last submitted version of the RMP was 2.0.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 2.0 is acceptable. In addition, minor revisions were recommended to be taken into account with the next RMP update, as follows:

As requested, the MAH reverted the proposed amendments of the milestones for end of data collection and final study report or study 005 (ALN-TTRSC02-005).

The changes to the RMP are acceptable.

The CHMP endorsed the PRAC recommendation with no comments.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.8, 5.1, 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to user testing from the initial Marketing Authorisation

<div style=\"page-break-after: always\"></div>

Application (MAA, procedure EMEA/H/C/0005852/0000) .The bridging report submitted by the MAH has been found acceptable.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

Vutrisiran (AMVUTTRA®) is a ribonucleic acid interference (RNAi) therapeutic designed to suppress production of both variant and wild-type TTR in the liver and was approved by the European Commission on 15 September 2022 for the treatment of hATTR amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.

Current approved therapeutic indication:

'Amvuttra is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.'

Proposed new additional ATTR-CM indication:

Within this procedure the MAH applies for an extension of the indication as follows:

Amvuttra is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN).

Amvuttra is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

*Note: The Applicant does not propose any changes to the dosage form, route of administration, or dosing regimen via this application. The drug product for the proposed additional ATTR-CM indication has the same formulation and presentation as commercial vutrisiran (AMVUTTRA®).

## 3.1.1. Disease or condition

ATTR amyloidosis is a rare, multisystem, progressive, debilitating, and ultimately fatal disease resulting from the deposition of misfolded TTR as amyloid fibrils in various organs, predominantly the nerves and heart (Castaño and Maurer, 2019; Ruberg et al., 2019). The most clinically important manifestations are the result of involvement of the peripheral nervous system and the heart. Accumulation of amyloid fibrils in the heart causes an infiltrative, restrictive cardiomyopathy (ATTR-CM) resulting in progressive clinical heart failure associated with high mortality and morbidity. Patients with ATTR-CM typically experience frequent hospitalizations for heart failure, irreversible loss of physical function, and worsening health status and QoL. Advanced ATTR-CM causes some of the most deleterious adverse clinical outcomes in ATTR (Castaño and Maurer, 2019; Ioannou et al., 2023; Ruberg et al., 2019).

In hATTR amyloidosis, inherited variants in the TTR gene lead to destabilization of the tetrameric protein. The phenotypic expression varies depending on the predominant site of deposition of the amyloid fibrils; however, most patients with hATTR amyloidosis experience both cardiomyopathy and polyneuropathy over the course of their disease. Wild-type TTR alone can also be amyloidogenic; this is the basis for the nonhereditary, wtATTR amyloidosis. There is no known genetic cause of wtATTR amyloidosis, and it is presumed to be the result of age-related mechanisms associated with alteration in TTR physiological processing and clearance. [Dharmarajan 2012; Ruberg 2012a] In patients with wtATTR amyloidosis,

<div style=\"page-break-after: always\"></div>

amyloid deposits are typically found primarily in heart tissue. These patients have cardiomyopathy as their primary manifestation but commonly have non-cardiac manifestations.

In ATTR amyloidosis patients with cardiomyopathy, cardiac infiltration of the extracellular matrix by TTR amyloid fibrils causes ventricular wall thickening, a marked increase in chamber stiffness, and diastolic dysfunction. Systolic function is also impaired, as characterized by abnormal longitudinal strain. The ejection fraction typically remains normal until late stages of the disease.[Castano 2015; Dungu 2012; Mohty 2013; Ruberg 2012b] Patients suffer from typical symptoms of congestive heart failure, including dyspnea and fatigue, resulting in decreased functional capacity.[Brito 2023; Maurer 2019] Amyloid infiltration can also disrupt cardiac conduction and cause arrhythmias or sudden death due to severe conduction disorders.[Adams 2016; Ando 2013; Benson 2007; Connors 2004] These progressive manifestations of heart failure (HF), in addition to necessitating hospitalizations or urgent interventions, progressively impact patients' daily activities and can markedly diminish quality of life.

Natural history studies depict a progression of HF resulting in hospitalizations and death 2.5 to 5 years after diagnosis.[Antonopoulos 2022; Castano 2015; Damy 2015; Dungu 2012; Hawkins 2015] The rate of mortality and cardiovascular (CV) hospitalizations among untreated patients with ATTR cardiomyopathy is high. In the Phase 3 study (ATTR-ACT) with the TTR stabilizer tafamidis, which recruited wtATTR and hATTR amyloidosis patients with cardiomyopathy, the mortality rate in the tafamidis arm was 30% and in the placebo arm was 43% at Month 30. [Maurer 2018]. Recently, with the advent of non-invasive technetium scintigraphy imaging for diagnosing amyloidosis with cardiomyopathy,[Gillmore 2016] growing disease awareness and improvements in standard of care, there has been a shift in the global ATTR disease landscape with patients being diagnosed earlier in the course of their disease and generally presenting with milder disease stage.[Ioannou 2022].

## 3.1.2. Available therapies and unmet medical need

Historically, the treatment of ATTR amyloidosis with cardiomyopathy has focused on palliative therapies directed at symptoms, such as diuretics for congestive symptoms and antiarrhythmic drugs, pacemakers, and automatic implantable cardioverter defibrillators for arrhythmias and conduction defects.

Center-based studies suggest that heart transplantation in ATTR amyloidosis with cardiomyopathy can be an effective option with outcomes similar to those transplanted for other causes of HF. [Barrett 2020; Razvi 2022] However, cardiac transplantation continues to be a less pursued option due to the need for lifelong immunosuppression and long waiting times associated with transplantation.

In regions such as the United States (US) and the European Union (EU), the only approved treatments for cardiomyopathy in adult patients with wtATTR or hATTR amyloidosis are Transthyretin Stabilizers which act by stabilising the tetrameric TTR protein and reducing its rate of dissociation into amyloidogenic monomers. Tafamidis, and Acoramidis have been approved in the US and the EU.

Despite important therapeutic advances, a substantial medical need persists. In the phase 3 study with tafamidis (ATTR-ACT, Maurer MS et al., N Engl J Med 2018;379:1007-101), about 29.5% of patients died in the combined active treatment arms during the 30 months observation period, and the annualized rate of CV-related hospitalization remained high at 0.48/year. In the ATTRibute-CM study (Gillmore JD et al., N Engl J Med 2024;390:132-142) patients on acoramidis had a 80.7% observed 30-month survival while on acoramidis.

<div style=\"page-break-after: always\"></div>

## 3.1.3. Main clinical studies

Vutrisiran (AMVUTTRA®) was approved by the European Commission on 15 September 2022 for the treatment of hATTR amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.

The pivotal trial for this application is HELIOS-B (ALN-TTRSC02-003). It is an ongoing, Phase 3, multicenter, multinational, randomized, double-bind, placebo-controlled study in hATTR amyloidosis patients with cardiomyopathy (Primary analysis completed, Data cutoff: 08 May 2024) designed to evaluate efficacy, safety, PK, and PD of vutrisiran in adult patients with hATTR amyloidosis with cardiomyopathy. Patients were either not on tafamidis at baseline (vutrisiran monotherapy subgroup) or were receiving concomitant tafamidis at baseline per the inclusion criteria (background tafamidis subgroup). Randomization was stratified by baseline tafamidis use.

The study consisted of the following periods: -Screening Period: - Double blind (DB) treatment period Open-label treatment extension period up to 2 years - Follow-up period up to 1 year after last dose of study drug (up to 18 months for women of child-bearing potential). After screening, eligible patients were randomized in a 1:1 ratio to receive blinded doses of 25 mg of vutrisiran or placebo administered as an SC injection q3M (every 12 weeks ±7 days) for up to 36 months in the DB Period. During the OLE Period, all patients received open-label doses of 25 mg q3M vutrisiran administered as SC injections. An Open-label Randomized Treatment Extension (RTE) Period was added wherein patients were randomized 1:1 to receive treatment with either 25 mg q3M vutrisiran or 50 mg once every 6 months (q6M) vutrisiran with all patients receiving 25 mg q3M vutrisiran thereafter between 13 May 2022 and 22 March 2023.

The study was performed in 77 centers in 26 countries. Subjects were well representative for patients with hATTRwt and hATTRv amyloidosis and mild to moderate symptomatic cardiomyopathy. Baseline disease characteristic were overall balanced between the groups. In the overall population, 578 (88.4%) patients had wtATTR amyloidosis and 76 (11.6%) patients had hATTR amyloidosis. The mean years since diagnosis of ATTR amyloidosis was 1.43 (range, 0.0 to 11.1) years. The mean age of patients at symptom onset was 73.3 (range, 35 to 85) years. Most (77.7%) patients had NYHA class II HF and were classified as having ATTR amyloidosis disease Stage 1 (66.8%) or Stage 2 (28.6%).

799 patients were screened, 655 were randomized. Of the 326 patients in the vutrisiran group, 78 (23.9%) patients discontinued study drug during the DB Period. Of the 329 patients in the placebo group, 99 (30.1%) patients discontinued study drug during the DB Period. 241 (vutrisiran) and 221 patients (placebo) entered the OLE period, 4 and 8 patients, respectively discontinued vutrisiran therapy during the OLC period that was ongoing with 248 and 224 patients respectively at the time of the data base lock.

Two primary efficacy endpoints were predefined:

- Composite outcome of all-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) in the overall population
- Composite outcome of all-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) in the vutrisiran monotherapy subgroup (defined as the group of patients not on tafamidis at study baseline)

The following (confirmatory) secondary endpoints were defined in both the overall population and the vutrisiran monotherapy subgroup:

- Change from baseline in 6-MWT · Change from baseline in the KCCQ-OS · All-cause mortality · Change from baseline in NYHA class

Additional secondary and exploratory endpoints covered among others

<div style=\"page-break-after: always\"></div>

· Composite outcome of all-cause mortality and recurrent all-cause hospitalizations and urgent HF visits · Time to first CV event (including CV hospitalizations and urgent HF visits) or all-cause mortality

Change from baseline in · ECHO parameters, · NT-proBNP · Troponin I · eGFR · ATTR amyloidosis disease stage · EuroQoL-5 Dimensions-5 Levels questionnaire, and · Norfolk QoL-DN

The results from the completed double-blind period and the ongoing open-label extension (OLE) period of HELIOS-B comprise the primary focus of this type II variation.  The safety of vutrisiran has been established in HELIOS-B and across the vutrisiran clinical development program.

## 3.2. Favourable effects

## Primary endpoints

In the overall population, vutrisiran patients had a statistically significant 28.2% reduction in the risk of all-cause mortality and recurrent CV events compared to placebo (hazard ratio: 0.718; 95% CI: 0.555, 0.929; P=0.0118).

In the vutrisiran monotherapy subgroup, vutrisiran patients had a statistically significant 32.8% reduction in the risk of all-cause mortality and recurrent CV events compared to placebo (hazard ratio: 0.672; 95% CI: 0.487, 0.929; P=0.0162).

## Confirmatory secondary endpoints

At Month 30, vutrisiran led to a statistically significant improvement in 6-MWT compared to placebo in the overall population (least square [LS] mean difference: 26.46 m; P=7.976E-05), with consistent results observed in the vutrisiran monotherapy subgroup (32.09 m; P = 0.0005).

At Month 30, vutrisiran led to a statistically significant improvement in KCCQ-OS compared to placebo in the overall population (LS mean difference: 5.80 points; P=0.0008). The difference was larger (8.7 points) in the vutrisiran monotherapy group.

Vutrisiran patients had a statistically significant 35.5% reduction in the risk of all-cause mortality compared to placebo in the overall population (hazard ratio: 0.645; 95% CI: 0.463, 0.898; P=0.0098; 95% CI: 0.440, 0.973; P=0.0454 and a statistically significant 34.5% reduction in the vutrisiran monotherapy subgroup (hazard ratio: 0.655; 95% CI: 0.440, 0.973; P=0.0454).

At Month 30, vutrisiran led to a statistically significantly greater proportion of patients who showed stability (no change in class) or improvement compared to placebo in the overall population (adjusted difference: 8.7%, 95% CI: 1.3, 16.1; P=0.0217), with consistent results observed in the vutrisiran monotherapy subgroup (adjusted difference: 12.5%, 95% CI: 2.7, 22.2; P=0.0121).

## Other secondary and exploratory endpoints

In the overall population, in the analysis of recurrent CV events, including CV hospitalizations and urgent HF visits, vutrisiran treatment led to a 26.7% reduction in the risk of CV events compared to placebo (relative rate ratio: 0.733; 95% CI: 0.610, 0.882; P=0.0010).

In the vutrisiran monotherapy subgroup, vutrisiran led to a 32.4% reduction in the risk of CV events compared to placebo (relative rate ratio: 0.676; 95% CI: 0.533, 0.857; P=0.0012).

In the overall population, vutrisiran treatment led to a 28.4% reduction in the risk of first CV event or allcause mortality compared to placebo (hazard ratio: 0.716; 95% CI: 0.566, 0.905; P=0.0062)

<div style=\"page-break-after: always\"></div>

In the vutrisiran monotherapy subgroup, vutrisiran treatment led to a 35.6% reduction in the risk of first CV event or all-cause mortality compared to placebo (hazard ratio: 0.644; 95% CI: 0.479, 0.867; P=0.0043).

In the overall population, 77.3% of patients in the vutrisiran group showed no progression in NAC ATTR amyloidosis stage at Month 30 compared to 61.2% of patients in the placebo group (adjusted difference: 16.1; 95% CI: 8.1, 24.2; P=7.889E-05). Consistent results were observed in the vutrisiran monotherapy subgroup (adjusted difference: 14.8 (3.7, 26.0), p = 0.0112).

At Month 30, vutrisiran improved patients' self-reported general health-related quality of life, as assessed by the change from baseline in EQ-5D-5L index score, compared to placebo in the overall population (LS mean [SEM] difference: 0.0308 [±0.0111]; P=0.0056), with consistent results observed in the vutrisiran monotherapy subgroup.

At Month 30, the result for the Norfolk QoL-DN questionnaire improved vutrisiran compared to placebo in the overall population (LS mean [SEM] difference: -5.3 (±1.4); P=0.0001, MMRM model). The effect size was larger in the vutrisiran monotherapy group (-7.5 (±1.9); P=0.0001).

## 3.3. Uncertainties and limitations about favourable effects

Patients with mild to moderate CM were included. Most patients were in NYHA stage II. Patients in NYHA stage III were excluded if they were also in NAC stage 3. Therefore, information is limited regarding efficacy and safety in patients at an advanced stage of the disease. Some information on the safety of patients at advanced stage were generated from patients deteriorating during the course of the study. The preliminary data did not raise safety concerns when treatment was continued. Currently, extrapolation of the results to patients with advanced stages of heart failure is not considered justified and the SmPC should better reflect absence on information on initiating vutrisiran in those patients at these advances stages of the disease and reflect the preliminary data on maintenance of vutrisiran treatment in patients deterioration on therapy.

There is uncertainty on the interpretation of the results in patients receiving tafamidis background therapy and how to place vutrisiran. Tafamidis has an established benefit in the target group of patients with ATTR amyloidosis regarding mortality and CV hospitalization rate. In the subgroup of patients receiving tafamidis background therapy results for efficacy of vutrisiran vs. placebo were numerically consistent with the results in the complementary vutrisiran monotherapy subgroup for most efficacy endpoints analysed but as a rule, effect sizes were smaller and nominal significance or clinical relevance could not be demonstrated for all of the primary, secondary and exploratory endpoints. Analyses in this subgroup were not predefined in a confirmatory testing strategy and superiority of efficacy in this subgroup was not a hypothesis to be tested separately. It is therefore not possible to conclude on a statistically significant and clinically relevant superiority of efficacy of vutrisiran in the add-on setting to tafamidis. But even when assuming that the numerically better results with vutrisiran for almost all efficacy endpoints investigated in this group indicated somewhat improved efficacy, it is still not possible to decide whether vutrisiran alone had a tendency to better efficacy than tafamidis, or whether the combination of both medicinal products exerted an add-on/potentiated effect when combined. A comparison to efficacy in the vutrisiran monotherapy subgroup is not meaningful in this regard due to relevant differences in baseline characteristics between the vutrisiran monotherapy subgroup and the background tafamidis subgroup. The uncertainty related particularly to patients with hATTR already receiving tafamidis. In this small subgroup results were even numerically in favour of placebo over vutrisiran for a number of endpoints evaluate. The same holds true for patients at NYHA stage III at baseline. Due to the low number the results in these subgroups should be interpreted with caution, no conclusions are possible whether these patients have a benefit of administering vutrisiran on top of tafamidis.

<div style=\"page-break-after: always\"></div>

Currently it is therefore not possible to draw final conclusions as to whether patients on tafamidis background therapy should receive add-on vutrisiran or should receive vutrisiran in exchange of tafamidis. Post hoc analyses indicated that patients deteriorating on tafamidis tended to have more of a benefit than those that appeared to be clinically stable. However, no firm conclusions can be drawn in this regard. Irrespectively, the results in the overall population and in the vutrisiran monotherapy population sufficiently provide evidence of a clinically relevant efficacy of vutrisiran.

Efficacy in patients with wtATTR was convincing, whereas subgroup analyses in patients with hATTR indicated potentially lower efficacy in the overall population. This was particularly relevant for patients on background tafamidis. Due to low numbers it is currently also not possible to come to final conclusions as to whether patients in NYHA stage III on tafamidis background therapy can expect a clinically relevant benefit of adding vutrisiran.

Secondary endpoints pertaining to quality of life and exercise capacity depend on both, cardiovascular and neurological effects Additional analyses provided did not indicate that efficacy on polyneuropathy had a relevant impact on the overall results.

## 3.4. Unfavourable effects

In general, the treatment emergent AEs and SAEs observed were similar between treatment groups and consistent with those expected in the patient population and underlying disease.

The percentage of patients with treatment-related AEs (12.6% vutrisiran, 14.0% placebo) or AEs leading to study drug discontinuation (3.1% vutrisiran, 4.0% placebo) tended to be lower in the vutrisiran group than in the placebo group. The percentage of patients with SAEs considered related to study drug by the Investigator was low in both groups (2 [0.6%] vutrisiran; 1 [0.3%] placebo).

Fewer cases of deaths were reported in the vutrisiran group (15.0%) than in the placebo group (19.2%) during the DB period of the HELIOS-B study. None of the deaths were considered related to study drug by the Investigator.

Overall, no safety concerns regarding cardiac events were observed. Compared to placebo, fewer patients in the vutrisiran group reported AEs within the Cardiac disorders SOC (69.6% vutrisiran, 73.8% placebo), the Cardiac failure SMQ (49.4% vutrisiran, 59.8% placebo), and the Cardiac arrhythmia HLGT (42.9% vutrisiran, 46.3% placebo). The percentage of patients with AEs within the Torsade de pointes/QT prolongation SMQ was similar between treatment groups (16.9% vutrisiran, 17.7% placebo). No confirmed events of Torsade de pointes were reported.

## 3.5. Uncertainties and limitations about unfavourable effects

## 3.6. Effects Table

Table 31. Effects table for Vutrisiran and treatment of ATTR amyloidosis with CM

| Effect   | Short description   | Unit   | Vutrisiran N=326 Overall population;   | Placebo N=328 Overall population; N=199 Vutrisiran   | Uncertaintie s Strength of   | Reference s   |
|----------|---------------------|--------|----------------------------------------|------------------------------------------------------|------------------------------|---------------|
|          |                     |        | N=196 Vutrisiran Monotherap y Subgroup | Monotherap y Subgroup                                | evidence                     |               |

Favourable Effects

<div style=\"page-break-after: always\"></div>

| Effect                                      | Short description                                                                                                                                                                                               | Unit                                | Vutrisiran N=326 Overall population; N=196 Vutrisiran Monotherap y Subgroup   | Placebo N=328 Overall population; N=199 Vutrisiran Monotherap y Subgroup   | Uncertaintie s Strength of evidence                        | Reference s                     |
|---------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------|------------------------------------------------------------|---------------------------------|
| All-cause mortality and recurrent CV events | Composite outcome of all- cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) in the overall population                                                                          | n                                   | 251                                                                           | 332                                                                        | Hazard ratio 0.718 95% CI (0.555, 0.929) P = 0.0118        | DB Period of the HELIOS-B Study |
| All-cause mortality and recurrent CV events | Composite outcome of all-cause mortality and recurrent CV events (CV hospitalization s and urgent HF visits) in the vutrisiran monotherapy subgroup (defined as the group of patients not on tafamidis at study | n                                   | 155                                                                           | 211                                                                        | Hazard ratio 0.672 95% CI (0.487, 0.929) P = 0.0162        | DB Period of the HELIOS-B Study |
| 6-MWT                                       | baseline) Change from baseline in 6- minute walk test (6-MWT) at Month 30 in the overall population                                                                                                             | meters, (observe d median, Q1, Q3 ) | -7.50 (-55.00, 18.00)                                                         | -30.65 (-82.55, 4.77)                                                      | LS mean difference 26.46 95% CI 13.38, 39.55 P = 7.976E-05 | DB Period of the HELIOS-B Study |
| 6-MWT                                       | Change from baseline in 6- minute walk test (6-MWT) at Month 30 in the monotherapy subgroup                                                                                                                     | meters, (observe d median, Q1, Q3 ) | -13.05 (-69.04, 17.41)                                                        | -47.33 (-91.92, -2.35)                                                     | LS mean difference 32.09 95% CI 14.03, 50.15 P = 0.0005    | DB Period of the HELIOS-B Study |
| KCCQ-OS                                     | Change from baseline in Kansas City Cardiomyopath y Questionnaire Overall Score (KCCQ-OS) at                                                                                                                    | observed median (Q1, Q3)            | -1.30 (-11.07, 8.14)                                                          | -6.25 (-17.71, 3.13)                                                       | LS mean difference 5.80 95% CI (2.40, 9.20)                | DB Period of the HELIOS-B Study |

<div style=\"page-break-after: always\"></div>

| Effect              | Short description                                                                                                                 | Unit                     | Vutrisiran N=326 Overall population; N=196 Vutrisiran Monotherap y Subgroup   | Placebo N=328 Overall population; N=199 Vutrisiran Monotherap y Subgroup   | Uncertaintie s Strength of evidence                                                                                                                                                   | Reference s                                       |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------|--------------------------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|
|                     | Month 30 in the overall population                                                                                                |                          |                                                                               |                                                                            | P = 0.0008                                                                                                                                                                            |                                                   |
| KCCQ-OS             | Change from baseline in Kansas City Cardiomyopath y Questionnaire Overall Score (KCCQ-OS) at Month 30 in the monotherapy subgroup | observed median (Q1, Q3) | -0.26 (-13.80, 11.77)                                                         | -8.65 (-20.05, 1.56)                                                       | LS mean difference 8.69 95% CI (3.98, 13.40) P = 0.0003                                                                                                                               | DB Period of the HELIOS-B Study                   |
| All-cause mortality | All-cause mortality through 42 months in the overall population                                                                   | n (%)                    | 60 (18.4%)                                                                    | 85 (25.9%)                                                                 | Hazard ratio 0.645 95% CI (0.463, 0.898) P = 0.0098 Uncertainty: OLE period in placebo arm on treatment. Strength: Approach rather conservative. Consistent with results in DB        | DB Period of the HELIOS-B Study + extension phase |
| All-cause mortality | All-cause mortality through 42 months in the monotherapy subgroup                                                                 | n (%)                    | 43 (21.9%)                                                                    | 58 (29.1%)                                                                 | period Hazard ratio 0.655 95% CI (0.440, 0.973) P = 0.0454 Uncertainty: OLE period in placebo arm on treatment. Strength: Approach rather conservative. Consistent with results in DB | DB Period of the HELIOS-B Study + extension phase |
| NYHA Class          | Change from baseline in                                                                                                           | %stable or               | 67.8                                                                          | 60.5                                                                       | Difference in %stable or                                                                                                                                                              | DB Period of the                                  |

<div style=\"page-break-after: always\"></div>

| Effect                                                       | Short description                                                                                       | Unit                 | Vutrisiran N=326 Overall population; N=196 Vutrisiran Monotherap y Subgroup   | Placebo N=328 Overall population; N=199 Vutrisiran Monotherap y Subgroup   | Uncertaintie s Strength of evidence                                  | Reference s                     |
|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|----------------------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------|---------------------------------|
|                                                              | New York Heart Association (NYHA) class at Month 30 in the overall population                           | improved             |                                                                               | P =                                                                        | improved 8.7 95% CI (1.3, 16.1) 0.0217                               | HELIOS-B Study                  |
| NYHA Class                                                   | Change from baseline in New York Heart Association (NYHA) class at Month 30 in the monotherapy subgroup | %stable or improved  | 66.3                                                                          | 56.4                                                                       | Difference in %stable or improved 12.5 95% CI (2.7, 22.2) P = 0.0121 | DB Period of the HELIOS-B Study |
| Unfavourable Effects                                         | Unfavourable Effects                                                                                    | Unfavourable Effects | Unfavourable Effects                                                          | Unfavourable Effects                                                       | Unfavourable Effects                                                 | Unfavourable Effects            |
| Adverse events related to study drug                         | Treatment- related AE                                                                                   | n (%)                | 41 (12.6%)                                                                    | 46 (14.0%)                                                                 | DB Period of the HELIOS-B Study (Safety Analysis Set)                | HELIOS-B Phase 3 study          |
| Serious adverse events related to study drug                 | Treatment- related SAE                                                                                  | n (%)                | 2 (0.6%)                                                                      | 1 (0.3%)                                                                   | DB Period of the HELIOS-B Study (Safety Analysis Set)                | HELIOS-B Phase 3 study          |
| At least 1 AE leading to discontinuatio n from study drug    | Treatment- emergent AE                                                                                  | n (%)                | 10 (3.1%)                                                                     | 13 (4.0%)                                                                  | DB Period of the HELIOS-B Study (Safety Analysis Set)                | HELIOS-B Phase 3 study          |
| Deaths                                                       | Treatment- emergent SAE                                                                                 | n (%)                | 49 (15.0%)                                                                    | 63 (19.2%)                                                                 | DB Period of the HELIOS-B Study (Safety Analysis Set)                | HELIOS-B Phase 3 study          |
| Deaths related to study drug as assessed by the Investigator | Treatment- related SAE                                                                                  | n (%)                | 0 (0%)                                                                        | 0 (0%)                                                                     | DB Period of the HELIOS-B Study (Safety Analysis Set)                | HELIOS-B Phase 3 study          |
| Cardiac disorders SOC AEs                                    | AEs of Special Interest                                                                                 | n (%)                | 227 (69.6%)                                                                   | 242 (73.8%)                                                                | DB Period of the HELIOS-B Study (Safety                              | HELIOS-B Phase 3 study          |

<div style=\"page-break-after: always\"></div>

| Effect                                           | Short description       | Unit   | Vutrisiran N=326 Overall population; N=196 Vutrisiran Monotherap y Subgroup   | Placebo N=328 Overall population; N=199 Vutrisiran Monotherap y Subgroup   | Uncertaintie s Strength of evidence                   | Reference s            |
|--------------------------------------------------|-------------------------|--------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------|-------------------------------------------------------|------------------------|
|                                                  |                         |        |                                                                               |                                                                            | Analysis Set)                                         |                        |
| AEs in the Acute Renal Failure SMQ               | AEs of Special Interest | n (%)  | 55 (16.9%)                                                                    | 57 (17.4%)                                                                 | DB Period of the HELIOS-B Study (Safety Analysis Set) | HELIOS-B Phase 3 study |
| Drug-related Hepatic Disorders (SMQ)             | AEs of Special Interest | n (%)  | 56 (17.2%)                                                                    | 62 (18.6%)                                                                 | DB Period of the HELIOS-B Study (Safety Analysis Set) | HELIOS-B Phase 3 study |
| ALT elevations (>ULN and ≤ 3 × ULN)              | AEs of Special Interest | n (%)  | 97 (29.8%)                                                                    | 78 (23.8%)                                                                 | DB Period of the HELIOS-B Study (Safety Analysis Set  | HELIOS-B Phase 3 study |
| Treatment- related injection site reaction (ISR) | AE of Special Interest  | n (%)  | 7 (2.1%)                                                                      | 8 (2.4%)                                                                   | DB Period of the HELIOS-B Study (Safety Analysis Set) | HELIOS-B Phase 3 study |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

In the European Union (EU), the only approved treatment for cardiomyopathy in adult patients with wtATTR or hATTR amyloidosis is tafamidis, which acts by stabilising the tetrameric TTR protein and reducing its rate of dissociation into amyloidogenic monomers. For Acoramids with the same mechanism of action EMA has issued a positive opinion on 12 December 2024.

Thus, there is an important need for additional approved agents to treat wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) which are safe, effective, and convenient to use.

Vutrisiran showed statistically significant and clinically relevant effects on the composite primary endpoint of all-cause mortality and CV hospitalization/urgent heart failure visits, on all-cause mortality and on Quality of life as measured by KCCQ-OS. In addition, a statistically significant effect was demonstrated on exercise capacity as assessed by the 6-MWT and on the NYHA class. For all of these confirmatory endpoints statistical significance was demonstrated in vutrisiran monotherapy and in the overall population including patients with and without background tafamidis therapy. Considering the increasing number of patients being diagnosed, the limited number of therapeutic options available and the still high morbidity and mortality in the target group of patents there is an unmet medical need and the favourable effects are of high clinical relevance.

<div style=\"page-break-after: always\"></div>

## 3.7.2. Balance of benefits and risks

Transthyretin amyloidosis with cardiomyopathy (wt ATTR and hATTR) is progressive and eventually fatal disease which manifests as destabilization of the tetrameric structure of the TTR protein. Vutrisiran is a siRNA molecule that uses RNA interference mechanisms to target and silence the expression of wild type and variant TTR mRNA and inhibit the synthesis of the TTR protein.

A large reduction in TTR and large, statistically significant and clinically meaningful improvements in morbidity, mortality and quality of life and statistically significant improvements regarding NYHA stage and exercise capacity have been observed with vutrisiran in a pivotal randomized phase 3 study (HELIOS-B) as compared to placebo in the overall population and in patients on vutrisiran monotherapy. The safety profile of vutrisiran as derived from the presented safety data is considered acceptable and manageable with appropriate labelling in the product information.

Therefore, the benefits of vutrisiran in the proposed target population outweigh the risks.

## 3.7.3. Additional considerations on the benefit-risk balance

None

## 3.8. Conclusions

The overall B/R of vutrisiran (AMVUTTRA ® ) is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends  by a majority the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of wild-type or hereditary transthyretin-mediated amyloidosis in adult patients with cardiomyopathy (ATTR-CM), based on primary analysis results from study HELIOS-B (ALN-TTRSC02-003); a Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy).  As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. An updated  version 1.5, dated 10 April 2025. and a final update version 2.0. of the RMP have also been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

<div style=\"page-break-after: always\"></div>

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that AMVUTTRA (vutrisiran) is not similar to Vyndaqel (tafamidis), Tegsedi (inotersen) and Onpattro (patisiran) within the meaning of Article 3 of Commission Regulation (EC) No. 847/2000. See appendix 1.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Amvuttra-H-C-005852-II-0015'.